var title_f13_1_13328="Pathophys allergic rhinitis";
var content_f13_1_13328=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F53928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F53928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Early and late phases of an allergic reaction in the nasal tissues",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 600px; background-image: url(data:image/gif;base64,R0lGODlh4AFYAsQAAP///4CAgH9/f0BAQAAAAMDAwD8/P7+/v/Dw8NDQ0ODg4O/v7zAwMLCwsBAQEGBgYKCgoN/f35+fn3BwcFBQUB8fHyAgIF9fX8/Pzy8vL5CQkG9vb6+vr4+Pj09PTw8PDyH5BAAAAAAALAAAAADgAVgCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYZQoFBQonmyOgmaOkfwUDAwUnAQSqAAMEpbKzeAEBIgoPAwGqAboAubG0w8RutiIMqg+3thQJDwnCxdPUZMcJDCLHtqcDANLV4eJax6fazLep3+Ps7VTHCA4IABPoJODu+fpGEBYWEAAgMKCwC8CxEfj2KVwYZB6ABwAZSpxI5AEDBhOgdBqxUYEnEa4AJLDV4ASCkF4I/xCggBIHp5euRgYoCeClQ4o4iRDwVpOAPRHCAgxoUGCZCQ2twBSAACujDluotg0testnAAs0c2r9QeCBMqMH1yWwQOLmCAu+RjA1SgRBA1szzbJo4IACj4Njy64D0IDn1r87CCSgoICCVLixAjhFgS2eiAYUEChIaKJBPbiYW54oQIGAAQEbPqhk+SKBg8U4Dio2IUzDA8CwRRbAzCvBi1ioZjPzyinxLRJMBwCcoAEAhZLHga6Y4IB25uUfBCwQUUHlBQEfUK9okDSH6t/3BjAYIHdHAt1wC9iOzUiBBlgVDGwQQH+DgeoDNHxMEcvcNvCxQGBXChaMZ8Fr6uz1yf9F+8XwQAYRjBCBSp4BEEEGr7kg3nM0HCQgazVZUJ4N7sEnH32g3beTfuwZcgoBF0gwHQoLSHDBTpohRMJ/OsbjigJZiZQNAI7VQyRlfJ1WwwQZzLjAARFUR8AGIiyQgXYpQGAVN5zMcJCPuJTUml83vBjjjCfUeGOCLZoyQAUdoMnCAh1UwOY9O/6012Dj3UncCMchgMoElDEXZAwFfBAhAFaqJEEHEpAQwQc5mlAAPmHBEBafuSn4QIY1nAKnnCvQaWelbdYxQXQ1YIdlQ7iQRYICDNpAgQAjHEAhriTY98GAMmR6xaq8zuBqqnnQasCiNURgAAMNBjGWeOs9pqT/DQgQgOaEKnVAggQUEjAiC8JSoSyzNDgLLbJ1mEalDhs4UG0ShuLQgAElcLCBtyR0EO6hLpQrhbs7xDsvu26YFikPEsibBK3rplYsjQZQWMEG4Gm6i3Mcd+zxxyDDpYEDC+/Q8MEIq6EAyT80HK0QdL3a4cQiSCDAwv6qRKUAGb+AXshABw30AwSUzLADL6d8BgPv/rBBMkJHzfEAoHpHs64qHQBAzgR4y/MaTAfxtNJrTICvEM9KrTZmDhSnw70lCLAroxUbMJ0BAJNh9hAGyEw2GAkoOsSkqPYwVtXYaiupaIKXsIC4M/y89uQeq9d4EIT/bcYANAMhAJlDIHDR/7gx3FpCBFCeIACwMQhF+esdn9I5ABgcYLvtpFZps9EofK45GQVUcEQFhfvwgAUoy5Aouilk7mXPTgSPgs0XVEAf87RXIMEBAjS5AvG/izEAv0V0ADoRI+cdA5O5O35lDQIzMb4KB5x9ggclX0A+CuaHD8Zk7QPC45IGs7bh4EHYkxCGbBA/JQCQfvZjDZo4EME0EYCA/rOCBi6QhAu4DQmHwwGxSLWAY8HgZ7qRwgZXUD/+kKCFK/BgBrswAN4RQQLnK4LoGEA6F3DGMyiqGGlioKX0dCkKNWSh/ZYIgAowqwMcXAEOZ8gFxSHhcU04XvJi4Ba4NKCHKhgZFqyYAv8YAoCJAvBAlSqgtVIhiYoDE94JbpdAKUZqAxhAQQW2WIT0RSEe0ItCAuQIwREY4JCHFIEADpkBDrhgj3DEQgEqiBD6ZGB/LaDPGdtoAgMUbwgT2JhzPrkD0YnoCpOMARNp4MlIXiEATSuBMMxIgkVeII8U9EAeNWkATpYAY9GrnBGw4bBXxrIFq5wBMF1ZhQDM7hu284Ajf8lBDHCAAx5YQJRKiKte9i6QdShAA4g2AAxCwZmqNGSrwMnMJqDzBASgzwXwhYFDUukDaPLAdQTARl76spbslEO2VhKRLLwzCV9r5xQOKssRZOCf4DBAB27HzU1+EzYMxQEez7iChCr/NAqwRIEwFuDEEhhgYRhIY5Ui4E8ULHMLDVAfHUI6R0qywJtvFMFLP/qEVMKTkTas5yEduYEMGABCLT1BK7WAgAc4QKZz8KkJ+CmAf2LAAxJl1Dx5hdMVLJWnTxjkEiCZhQJYIDIrgEBB2yDWE0jgoeiKEgboBICHAmA+Fs1pE/kIViSQ0QhYzAJzPpilD2QHDn/N1dnsYwAMdKBpGLCeAOaZVxUEtq9PSCISpngFbJSTBavCAAYyQB43aLYEtFRksQ7wUNvlsasp4CxmnbBCJMjQCqwI6AgelEetFnMNtUVtBkxwADnO9QO9fa3Wcnrb2TbhgYC9YBUUQC0WiM57//0iAGHRAF2TnjRuRlXjaI/azeWmYIDOzSwmhdA/KozMb7NiwAXah4EPPACMYJifEdqb3iZIzwjgkwICKGABUpomihRjAF+VQkgiBLi/TeBcEQTQHNhZGC7MuW8LIMAyFsRrrZu5sIg/JrsJ5xDCSFje4LIzYgsP1gUctqFbCQBiS7X4xplRsRCch+Im7A1t8F2CaRCXAoKpAFw1NsOPg9C3HkMhbEAYmxVEV1oWjAXBJkAyEWRCk5e8DAHrQYAGAvARj7gAyk4bkpOdsDIZ48BlM+AySDjx5TCP2ZwjaKqCWyA6u2WZxkQQClGMYhWC3ITKIshPA07ZwBK0uWVIW/8zFBTWg5N5aSqEbkaViTSeRGtg0fgVAXMWLAJBYbdmgB5CXvKsIKYAKpREktUDStLoElD6aKSWdBGMnAODxVlWpW61XygAawTIGqol0FKST/CACvRWy4HGEjiQ9xAImMMcBtFTC3it0d/q+gnnuoG69jOeAOR6NQ09i20gcm2e1NrW1wItcqEdaOiBIxUQeE27z5HtGITbBuP+NhWI1arDkiAaKqkLBDBYrnsvRd/ewPa7bc0ADbMAAqJZ9g8+lG4RiAgV4jlNAtxdnImbgOA0MKHAqSCqOL3AVHcaASvCRQALTOCLyWadcs4iKFQwQOQkl4GgeLhhjf8ATMAQ027/UYNteQBgzya31Jtc7gKYk3LlSzCTjM5rIxypgAE0V4ma8+yAHyldBA9gOk+cvucZODXXSuCUOnayoRJgWyAY0YYFQB45WJyJ62u6Otaf+x4CxGc+9VFRfvAskrA73QRyVwXdGdCzu18kyCvwoyJKZPgTJR4/LBr8F85DG/W0jua6bUJMH0H6qNRG9F5g/AzArpIMh5o9UYe9FB6w3Rwg/BaCKvDvcq97KFDbB2kZwchSHxviF78J2ToCNiKWMuc/fwl92Q7cA2bA6jP/+k8wkgrEvwOzopVd1gc/Eoaygk73oKlPRf/3i38S0y8BcimYjF5rELPbSyT9K5cL/8AC/9hWfsCGAlpCAMhWA8G3fQsBgCuHbYNREAFBNZ5wFTMBHgFwEuM0AOvRF84QRkRWAkRDAJhnA0gxfwoBgQLXdAkgZgERGWYVEMlAK6pQANkgFGDmAHwRGQpwSihAAb1XAhYgdqpWKxilgrqHbTZXAPMwRB54d68BEf32CpyxDFeBKsfHGOEiezfwYoDBgt+GbWJGAfKQIKlQgPLCg1WYCvlhEygwGZkXLkZngOenFWKoa9jmCsmgARlhbDWhZhjIb44RAAMiGSiQfSrQGRQygkdnhguYD3m4ZsSUERRweURiEQxAE6gAEJPhEFchHjQxAeNBfSVAfijgAOFygETQf/85MYnql2yg4nwxhwKwCAPU1XYTcYux6HH74Xz4twK8CAMpSBHD2ItlMnYqcIylMR5eSA3MiIw04BoBo4Q/wBx1GA7RCHtmliXZKAIU8I1V2FNn5X/DsI2ip1ZWuArf523LaI1AMGBltw/omF59wX6/AQHzsHB0diDApwsTgACKoQuFszIvUI8wwGEBKYnwCHtjIRkAkQrxABC+IToaoAoMABANMBLltGoIeGLsOF3V1Q4IiVkrc5HnAAGGOHL9pg7YkCc7hwKoKIwNOQS5RZI1KXoKEACdxhmRIRz2oA4FWIU5lQwHmZNC4FnPmAkl2VdmFn1P9xoaYJTHwH7x4An/knEQORWM5IKUQoAA2CgOTQlWtCIeERGOwBAUt9AAncaWqLCTv/FGOKgpXjkEBVAX5lgJYymNKZB81cgFAyZ807CXfHkCaHmUXqCQg1mXhWkDkYaYsTeStECYjRkKbAiZX8AKQ8iUjFmZMsBxmDl6zjgLlOmZM9mVYwCW8VcKpVmZRkmXZUAXd4gJrVmYUAmbZRCYgrcItcmXc9k6ndkE78WZnqkE6IabZwAxDngIvSmNwhEswfkEmmkJzYmMj4mcaTAteTkI1RmLpvE8baCakWgI3al+oImda0AXFvcI5Ql+bAGccKCbkNCe1/ea8BkHy8ee0VmcKnCb9xkHytkI//RZfEOJnnAQAN2nCAOqe8f5n1G1d9tZC/vJnyjAfuBpB/A3nnuwoLB3nQ5aB6uHCBw6eB4Jnbo2olinATpnoBCGoivHe/AzoWHwEkSyYLspBi4qcIJ5oX5wkwVKgvtnBjmqa/5pooAgDD+qfIQiB0MqaYrYITIaBkh6YvmmIG/QpGvWoEb6B1M6AqHkgSM3D0FaBljqZBYKpYHQpSbAk6iwE3FQpv2lktyxlGsapWCgpi70pnZanDNXc16Bpn8ACxHnACCXPGNqDXvqmX2qEnQqc4maKnCaXgmoEjUZqcVgqbN1KQkXofwmaZiKWZrqEwz0qG3yqX2lqY8HqHpQf/+20Y0msR/uwQtXSqqFqalIaaokcjwAET+nAB4TYG2baAy06ps1x6mO2gcSB06uc3KbKaTDKo2TIY7viKzuxk6ZogATsJ5rgKtgxYqqqgfJOgJ816mldgoampnPKo3n2pfpOgXhaovQk6RnwK3gR6808K4hCRLa4IjOSqFbYK8yUIkGsXeoUAID4A88cYkDYawG1a7+Gpo9BrDFJ7FNwABnNRONulAO+7AtQLFMsDI0NwDEcaPSubEcS5OjwB1hV3Ng4LGi57JMsKgUIq0gZbIny66lAAvhApJYALNY57NLYGzhYrNberMaKwsItxN4ia5G20xE6wZagjTyuK7u9LT/TXuss/CessmwRgC0Aue1AuZUVJsEYHuiVhtOe5exXXu2TkZ6mbGc0yoOqtmsJXu1K8B5h4ci9gF6aou142BWn+W0dosCWhdAjNJ1tQix4TC3gju4JNByhmsCVsej7QC4fYt8bAtWKGcsBseicguG55S5CvVvzfIsS1m2W2C5oeu43HYDvvaXCyGQCRqzoutKt2Yy7oizEjF9cLsDqLsQj+YDcIaaxiiqS/C7CoFmPiBlKIsTvGuctUtFSwYETda8r2i8R4C8+RA4dbQDPAavf/G8a9u0EkYEvhO3f3GTRaC9ldtgQ/Bg+QoY4isE7MsO+lU+PFu/Y7B8XGu9D9td/0SAXuDbItS1o5h7s8FlBM1Vp8jyXv0bvw97WkYgWwyMLAVMsgSIwdeXWAH8RvqLBg7se5Jjf8XZVklAVhWMMBdMA3jreSnCt5UpVahlO90bW3fUW51UKR+sBiHsM363dTSCuBrsqcdUSd2zXh1VXi6lrNELCStMgFMXuY5TJ4n7fBmlIwCQWopkALcEALm0S0qsOkwcPurZQ5srAyqnflcMFNE0Tb1STdeUTduUVFM1xuEztQuyLOJmurG4xt8gT/RkTwCATyOgT/TRT2FcxwPsP1t7cA5QxDXwutdHUyAiAnaFJ4Y0UbhDx79kxxmExyLRYbjbu/0lw5hMUszzXf+0o1KMwlKJbFI63MSXsHrBW2ke6pDuixBAZQJCZQBEZVRI9cokgMIlsMN1oLw9wLzFx8FDcFkpDEfT+wPVW3wSXAQUXMyyfAncu2JDjFkJXAQLjM2uVL6OczuudQIp1QE1rEg8q2sA3MzStcgz9F8m4MoVcB0yJk0SQMjf0819db9EwF8QnEEArVT/ZNAsINCiR88OVjjGDAfv3EkH7TiXc17xrHvkLATnq7sz9M0IrQLX4QLhPHg6hjmU4r/+U80fzT2K1EYXgGVS1M66Fs0+MM0cnUHMbFJtxNIAUFUA8NIw4My6h8w8oMw3HT4mrALelMXxcR+24xmH5GYmQMz/3CjKRyN7D+0GpswCPO3TM/BVxXe7OmBpHZvNk0DJLtDVE90COxXWj1wwuXvUw/dMZcQrXo3GZp0TpJsufKy4muPHQ+BR6nfGMZDGsJtBgP3VtAPJACWNkPtyVIzBWd0GaF1LdO1CWtzJtfrDhqsmXvet4bPVInBIAsA8ueRIV+XLypHZJADW0Fp4eft5K3K54+g/SU0CL30AcsIBTRIBEnAhEbAAXcXaI0DVjem26UHKAx0+zKxJZ5RI0jQCHfAZi4QrsUDcjHKojovS4aPSPd05S93TF0BH64Dd17zdoB0+Ht3TRTxZIlA7FTAjeXTdNjUCI43eRes/EX0hjUUC/wtwAUaFK291VI5E3xZN2+48vnBU0Owl0+5Jt76b15PA0O/rz9+2hfQr4ZOQ0UGw0ZVZpEEw2W9Q0kDwvY35pDap4ZNA0z1g05VZkiIOB0RdMMpYmWea4u1Uy1ftr1yZ4Qol1jlA1vxZojj+428NL3HdmNSo4KPLAHoMcH3trzDK5B9F2DBg2BSK4UUOVo9ddZF9syDu45nK2YD32TeL4vXWXy2MeC8823Y7ljHeB623MSQ8uDee5p6q4lTU41vuZHE+DkSO51mq5xm05NmbMZuwES+oAq4aPn8uDlN+6I/bKVUcyoTOm5cePlou6J1axaLzno6e6ZoT5n3ehjkiKP8yMUOPXg1ovr49cxAJMnIiW221PXwqSKNgtgIWzkyEKSywniOEerAD6D+556M8SzSid+euLs7rKNd/Q3x4ehRLOnh8zun9MIDiMSjL/exKGO3A8RrajVmBvux5HgN4+qUJEKZW+m2GjgSrzgfQDhI5xKaCinWR7u6iPpndLu8rEO59tenkPugwUO93WajwhHWkzukRm+8p0+pUvvDoXZrvvqEMjzDK/vAoNvHDUO0B7+e33iW5fgIqyQ0CN+4Y36IqaOwVepEbwe78qvAZv+81cWKV3mP3TrYVz5oyL6/ZTrPdqtypkfOkEO8z76Wo0KrAEKxE6u93IfSjQPTy6rf/a+bwkl7uMODtHJFoY8vrJqvxeZB7BB/sHkgCCnuCmHXxVS/wTSunHH/y/eX1TEkhB7LrlAvxTSuzCJ7eKH+1k4q90Gu2JwTyW+QeGvDAoU0hqfr3Vh8wopqkP9gA/WD4mhOqXe/0xHn1/C7taOfzroSqkl/3MW/umV8CfkiuKGardbv4LnDuR29sE0CKlm8Jl5L4xxv7lwD1IKkes7Zm2cL5B6z6LYD1B+etEEb8iq/2GuKmBX/0JKALIeikNQv4+E270j/9x+/x1l/71Z/9aY/9MfAW5iYC6T4C428CsaqPj2EL6wETeb9ycH8HuSc6vDBO6eB08XA+bGlthkgP/ywBAtBQAERwkoC6sq37wrE807V947mcFKdfJHRC22loPCKTyiUTVrw9NCwEYPAIACCPgcuhWFEJ01KzbD6jbQrNgFAxbATyjaFCGGi+6dpz7/8DBhJh3ThQtYxYADAUcLEUMLgMUDTolRRgCmpuCjYSXEgsxCxIXNylcAL0pbK2ut6s0ohlDQxAVPUMBDQCTNTyOE5pUFgwhPm8JivXNFZ0iNosdFSMpMYuY2cHXstYBKkUjSBYIPCyKDjIXJFpt2NPfAgYCXxMcHK75+sb4cNAGIPDUk2FORa6VCC4JUUFhVuz9kEMpICBgQhIIhhgYAlQv4geP7Lo+EJELQokBv8CKAjmAYNaUh5YGMCA0EOQNpckcLCByQYH3zgSuikUpMihRj3mlFBGgs9tQY9CbVc0KlVs6JSaYboxzdSqXv90/Sp2E4OdaDZEAvt0LFugbd+6mmDAjwF7fsLCzasDr96+RhJ8sLgnwgdUaPj6TexkreLGSQbI+yMg2GHGji/PQIx5M8EKgioYNqOZc9/RpB0P6CCoA2XRlk+TNg3brwIC0A7ghrYBQ5kFBLY2kT17rPDhcDVcWEFATgXeBg6YubDwTHHjVatbHzsAKzsOc58DoGOAgwoBBjzwFuB9w4IL4CO4R89CQuvgr7Mrxo7fq23lKiR4AAB45C1QQQQdBIj/AXkEKOWBBxFg4BmEAETIgm9c3bdfaRlqqFgCniknwAbNCQjdAXR8cIAEGUjAGztyqDBLKQbUBEAFP5WhX4c26bjjUAXMpRxuKzzHQQbOmTiiPLPASMYGF1hUowGhMdGjjxFZeSVRZsXYwnMiArBABgdgIIp3L0YmxngARFDjBhzyA6eWX2U5J5aRdcnCc2KeN6aRBhyJZpcRwlGjAHIKUaed2ii6aD4B4KnJoZU5qlejlTIaqSCTUocopkNd+ukyAXCpyZuUispWqKm+AmQqU6LKKp2eyirUh0lgsJME3M1wY6y1UrUqsKn0d8QBczU5w4W/DnuUsM1qsl0N3nlA/x61vB0LQLIy0IchtFE9+y0gyNFg5AIRSMCBB+dWsEC228YgnbfiGhUuvXvUBk0M1a7gwQXM4Yaspi/4BlyVtN6Ljb0Jo5HaDOCpYEAHuB3grsA0sLbHwgwjsTHHTRQAYgwCJEehAAGGGcG7A7sAmsYIf+yKxzEvAZkM7WVggDwb5JyByhfLMNldMNNsDdFFn5HJDQUE5gdhVOZ4NNKCzDz1Ck8oPYNcdNn1stX6VP31E12VlQZabn3tTthWj43oVWdohXbajEo9d8eEhJXUUk3Jbfeodc+tACYGC45JAYdcjTetOZWKRE84Du13Nmt/2ghKIelywlZt5zBRRRdlZP/wvJIrQ/mnTyiwxS6q3Me5DvCwbAM9XVMNOOkH374XIYwAsE4AmQewueJDNPPMDdJQA7VauSdjOqZFJJBWEQE8YDjiAWFvhCeg6OsCKaZcvonzko/vaBHmTN/68Eis0cYbccxRxx15vFK+3fbbWQQChvSCRT+u40R1tdgF5GRmO+bdDYE2gIAFLHCLf1DgIAGIyS9aAMAlpE8qB1TgEPBXqUM84BaZWR/u7OdBsW3QbixhAO1icEElZJBuHGTFCe/1wiTEcHIpnCEOakivGyZQR1mLEw/vscMiJi57Jdwh1pRHAx8iDYrfCoBdepRDGJIwB1Kk2RZl1YAGAGAcYOz/X9RYZx8lavGISBzhGpXgQFUEowHk+CIG/cfELPZQjW1czB6P8DsAoANHumiAF7BoRtwdUnd9XN4idbA/ElCghTlRwATSEsQ7ojGPjfTaJnEwAQqkhH8t+OQiWpgoO54xkWnsJLNYGYPafIEB05mCAwqAjjESUUdA5IMeWdnFT0USABqwpAuGCQBCim4QqsQhHmHRy07+slIFMMQjZSDLXhBTkbpspjJdWUZvyuAgpJTBNKnAwlxicpnOBGcq2ekCBgJgkjQI5i07aI9tZnKd7jTkPltAx4PQIJDHxGUN6FjPCaRzNNFk2EIdJcfryeCPOdgfGAdgF2QOlJn57GY///34TNLR0QZizIEvVAEQFZQUox7dKC87mkCXHiGkNpim4PiGkJlg86UK/WgjG5q7mYxjlirICQnOSUR1chSmilQqRyJBAVC+QAPkqKc9WfpEni7Sp8Mqxw8gKgN0FECqXl3BU49ZyBvQkaIoPZpWxdVWVqWOABmIA88I8IBkGmQCRJVBUHMqUgeAcZxmRYBMk8pUfR4WBoSEkgo6QAACPAmwM0AmTmcwzSAYlQYlpSkLIqlSwyb2qqF9QQM+wKsPPPYDAODABwjqgi+WlA/GoCo5C2kBoYK1kpocLWhD+7bGCuCxbvjPWRVbXBpYNKMzwKlEWyDVUiKWt2yUrgoeUP8yADj2sTlzEQAu8AAZFDagkn1iJBJAgAKqQBe0nS51I4pV5iGAAIIJj3Chw4I2jdUI4X0BWKtwH/Mm4LPubS97eVuADLCAA9rV1wEEcIAMODENyX1uRLmgW9ES2IXvzR2pWqAyBgs3AxteASER0N8Z3Ba6Bc6wBUdMOkitAAMGMABv3BWB4ArXxRkNJg1out4XvBVaQTYfl+zgBjE9dgMh1rEKSmwDUu63xSzmI3UPvALUEiBFwnWwgyGciijDQK0YnrKUqRtfwWS3A216rGrYRID8agPMZSZzSJjsN+uuYAHQ4MAG2tzd74plyMMS9KJ+GwMOHPc6dp4hoRdVWvL/wIC1rlU0nefc3sXOVwXwGS9xFs3BRjsqrnMVUQbsileogJpVqT6NnEeCUBTAmdKVTmI/nVwDMTd50uDV9aM8fTsHCDfYNXIlj5ELaBKLkga4xpKvSTcBYT8Wqq40aC1pIFY60nELTwZlYcsBBhwpYCOGA0I8BzcFCASAfikxXBAS8A0EoHfVoYY2AUQ47aZQOAZEVSshE9BXy3ph2RogQApUsgoTnOAWVvidXRLgwAKIgAQID4DCC6kSWtOZAtCO9R4hwD+AwgCnsc2CIS6LYimMXAUWoB5BKHNwRJAgvirHURgQwfKLW5W6DRC2tMHJEnif1wmR4OwKfh6AbFqQ/wtEH6ox0pESlz9l4gongcPjifQS+GDqAxBcfZCaYQsE297sLGtzH9GUynYWlGhvAYAXsZYJSIEST68zCwiOiSDIZADemHsvKmh3co+gANXrurwrNXDhcnyRCGDAd1M8hRQf/QWLf8BeJeE/pBdD7981eNRhvr8goMMgEod5FUQA5GbfLr7Rdun+ILD03nHhxC5ovVidqwjZMx0h6eB83UmfEyo84NjVqFE1ChCT08+6uo8V+z5z0gDBOjm5+gasFc5RbemzAO5kbcA0azGABEzQ+yXwvj0G8g8EIOB3tbjr+GtR/hTUAvnJN++blfpFMSN0sJNtAK6DaWuioN5P9f+cUlER9rSaBV0U/xyg2gTg7UAA88HULg0YGTlLAyZfzEighuUcs12gdGUglbVV4XVgdnyg/IWgBd4EuvnACrJgC7rgC8JgDMrgDNJgDdrgDeJgDEIgZ5SgC/Qg2KCgTQzAv8hBERrhESJhEirhEjJhEzrhE0JhFErhFCLhBXTdZvwg3XndR4jgHgyAfa3RAVwhZmQhrZ3gp3zhHomhcZRh9pwhpqRhG63hcLThIb1hpcRhGI7hZdRhHeoQGoIhEs3hbPQhNwEgIKrhHjpGIW4gRHShhAViEQ0ibAAQD7AguZXZHTpKHqqAuwwJrnRPK+TKEERAptVAJDLBJJ7G2Fz/gfvAQRHSgR3owjf4ocIEIUhwIgAcQAWIiIE4Dm8Mmw5kyxAMo+xExq7UwEMEiRmoYmxgAQN9wAVwQChaCAdcwAcwgAo24j48YsNE4jDGQZi4R2S0Bxx44q584jGqzHJIALqYR4s4iGCYxwWIwgFYI3gIAC8GogTM2DGqy4OEiXl4wDL+Rz92onuwRz+qDJlgxYGEx4yRxwGwo7YUJGO5o8QQoyI2huBZgM6gIrfQCKBp4qLk4jB6gFKMSXjIA4usFgbQwwZIQJPMwnO0CZnsYsXwojQkRzieiXlAiGesyAFkWsUAwEkKCHt0wE7KAz+2AFEaJUtyAAZcwAVUjBwQ/0ZjJQeBGEhNAiMAAIi7eMZNFogp2kAzboYCDEAFQJoQcAA1FA6q3eJHlOQH1MFORIgcuAcGINgKNIlMRgx0zMIwgke2xIMciIFfFuMK3FgdyMNgzsUH1CNBsol58KJeskBfyoNR+uKJGECKsAMZeIB90ZhgfiQNmOVlEBJ7IMEC9ASvHSIcfiOyBMiDUQwGJCZm5gl4BGaQOGYJUAx0IKZkRoBaaktjmshc7OZ9Eacc3GZkwMixyNhqBYpu+gfEPAdpCsFpNkYAeOYSHMAHxGV0kWRsqoAHCMACfICLlEnTnEuTdMBOtMlflkBkyme2YCSFFGeXPFhT7uW/lIguzv9FSp7JCuxnd50ne96YWTTJGygFmIgJYEKDGLxnmIQlb5bmDGhnYjwAiTRBhBybUHTjGZRkkIhJi/SMPPxJRTRJgRSKfArAXGFntiyAB2RABgSIXwqIAfDKBeSMef5ntuilv0gmj54HiuZMRUTAdrkniPAJjQLnXJEBzmRARFpodmpkXgRAu5xBgYTnmG3ihSJQhupFabmIu0BDmegAMsZYa4FKl0JELvKQmMIFOoDhd5YMxOAAvBxAonlEiJoBnM6QnL7FAJTKsXwOePCjzqiAd6zJAQwkPeZnC2zAlcoQbCYiZkCAlhLocyTHYIrCSUbIuSgFBlhEUkaqhVTADnL/o5vuA6C2wHoYAZjKwG5YCG+o6QzcqhLQap7xxq4ygWSqgKCyhQWsZbB+B0ZAx2LyImFMTCciSM6caoIpAo+wqj64qmK2CzXeALDaAJ5SyE7ACwyE6xF46yh6qxIEo7CKBQQAa7YcgHsI5XLKw41BawY8w8rAgAGoaq8hYgvwI2Plo4Ml2Hm4yL9aRDlC6rzG5H06amj+xz+KgsTEI5s0KIpCpLhOJY2xSXzUmHtAasPal3rAQcQgCECiy38KJHc15aPW4z3a17+mK6WKBQPwirFGTAXgRn8KQCmGiRj0B1OOq7asXA4SbdG2IMh9qb+uyy565ZjMl7qwCyksrWd4/4BqRCUZiOVWaq1FjCyCHKVOAmhxhurJvsDJLAAGqNaEVEjVtuRwlqIvEgB5sK05mqp9HoDXKggMkCp2JYdPVgjUxqcLqKtXAMYLDKNEQgeRmmeSAopSSMAbuEe0ssB3XoHRWm7RRtiO5KLDCohtSqa/AAzn0tgFVItgiAFpdoBzqgbEqMlxhq1VfkCzimtkIKp7iAHpckCpqi472G3Y2u2KtMgoPCvQiAG/fObkyqxXBMB1acIFVGut5KJ1BoyXTExuSK9XXiNghm2J4Cbr/uhc4Cu9cmukPseTRMl/ZC9uJmdv9u6J8CIM2KvFRGrr5klTJm9VDECxCgIH3G8n5f/ihBbI9vIlypwLAIelCoTj6VqoZXbuf6rL977uzh4sk3QPjKCngJBHfNpXHDCwxs5Cn0Gw3aLpmThk3YkC0KaJSvas4fZvVBTLJiwLJ4TbUI3b4fAAJtZA4eDI4azAuJ0aW+SilFKpC/AMoESAEGvLkYqCArtojdLukSKJ7woM47JkhVzmG0wphbzPYSpxEmdAmgAKpLLvd9hjz/CGqc4H5BJvmPRjzDbGrbCCrxiRCqAbTGjOwpUVH+gCBQCaeQXFxGUuEMuqJpwrDnSAny1BMN6AfDTB4FKFq7ACrMxxDwfDQCiyD+4OCVzBtB4vagyyIBTyDZxnGVxyDTSOEjj/MricMrqasp2tQkHgQQ+YEpXtnSEwwDf83WVca5i2sLPETnmsRzkmK8eKowHQo0QKQM26AKeIz1PA8hVU0g/D0e98VwOAkgbYxcTp8ieTTiqj2i+XQIM8SIWoLdVaLakSAJnMADNrwitXcgrkXzw5HZBVjx7AhExMaynrRS6OojaM7xGUo8oGgq+Gia0qM/JuJzgzSQpjL410V+nWb9C4sjO/M0PcwuKlxRpYmijdcic3xoi2gz4LwQWohraW5T/LQLmCKzh7s7Ossn/Mb3gwloxkr0e/wKncAwUpXSW3hFF9nyNowIcmkjWvADbbdGKAtLYYs5lcLAYMZGRcC8U2/9jkuqwuhuzDOsgCmEebMcjIFrNz3lgEMKr+giybVIB/rkC6TKxSQ2o7Uqy26CO6THVZawusCkjJWsTJwshY2+9GovRCd8maaDACL4lJ60kgJ8MwTdAtUAB6dQhI8ySNtcvJpqc0rNa6DKe7fICP8mVFVAiO0u2YjKVvFqVqpGQC60xbiqpyvu0R22sg0q1SrhYZh21Qqsxm7+zWloDcri5SJsfKjG3NtrRRwDEMADYZEIqSJfGMicKLvvQKyPE+FE5Hz7LmkmdhBhez2lcFbIBTEiHOJmZ5pDBou+5/7uZdkgxyalrsRmLqlsfqRmJvYjf9umuQDKN7a4tqrK/rrv+MdgtuLx/FC2tCDHsEgJ8GSKczxUwmtEqDB0CmxFCM/LaAX5L39lIngNImbnSlpr0oQXZvfLtugg/JGNtspMLIfktxfopvX3+0/gYC/86QA1CABjg2DoD0fZLqBOuiCozJyXTizyxzCk9o4PameSPwM6SnCmw4zxJ4B0exnrgujhcleTBlgQ6jk7MDCJO4Veo4Qm8n8wqC885QsFlACEnzC4D0jNbog/RMg9SoWRSxz4R3TLOockOweYexKOgloCyJprX5hDuxfEJ52Kq5jeqiGkeMjhbji35xjOR5CE/xn3u5h6gWJ3xA5V5upmv6pnP6ptMbAbCQa8LALgOLSJf/pYEbBc3+ooDYgAQMbafDeqzL+qyfwKfPYg6Qeq2Y+imi+lCwKxJcOA3oKw8FW6gbQa7fznBDBbEqC0I291IbeblwMgeVOQSceThxs+Qo+1FkqmEDAFTmisVG+82kqnQhOwz4qifWJgv0sxEQNESgaRls+1HYjN7upQrM97iPTK/30bm/AJ7eWD7+C6/MeQ6E8kmbikCjMr8PBZ3CQGKKOHQE+8Pz6WHlInwQLMVudbA6CM66QCEfi1bzpbvco4IYMzB7tcQCpFcas2BQCwdwgH3ZY8BCR1QjbCjOI6kSczqWR8a7tciWDMYLbA7M+1GQKcEgqJRPvAug7b4uTQ3H/9O7BUE5WA8SPCBO0M4Mw8XF80aFZG0p+syDfjwqZktK7qffmlZRKkXclvbXmupXMq25oMuAjodtA267sO3VrsCTUEjudr1n+CXekoduNghKJi44PzzD14umvuqRHjGNGvrSo+oBncAACYTFKd2rXzuVJYFKXP0Z7LofwOmMMHGJTOh/eolozlhtJwcoxHR+oni2iK5TF6vWbi/o5uO7QjQLQOZ82G5MA6+LXLgcMHDQykDRQ8WGKjwSeGg76cLm7XTHWAH4TcAWpEACRNAYBUADWBQCWH8Y/U4AUAEvpN8NZ4E1U4AecH9jh9EWPEB+Yf8AgFEBmMAtxL9QAUIumv8v1looCAgCABgHiZZnChwG+WEfKZIEPd7ta+4qaeqhOpdNx1fqHJYLgOTyWdlSm0sEcKthSYdNZdTTiVw4lvl8GJzX7Lb7DY+/A1H5+/AJ2OEBPWlQMKAQCFDAUFCQYIaYoKCwNvEAkNAQIJhgAaDAoIAAiAUBQEGhgAnwoBcgScgg2QcwMIGgIdlAgaBggUChAdCgaLbZCahAkJibMLu3fDYgBcQBEHFDpsLxApDxDLSNJPBVtgVQo2P0Q9axAbBQMX5BgrFeUdF0kEHjQbIQsbIxgmJAAjwD0aYBSCftBoYm136IEbDgQxN/y9Iwu4gxo5wGDjY00SjAQSiNZl7//UH0gFABC31CTRgwgJKeBgMarHGAAIXJGxoG9PEpbicAByiIBnogCcCrT4QooApgocADCg0enen5U48ODRNIYnTGAkMFAxuoYeuxIcMFbWaEpKg27aOWh1gMqG3Sg8yCtRmi7c1g4F8RgAEBpLUbQQBgAx8HGiAoluwNdpIBcACcIV6YMhIyeAhcUY3X0aSZKRhQIdpFDhUEldbpB1YBWBDUEGo2eygbHSSEqkJU4JEOobxvFCBgYeTS2YQGaACeE8IDB7lZ/EYkvHfs13DAcm/zBA5vjBWufMf48YLAPRbPu38PwUJhOxIMJHdvUnYhC7ZFm3lgUwIP5KRALykM/zBSAkKtlNMkQflxA1WFUFDIAAjct1yFSlEIAC65TaAHBMCQwCAJihCQ00omAgBBde/90c2L5YmnUXgvLsOXOqHdyONrEDDwwQUcNGbGAhxAwcBI+MX2CSz9rYHABAUEUBsAtLCQAEw1CcUiAwMwYNNwEE6ipSKEJCBShrdN4CUnAXhp4VBWofDjlza92dWbA1AIVI/e9QhooIG2J2ihzCg4AAFj+SPCBgZUQIBPIxp6EQWTUmpHAhxiKsefnH4KqhyEhkqqGQlMCVMfiZTKTFesvtGAi6+y4KlXG8SDQgTmmSFAQNi8uNCs7Pkn7Kv5FYtsstzVSpJbTqzHggT5LP8w3mtC3KrsHcRm++mx3H4Lbhy1RiBBr0cY9phqvXoQT32g/YDCEk5w4IEHVzwmgEERXGAAu9KUGxAG9V5xwJEGYHDNO07gK00FF4wgAcH1riBAwtmOGq6h3mbMccewbHNABQewc4Vf5XWQD8ItNOGBQM7WQNYCRABwwQUj3xBBPGK1IDI7EM3ca84fCNTyygC0vEAGSqgQQXlNX0EA0dAWi7HHPW5sddbK1lpNXo5G0ZkEuCb2KBjPwHwCGXOR8IQBZnHjw9rjjEA2OEKY0ME/AhxBV7JVa/0e1oAPzirXZxWc2Tle5Jva3PCWkdcLa1cBNRKROy6OCE1HgzY3WpD/Ew6yfxPOneCkn46p4Z6rk/QBwV5jDwkPP+745WsTlJDlaUv+z0Ox0wyGaiZgcE8J8fQt+raov2b68s77CfLhSferzWV2xbNWv2an0LnavQMQWVm6x/2949l7MIL1PyiWQflaJP/8d83HT/93zNaf9ej4MzP//v5ndL//ZUx/AoxD/wqIwO7EKIHcIiAD2XDAB0rwQAucINWUZ0EIbieDHKRVBTtYKgeCMIIgRGAAS0gqEXaQhCj83wlb+CkVcpCFMMTfC2tIKRlmkIY4jN8NeygoHVqQh0Bc3gAeJoIkKnGJTGyiE58IxShKcYpUrKIVr8jEC2AQhkQs4ukg0Icw/4pxjGQsoxnPiMY0qvEnPlmjG98IxziKUUlA7KIX76ixDeKRdHbcox9v1Mc/CiuQgixkaQhpSFIhMpGMvMgiG4mpR0JyknPQIyW/JclLatI6ltxksgRXHUdoYk4aSYYn75jJUwauk7x5BQToqJ1lTOBSquRiJ2tpLFbCphCzoUlNnBSAQVBgAAMqRAMeEBOaJAUCjwiAMkmAAGTeEpf/SyU1mcfKMAKlD5jARSiQUgAENMJKrriESEQRik8QIBQUCMUhAACiaz7QmvIcjeCMgZJUBNMBz4llhzRAAS8pZUwD1Y+YMNEHZNYzgfRcqEbuuctXKEBPBQUAAzSAAEJwKf9DYjIEcGjp0Po1NKSO1GUs+yBKBNwgAK5CEYvUsFE9qFM7CHAAMEBK0ueNNKd7gOhJg9mmUGwiJvEhJkwJytFYJqBN0+QpH5vq1KtBNaqe3ClVK3lVh1o1qxrkaj236tWSTDWsjQQrWXd5htxkFDir8gU34wAdFBSISjlZazjPejqz4tWnE4UKKtKZEprIag0E6IMFFPGjWGkgEyvpAwNchVfA6fWsPkVBk66Egga5QQc0yYVmU+QfVERWsmMd7UNNatnc/HIPOoAALyCLgttogiimtdpkyVrZk+iWtSw9rEm0pCEUVKu24bptWHOrn1MYiAWiJSwiSODaFBjHP5v/eCmYiAsu43oVuU1aiVVWhRXoXqpa95nCbRBw3bpuEbuz0i5X76mldFanAXAixTGnRAIHkFIcckUmTLpSAAfA5LqxLS17OeXerCLSAZG4xKa8kiXNHhhZCb4qIhFBCwTEijQRnnC2KkzVR+L3NV+CiYc/aeATY1XFhgRxVLHG1uey2JYz9grW2MhCesq2xqBysVNNZxIRaaASOkEABGxxC2AKk5g50VSfaGIpNkBZEVAJQC/3ZBMeF8rHPAWyHwbAEo8WggGw6ApAT5EScT7iSjZVhi1woYszvNmzPwoOfb2p5S2nOM8p8PJupXMK+U7BJLMIqBosIKWcOMWwgxXF/1OichsJ8VnPk+bfLX9bHZvStkkr9cNFM6qGQuPEOXE1A6kRAerdVhpQXM6pn5OrFJbo1hZKaWl0bEOCQwSAQ7hg0aR2Dc1BkFkpSUFso1dNmlaT9NVN0oRLYQEnRQw1AUVVaEAfSwI2fekR+mWBtjnhJAhE00sy3TOy5aDskPIQ0KrOiKbOPUhzT5qHFphTszOyYXjnUt98kDe/8Zdurfr73/QL+EINTnAED1zLCE84pRqOSwsQYOIEoK3Dh7jwGT+A4gR48MXnmXEWQ4Djy/14AR3AcY6bvBgUx6nJ6zeBlE/c4wlnwMQz8XIEsjzlsEx4zAmQlJwXkAIyl7DDG/8w8Z4LHX9I5zjNHT7x/S59fxKnuNIT/qWpI1ADHDf6xVmq9QKqdOZLp0TYC7jxdZ597ftLwMS9zva4n44BT5e73QH3yrvrfe9ymJIc/w74wAs+jMfOs98Hj/jEK16MhddpYLAI+chLfvK9CnlkA/B4ymt+85wXgQEsn91/gFAAoKes6DtI+gIG4PQcTD28V49C11eT9RmUPbJhX0Lb7w/3oy89bmlvQd0DHPgTFP68iS9B4xcc+WxYwhJwZTR4LGFXK1iAFHKWAn64jgS6ihcKrJ/9vEmgCdZ3/q7ioPw8834ZwUoB+MHnfCZgIP5hmT48PrIA6GMfBRgQgWrm73z/GJF+OsV8hJVE64EBBCB6BvAwZDEFJJAB6yEy3BMYHvAO78MbHUAAK9A0EtAF+RAySfRBZzCAPLZ+e+AsB7GBTiAAF/AF+cKAScQCMRiB8FINRyMRJHAZHHAkYIBEBdgGJbg8J0gjLPAw7QA31PKAPOME+cA9/6ANGIgCX6Aw71MPv7IMQjhjRCgHKUiF8fIrKQgQJ6CEQgAXDrMeboEXIwgHWphXQGgGCigC6yERifMDO8NfNOMF54c5FdB/macDxBMRXPABS8MFLygAbMgCbqhiXBgHziKIM8AFYfiDM3gCETADMdiC2JAO9EIDEQh9mgiHa8CIhOOIbbCBz2cZ//mAECUAGH64hOtQiLwSGAzoDs5XDkfgAarRBW4jEPZgfntQih52im/gLOawi5MIEEogLykQgxXgMszYAdiQODnoBGsRA0kQgBcxjJI1itJlhGORAUhoAhGBK9Uihi14AOYhhQBQAa+oMLnyNtzoe8f1jW3xDO/4KApzg2IIBErwEWb4AtPwGEMTLTygiG7QjVpTjITFAtaYOD0gA02Ajt3wPpizBcSjDzPAAeaxMzeYhfW4XfdoifxXPIOIBLTjjM8gkAehI544fiQwM/4ojCL5SSRZF4+xAZ4ok+ogBJ1BLY9RGOl4elJoDiSwi/awGPGAB0I5NW1okwqGkwCxGP8bcJRHEw39uBhYSDstaYcAIBEdII4XgBdbKYBRWSwNmUALyV5qiUBsaVtTWT9wSVxuWUB02TF2KUB4aVp6+T98mTF+6T+AeXlyST+EGXpngAG4kn/8d379VzFv0RgL5HyT6XzQNzLhJwDjB4Dmp4rrUC7Qwg/exytoGWLAt5j6AH0Y8Jj+J5mkaQaVGS+XGS9EEgHil3/xt46fuQChmStSECOIiUnAZwAfQDC/8gG/soM9CA8KKFwG+A2qIYeb2ZyidxkeKAAt04IveAAuKBBigZ0Z0AQCYJB5iALC+XtnUJzHiQLJiQLLOTvg45yxKF0i0DhYcIDV+Z4ReADZWS7/LjgG3gk+0Nif4jkO5Tlc42Ca7UWcLYgETzAjj5Me3/CcZ6ADDWGewIOEYLkrH3GD1VA0snMEApAW9EkDC/pjDfoO1QCh5qGGskOhJvqAGDpcR9ieHaqMORqiNDOiJZqhCqp6xOkC/IANu3iUiiE2KVCH5+iQB6Ew00mHScOUxcMCH4oNBNAYDZGfCYqe9qieQwqiHHCkoKikUiqj4jAz+DmHMGCmv1Olv1INWPqevEOdXIqirMKFJtCdejEDGsk22BgPntiKCVoXgPERqbh9gqoOIAmGjZqH3pM0P9qlI/mle/oCg+in15gB2aioZ0oAdsEYNkCbncqoOYoE4wGp//dgp0H6pSVQH06QnG7Dh6/qgnaBhIRKDfRAn7U6jtIgiW/qqBHqpI6zmav6ekLqqi8gAbFKALP6Arx6qw4ZMocajrbqq2gAp9ggrEAzAsVKgndaKnmaNmOBlSRgDjE5rBB5PE06jfSpriXwD71pqtWQnfowgTWQNMZ6buLKMy+QjIZxBOg6M++KqzJ5pQ/5EREZr+thpfhgryeArxmgr/7DryXAGL+qkWJpF2TJky6Zk/OxhDXzsTvphB77F49xLtVAPB+gI71iF+qiNxO7ahX7GCgJPvegsXfRsQjxqY8xNbwhsj1LFjvLOtljACmLDSvbso/RF+EgADI7fLEHrv/LZpjxM6k3KbX6Jpj7c7UUVrXP07UW9rXOE7aDNLbLU7Yvdraok7bGsran07Zd9rakE7fhOreEU7dUm7UCtLX4k7fqdreD87c9FriAM7gHV7hac7gIlrhZs7jy1LdzObWhgnmdZ7mXi0Wfp7WZh7md67lMpLkCdHiLR7qlG0eNx2Oja7qry7plhLp8B7uxK7uzS7u1a7u3i7u5q7u7y7u967ufklEIFE0xgQKmxAazNGGVEACKkACwtQfi5DHQmwJ5xx3NmzFc97rt9h479hoP0AuahbyEem+1RUwFIFjcmynOex7jSxLWaxLWhL7KwhJBB2VVMRLMlAuiNbwbNLz/A5Jv5qsAYIQgmkIKxoRMVBZmL/UAjxDAliAio/AITrZBCoBMQmUBzQVdg1BYoeBkveAcEFxbmAVNgWAJBhJMwUTBCEIix/QJAdwbxDQpvtQACBAbAWBkSEbDztEbNNEV+asHKXy/OFzC1gFd0eEI6eQTE9VgsnJkIFwAw1RMEqwJyBRl8YssS1VTJHBnAXwbgIBe/fRO8YQCvOALlCAaNbES4cQSs1BO4kQUdRbAt6AiaXwhNsxmyVByABAVuyBuF+UixGAMjXBYyhALbEy+WRZbe1xvWJDEe9xOSnEJjKUGkTAJiNxNLvxOhlBms3AIFyIcNsELXzwbjpxOsqAB/528yKlVU6EwXWgWTpZQCjhnWaYsCeN0x8pQCpMgyeEyAb0gIZIWXJ/wCQilCsQyFVVBAvWWC8HMHEd1EpGmWqdyxs2sx4mWAllCInwiKzNlJbDFFOvFVePbxbOhA9g8IRXVyjgRDPyUG4D2AII2zuLQHLNhzk+sH/EMG2BkKU/yvgSVWhpSaAKFaHfFIsjUyuBiAV5ywbAWz0xxCIzAAtJBHeTUy8ysIZiGz4AQz4Qgapp1G/NMK+TsT7plxV7lvSwQzzrw0c68BYRAqBMlUEOBJiQ9zfKsBt9MIjdNzbA2IbeAIHqgUX7AJf/MChjF0QCFE5GQHSU9K0sFTUShCv8m4tToNRu/VFM3lQIfogcXEmcb7cxZrMnd3CG7fM+4ZlEuos4B4MHbTM4pgnOKgNNKAXdX5V0kIs26xRtp3QsLctMJIlePoFK9IWtljdfZ5sFZpteEzdMWJQmnTM1gh84hrSEuVSW5cQi/VAzBxS0VTQJUMW5AEVAB1UsCtVRfsh16Eien4CpeHWt28gcIMm7XxdrX5rz01Qo5Mb6fgCdK4SXarCGmEFn0BROkkNIoYNvFxNdkAhOIPFRJQgLF0CBxrU5fUkzC7QsMcNuKPb6PnNkaMm1DTdMswh/Wht1dgQmxcNAglMptAHEsoAF5zHbstln6Jt/sPbkPNddht97/qPi7/e3f/w3ggLItovQVgQLOtWS97pG9kOBygNJo0gsqEC5B1UK9F0Go53HhuMTU7PsGvHHgbcDhPOLhZ+C+940l6htJe4JYSGYVllBMkIzcYfQIU7YGXKwVz8RLLMLiHWIJNsxLr2TjWIDjMH5rfZJWUJwiLNzOxJThmlQbCzxmDvzCluLDvvYczKQJI1G/x0ElSgFdxMTAAgzflgVQpEDDRWa+B6zFKv7joUDjKRxlvoBlXB4KeqABViEiLpwqDTASBXLkTGbATfLkgI1MyM3DwzsbLvzEgG4oZ2Z2hXwl8UQT8DQTtlEAEKBfcxZni+AAFKAV7FTnMkXLp5AK/67AYC3S6Z+OTpQu54WgaFdny+UUy75wC91NTa6VUYxVbxeSAI4+w34MC2GG01vMTIG8Bbg+x4osdX8w6plMZpbgxrQOZzR86pqOC8ybCcReDKtyAyctJ4QATgqQ1ige65A868ieCWT8C6AgCqRgCmeyZkEnKD8iIuHtAGF0A/feBzpA1Y7GaGnlH2JSUDhtcVDtB7Il8PoeADcwUWDWSQHN0hGSZU1OSRQQzbfREkkCDE3C8dQMzPwVIRdf07ihIe4c6iexaFDhd539aLMhHYkiCogM8rpc0BftB++sx8sO8ZFt8X8gIFRhFQLf0qEGUDFtKAUwAbKG0/j0XEyfG//NdWoEjdIB/1OEXRwVhfCx5PS5cCed9GlBPQWcJk8dj/FAnfQypVppryH3dvVkP/KmttOa5k+AEPU0/GXPgWpKvQVsX6GA0PNgr8u0dgZfH/HJ9QkSLdKRXdSpZiimNOk4rcMOEvmItSnA1iGPUO+xRfUFpSZqICH2bBJZP/AGcirDJlp+Ll23FtnxFNjXxBVjHVwMkACOf9NZ1iQSUiVR7SDPxhNdcSEWbb6SjfGD/QpZbPm48L68dho2kdm6fyIN0lpgltO1ZllRoQl5TNmF//q/r9UPYl5qkP2UItyyT9i7gN0UYv50hwXRBk9twm2kJPqv0PnKTbyhv/nFf23/FPIAvW3nIPAA4whZwzMAQTASADIMwUvaN57rO9/7PzAohD0YjAag4BgwWg0GMwF4qgaFUeGUIkJbAcYE8EIUj0kVwAqgQG7qAlpBQIwCJzNgAmUoWCQ9k0LCycRY0cwKmBiJQ9sZgAKUFATDiIaIjQmKit8imRHSlwxdTecLHIDm1hBrq6tNAsXrbBCFFC1uru4ub68vgMUPBOZKy6/rg6PtMXOzbsOV82yYdLX1NTatgsaPhQJJZ7aOQvAItTh6uvo6e7v7O3y8/Dx9vf09fr6+fsI5NsKtfQIHEixoMB2qazX6HWzo8CHEfAEaoMBCAQWdWIgUpFiWkIRGbgUo/1CIBqEByW8IAgyY4IjiMjIYCxAIAEFBm5Uz6OBkyS0i0KBCh84i0IYNgATfLgFwkAABN0FJg32EZOGpBnIKtKaZAFXEhBYQVKBEQA4BBW4NlBIokADVAy8ishRA4I0o3rx68ZZqAZUCFGAT6pZIcQqNpXMajAXg9kaFAzqoKMS1U+ABhQbfFj1ywOhRmmh7R5Mura8vAAYaEKD6G3nCg2+HbYTr5OcxZ1QDNBToTWeYgys1UNVYlFCN6eTKl69DPSeVimgM4CCRAxpLuQQJKqWRgnv6FE6yYCiIFlaMZBWZk8g6Lpo5/PjyeaFWpd5ImEEtZ9OGIutLEyPgth1JaG8AwocoA9DxxWAqJCDDAFK4Nx+FFVq4Dx2pEHMhhx16CJQmCn44IoklmngiiimquCKLLbr4IowxyjgjjTXaeCOOOeq4I489+vgjkEEKOSSRRRp5JJJJKrkkk006+SSUUUo5JZVVWnkllllquSUrIQAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic showing pathways (including significant cells and cytokines) underlying early (left) and late (right) phase nasal reactions.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from deShazo, RD. In: Cecil Textbook of Medicine, 5th ed, Goldman (Ed), 2002. Copyright &copy; 2002 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13328=[""].join("\n");
var outline_f13_1_13328=null;
var title_f13_1_13329="Acute paronychia toe";
var content_f13_1_13329=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute paronychia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Acute paronychia. Note erythema and edema of the proximal nail fold. The absence of nail dystrophy is indicative of the acute nature of the disorder.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13329=[""].join("\n");
var outline_f13_1_13329=null;
var title_f13_1_13330="Normal voiding";
var content_f13_1_13330=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78239&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Normal voiding",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13330=[""].join("\n");
var outline_f13_1_13330=null;
var title_f13_1_13331="Treatment of lentigines with intense pulsed light";
var content_f13_1_13331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Treatment of lentigines with intense pulsed light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Facial lentigines (A) improved after treatment with intense pulsed light (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13331=[""].join("\n");
var outline_f13_1_13331=null;
var title_f13_1_13332="L2 lymphoblasts";
var content_f13_1_13332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphoblasts in acute lymphoblastic leukemia FAB L2 morphologic phenotype",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow aspirate from a patient with acute lymphoblastic leukemia of the French American British (FAB) L2 type. The blast cells have more abundant cytoplasm that those of the L1 type. The nucleus is often fissured or indented. (Wright- Giemsa).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David S Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13332=[""].join("\n");
var outline_f13_1_13332=null;
var title_f13_1_13333="Lymphomatoid papulosis 1";
var content_f13_1_13333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Lymphomatoid papulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDuHk8xnDbT/ujAz6ihI/LUlWA3HDcdcdPyqPaMZQj6dCKkQgqfvOoyScetcCZ7uxGxKuAv8Jyo65qib1VuD5Z4bPBOCK0gqAfKwPsP0rNubFJpDIoy+eeazmn0NKdupct7hZYdpAJ6hscipFXcRzuXHQcg1HaKI4gqj6g8A1MqAyB4weecdxVJNolu2w0RRxlcAoQMMw5DH+lKoVIiMtsHO09akBPDKoYA5KnoaYzEbcbcH+70H4UxXuM8zH3eg6+h/wAKmGNuVA2/3Scj8KqyfK33CjMOlSrIUYrjaOMoe9IGh4HG7ackcY7fWgkqQQ5AxwBT8ffRSI8gEAmopNqkKuV981VxBjJLqV9GCn9TT9kYYNnk8Fccj3qIAhQdxCMcZ6Z+tKJFz/DxgZ7Gi47XJQFLEP8ANgfKV4P5mhP3TBlBDDoSMA/hSO2Y2EIyGOfu4pN7OgRmAIOQD2/GgRL/AKwMQFB649faopGXaQ5bC+2Dj0zTgq5GDjHY9TUcmCV2uTt/gY9B7UXBbkDqhxtJfJ78Y/xqxHGQmZcbDyOhB+tVyUaUnYu0+vGalKoA4GdvXaCDiki3sPQqhJVwoz3HI4pXO9hu2g9Ov9KaGO8BjwxydrdcVEz4DZyB/tHJFO5Nhs0XyZRjkZHKnpUKoQzBmAIGU2jv6k1dh3Ficlt3I7cfWmAliygsiH07j3oauWnZWIrd3aTlQcn161KrbHJwi4465FOdAMYCsuOueSfpUcsfzBmXHy5AUjJpWsF7ih23r93jkEf4U92IIJViMcZ4P4UyQgDGMMPbFNEny4Jxj+I80hMlkYlASG3AdW9KQZIJUBj0JAxxioZWLn5cc9AOMClDMFQYYkcDn0qria0JFODgLuBxwaikaRGCg4GOVzg0rsJPUgjHzDGT6U5ncrncenPAOB7UySMnbls7iB3JqVCGKDbn074FQs4wAQxAPBHFSAgKFGc9SfWhuw7Cttx95uvUDlajdSzfNkhuM59KTkOQwBGcjHpTjyM/OcZxxnFQWIY12hXBCnjGecfWnjaF5zjbnmmgEn+L244FDEKzEsP55+lINyUy4UKGwTgEE5B/CnAkgM6HjuB0FV02gHaOc5OeB+dSq4IbJK+4HWgQrbWZsPtwMncOtRrs4wMN04PFSBwU52g5+tNUpgndtz0wO9ArEgHyAFfxHU1XkUBickHsD1P+NS/e5AGRjGAai2glRuBA4oYLQNxZQAWIPQ+9BBJ2EYcfeHf8adGvzLyeOQDxxQDtYFt2T0OeaB3GoVwcN3wARSMcrjcTu6A9qeuFYuSTuyct0pjhRluSxPJPUUAhFOwgYHy9j2FScYAPJPc9PyqPktlAMnAzmnKcHOSCc/MT+FAxV27sZXHTJHShcEM2d2OF7U2YLsOSTkdcetNycHkEYzx6UAI+S69Rjg+49qTjDYyMHAOeooB3Z3cA46UudwIQcjINMRG23cBggdiQQSaYi/Ic54zweafOpVgz8lfmxjgU70HQY780Cb0RWkkBOHzycYBpoYD+6B1yadIAxUMMcYqJwWGeMZHzegoC6ELHBLKSMc+hNRSOAmODyR6VKcMHDAHIOMHv61DIAqgnjnt60ElV8BT1BBxyOfx9qryyZByCBwBVo8bjgZPOPxqjOSQckE4+gFUkK5z/AInuBFp8mcru4Jz0orF8dXSh4rdN3lgbgfUUV7WDppU7vqfPY+rJ1bLoe57cBiSD33ZpsjFSAuA3Q89al5IxgZTnpwRUIZTyF5J+6eRXhn0UX3H7SOGXLDkY708lXzgDPqetRzMIjyOQfqR+NS28w4WUNsJy23k/hTAPvE/JwoySD+tC5LYBBx+tOWMyyEDG1V4DHBpvlckS/IRn8falcBMfvNwfjPcd/wDClLfNwMs38OOOKCu1SAB/vdwKTAI6jjkEDn86AGAM2U45GSD7ehpDEGXcNxcH7p5/Wnq5U8gnHQrwfrTp9jLmM7geenemkg1uNTbIih93A6ngj2pX27FGBuPU/wD1qFDg7fL8zuPakYl1OwdePp+NUMQsNqLtAI5bBPJ7GhmeMkptf1OOD+BpGbKEFRkDO5hzQG2kb0XkfdbPHvmlYBYmAOzLcAEA8c09uSSmd+ckADFQ7tykMwznuCcfU04EOSfu7Rgbfur+NMLFlJGYbZJF3jojDr9KhIODnhevTr7UiuC33WbH96lXcFYIcHuC2Klu4hrKquSoBGOAAeaasUbFsKV7/Q9xViKNpFCE8ryABx+dRFWk3bcbs4LHJzVWBMgeLbglDj/ZNHXJblM9fepiVRcYxg4IYcE/WmqIyc7UDdOT8pqWWmG+NSQEyq8ZXjmo1mVM7lAU4wTyT9Kft2gDkFunOQacWO8hMEHj5RgZ+tF2FwIcnpgEA7cVERmYN5Sk+g5zTzlJNqhvlwSAD+PWno33FK7hzwByPwpXBaEJ804B3bQ3JBzg1IQxj3ZfKnHTg0gj3svAIwcKx+9/hTl3kfecjPyr1/CgGxCuQX5buQPSkb5QDlgo+YBev50Ou3OMZU8nGKMxqFG4s5P3RxkfWmkJsriQAlEJKk4ORzTwCyNtTBHYcgD1p2VDE5P+0Ow+lOVN3OSMc5xVEkUwZj5mWY8AZA4oGNpJA643Zp33hjC5JzkDkf40/wAtmzkdOx4FSykyFcqV2j5uo3c5HtTmkO/AOW9RxS4IJGN3IGGaj5t4Vhhm4PYUhoGkVFAUAY65JOTUbfdwoZjntx+NSSYVgCRjGMqMf/rqKM43bs7sZAIyDSKSH7AeORxzz1+lKSUyUyBgqT1+v41KFXZkEDkHGOuaSXDMQMb+w9RQK+pASzEbTgnofWnxltowWZ/1NMClGIVSM9qlwwA38E9x/nigb2AlvKx1bPPGNtBVWADfMB6cCkYDJAxgjqO9M3Akh92R04oJJUb5SMAkc4HFRgcn+6eRxik3lOCflz6UoZPMPzEjHDDkj8KASFI65BB44P8ATFR+Wxxyc5xg96mQu2cg7e3uO1Mc7AcEFQOme9A0MdCx2rgnGCDTukagEcDjBqNmC8bRy2Ac0D7+FwGzjigGhGUxkkElh19jShSckjPGeBUoXGeBxzk96QsSwx09u9AXIWQ7flYhvfkinq3yDLHcBjGBzSSsec5APO30qKN2bGQOuffigW4krEtg7sj/ADmn7yvAb+Lr7+pqIg+Yeuccc96YFfc2DjByaBNaA5XOR1BPQ0yRiSC+cHilbBYt6dhUchZpSF+bGeTQJK4rsRliORzVeZ2zgjLelSqu8Lk1DO2+TAzjrj0piIJXxnHVuM1n3BVYjjO0nFXpPuD+6D0rNvnCLIcgBRu9ulXHXQzbsea+J5xNrE4zwuE9elFUdQl825kckHcSTRX0cI8sEl2PlqknKTZ9P42MMOcY5wM/hUGV3b9uzHRuQD+NW8SSt+7HDZ24XnI6YNVX2biHLgKTkdlP0r5tn1sBwl85Q7glick56mmsuEUqc9M8dPbNRSEAEeneljklZCoDY6HaODipLsWV8sRqZFOTnHP3v8KeVLAlWDOvRW6H/wCvVONJCh9AehqxGw8zDrgH5ThsYPrQmS0WhIryE8xei4yAaYY1YJsaME5zngj/APXUYnOCjFcE8HvmpA5dgWVcng4HDe+aehFrEQU8IzdPuc8H8ajkLkbGIwvTA5q1cFmVE+QheFbtj0phJJP7lQTk/Lzgd6LAmV1bD/MTvHBwOcfWhG2lsjaSOp6N7UoIYN8pyvTsR9D3FRIrOu9zlc/nTuWSugJBQITgArml8suwJI8wjv0+lKMEgK4cHopPOaVZOMr8rHggnJP0piIxGFy2/GCMAZw1PVAswdo1aMjJ7ZpkgJLAKDzk84JxQ5DKuCzBuTx0Ppilew9RCpcbQgz1wev4GlAIjIDL+NIdh3AM2FPGeoo5Z8Fgy8ZyPepEPEhYHewDYwDnpTpP3iEs3yZ64yMfhUWSshBVufU4zTk+eUA5BPIAGcimmNIjEZ8wFHDDPAH/ANenGLa+RhMdT1Bp5AYOu4KevIwT9KiTcGGzKA5wScUhrUWCSRUMEWwxscj5efrnrSBvkBYYbtg9T3zUceXJXY3y87gOQKVWQljGOnY84p3HYkYB9rFnB7sefw4oMiKB5TsD0yvFBkESluNxOOcg0b2EmchmIPG7P40h2EO0uRhth4+Y5NMYAEnHX+7wRUpDtkM6M2N2cZ/yaZLFtUExfP1PGd1AgeVhEEQHDDI46/WqYO5wclSDgA9BVtkKnBC7uPuH2psZJOzG7Bz0zgmmmUmkCq4cIRuI4x6n8O3vT3I2gKD05Oehp8jMjHzDtwBjvjj24zUbAEHGWJPIxTRmOR9m4FSQpwG9KkR1J4zsAx8w4qp5iAghx8xPAHT86m3AblDgjOclsfpQ3YdhkmSxwAq8Z560vCjIQ4xztP608qUUZHGPm47fWg8gNhcdCBRuNaESAfeUqNwAJPUCkUkgHBzjJIHT2p0pLMoOSuPvEdO1GCy8lVJOM46VDKQqEEjLfMegxnNJu2ScsD9KVVJ5UgY/SgKVYgfMp4BXjI9KQuohLBBjdjOck4pqld3cHGAAM5pyIXDbSoHQL05prfI/8KuCejZphoIVO0BeM/d9KG6ckr9eM0RlsbiRtJxjvRIFUHLbvTsaBERJzknA64/+vQh+c4Bx69M1MqgqBxknuKe5IxkgD65B9qB3GjI5IJOO3b61G4bPQbR6j2qQkSEHrng8dPenbcnCtgDgHbycfWgVysYVDFsg+nWncOnG0Y6nk1I7EnAyOOBjimMMjnK88AHg/hQF7ggCx4yPfmlZ1jcDahH9004D5SGJAbrkYNRFvnJzj09x3FAEUhU/Kc49+KTcDEVyM9BxjND/AHxtHTOSvfPShVXPuO2MUFPYYcEgLkgYI9zTvu55yc9v880bQCUOQMYIHU5/rUZB5C884HFBArsM8k7v4RjioOVDDOSeh9BUwCn5l7jGCetRnHQ9D3oB6CcGPGMg9M1UY5JAx1wTj0qzM2FAU564z61WwSGLYHpjrRckr3DADIIyeAB25rnPEMoi0u7LnAII471tXkvzFunJx/jXJeLpwmmMACQzAcmujDrmqJHNinyUpM4RxuJz34opD6duxor6NaHy0r9z6hEwMWFONh4Uk8e/1qB3ZJd33ieTzk4qcAnI8sNgYwRz9TVPzNkwIOGU5ya+TbsfbQRYwZSoBVgRkFTn8DTo03NiFWEoJztGTVRZPMVvMBWQ857VYtsnKybVOAysTjI9KEymrEkBVduxsPjseD+dTI2RvABLHBGB+lMj2gyJJGMY5xxj3FPQZYKdu7oMHGaoybuOYgscM6eocZIp0SD7jnjruHzD647U2RyoKvlHzgEdz704GMKS65bH8DdD60CEGVcqzgjuQDj8aEBXn5guQeFJANMYsNrBlZCCWUH9KYrRlMLvjbjhskfnRe4NE0jCRtpJDLzh1/zxUW0gk8rgcryQfcU9id+JGGT/ABEkg/jSzZwu5xsX7pJ6fiKqyJuRGQof4eeGwB+eKC78NCgAx/DkjP0qVoywBi2sfU4z+BFNw0eekTqM7X4Lf/WpMpDAW27VjZioyUPGPpTFJ3KyFeO4b9KWMyOxI3kjqDwfrn0oDgsVx8p5ypyKRSFL/vCFPGPmGeG/OmzIoy6liM4xig4Yrv8Aukd16CmvtXc4BI6HJxz6/SgCGa82/KShBHQA/qaWKZZCgQqpHRi2QT61HNCtyWMbhSB3OVP5VEkJWYEpGOCuSe1ReVy9GjUwCeWGDzu4GT3qExso+f5ge+7n8aREIOCvI5yvOaXzBtKKxDZ7kZNWSrjRGNwxv2jksc5H5UqjeowAw5x15+tOUbtpLvkdMDkioZJH3MQWVcf3e34U0u492KkiIwAbLD73BBNPJA3EPtIwcAf570iyCTbvy/HB2gEH6U9GUj5T17lc4pDeg8Roh+cKW6kZJ/D60pU7gFYhc8nOcfhSAqg4c7Ou5lxn8qf0JbO7uQW6U9LGbImHGRwR2X+dEihinIBI43DkU7YpYq5H1D9KbH+8lVcnOfUfnQikxvG1x+PWk2sAm09O46ipSUzmRA6njOcc/hSSkArk5JydzjGf/r07ANHl+WVBw/XB7DsTQxKsSMOp6jGMUzzBgZCsVzgMQKkIB2kKuzn5h24pMdhxKkcKSFI5z+hppUOTvUAcZz2qXeu0+nQfKelMA+U4wRnucGkIHQbdpKxDA6c/nSbAFzxnAIBOCfenRMQ2TnJXPAA4pshRhxzjgdx70MZGdqgHaWJPIHOam2jgAY4PGOntTUYEjahCn8QBTw2GdcuR944PApAxj53cgHA49DWdcyEfKgLr1zjGPUVoPJgE44JwADxmqrIA/HzHr16UDhoMDSAoWK5Ax05Bp3zYOfm7DawP40MoU8+vBzmlEeHI4LZ/h4xQJu4IQRgkqx6EHJ/CnEAPnJwR0xTXG0/MDkdc8CnkFQu/aGyDnrn2FK4bCBsANyu7PDU5nL5CjOBz2NDBmU5DHPByf0FMdXweu0+vGKLhZEbOyNuVdwxTjkg5wTjpngUZUKGOMYxgDNGd205GfcUXGxzHKck4HT3pJXwMjGcUOSDksCoOT60At0UZHXJ60xELAH370qtgbcjGM+v4U9kbdkZ+gqMgMcrkDAJx3oAi3AEABQQOTg04gFhg54zjtTzuJyxxjoPWot3VeD7UCGc9V+gNLIMLtXGfXvS+YOpOGprschs89Nvqe9BLK2G8w9l5wD/M1FKD8wHJB49vercqEjIOBnOapuCA5XGOgz2oKikzLv0zlskr0XPpXF+MZSY4ATwc5X19K9Bvoisci9wNxHpXmvjB/wB6iLwcc+3NduCj+9R5+Yy/cs5cn05xRSY9qK+gSPmmz6jljkIG/wDeAcc9R+NUpFG8gMSVB461bwA5G5dp4yRg1Gir5gYHO3IK55r5F6n2sXYrRod+0EkfTmrDYVwW2njcSgIDe3tSMjqGaJjzwRt6VIqmMkTIfMP3WJ2n6470KNi3IkjcuwUDcvUDJyKeEYRlmViw+8nbHsKiVgoAfDD165/GplZMndncRxj9BzVGTJVmUwqjltuchGOVb+oqDdsYtvdMHgjByfpSsVZN0e0YPJKbSp9B6ildvOB2BgzY3EcjAoBIFk3KMgfNksT0b8KiCISQGYADH1PpUscKoQhILscc8H9acY2jA8wkc5CsMH/69ITaQqPlSpClugBOMfhTZmAXJBBPAIPIPp70hYYDJtyOm5jz9KhaRBIzYHqS/HNNsFEcsrx7SQCpOCSAR/8Arp4JJyWY8dHPb61HuRVBGTnqOgP400lcEowGf4WJ4oAR8E8MQGPXdzSeWI/ufOp5461MVKkB1VAcEDrzUSsCpHRunPGR7UFIdEyyROGbDdn54/Ko3kcKoZt4HQ7uRSDIbdHyyjGMdPrTslZCZFdcckAjPtmgdg3b+m0ZIzwM5HrQV+ZiWG4jowGKY4/dkghlJPH8QoZgECoSeTuVl6rQFiWT92gKjGejJ6/jRuSVvmC8j5Sy45/Cqm87txZWHHJB+Wpy7SKvlEMOuMEgfhQmVYfkR/LMjZJycNiqd0W24RHLNypLA4H07VZBD/K0a9MkHPzH/GmbVKnYNrjsy5p3BSUXqUoXaM/PkgDjK9PrV9WZMgsFz1AG0VGqKHZWAYYySp4/H/Cpd6qj7gxGOmOPypFSkmOQM20DkA4HJyT9O9OJOdhCiQccnGaZGxY5HJ5U87TjtzUqRZVixOVHDEHg07GbsNYtGCccHB+YUpkYsSZVODgcY4+mOakmUrjKqpIByhDc/U0nDRlCRv7A8bfpj1ppCTK8gypb94qjluKozXC7mXkuABjbgY9Sa0JIgVXq3+zg4BqhcW6yYIVgcEFQcjP+NF7G1JxW5E864BRlIGPWtO3YMNzls5yOOv07Vlrbsr7flBH6VqQ5Hyg7vQr82fwpJlVWraDwxHKdh+BPvSv94kEEN/s80rDe2drZzjjj9KeiAHkHpnO3k0jAi2sXwEVlHI49KV8q21F2jbyQxJ/yakiPZmfJyTsHB9KTcTgFsZxx0JHpSYyBzjjJLd/elLFhnrnqBxil24HCknHGTUStlgOQMEhsd/pQMmAzjaAfcVE8KsMqrcnofWpYucbuB97n6U6XCj5gzEYw2cCgjrYgIAUruyp7UYJJwF9OB1p8eMKcHJOPc0/y85xhR149aAbsRogVPl+8c7jg06U9+CPYZ6/1qXOMBucnjBqGQHGQEyTwtAXGA7QxA6+pxzUczkqxUHB/Slmzk4Iz0OBxn3phiGQT1HXJJqdSxwBVB8m4kcnOB+nWlcI6nIyMdj05pcqAw+6OOBzn6U1w2cbl9ABTSAHTAxwvGOe9EQxwn3dpBNGcjJGR2wcnOaUKT8rLjg8460wFHyLlsL6e/FRjHAOQM8D2p7Ehl3ZXjOCO1IHVcsVO4cDPf0oJZHIDuJHO3n6VAQAzMOTg8VO+C5J5I5FIwO1ieeOuKARWbG/P3j9KRSgYLwGHQ1MxVCWIA478VTtZPNVsAZU7d1HWwElw21CccHjNQxxmU42qRkEDFEmGbqOOoPenCVlZNg+8MAjsKS1lqVa0dCtqAHkT4zvPU+vFeUeLiPtyqW5VRketeo3zAW0hywODXlXi5s6sy4IAUcV6WB/jfI8fMtKJhN7dKKaGz+B7iivcufPn1OwYgHBXGTnb/MU6NwcYZXK9Onf0FTHCFNr7SOh6nH1qu7biWcgryMjv718mz7NO4RxoAGZWPzfMCvP5inMofBVifTpj6UAtGBkOcnPp+tODLtZlchs5II5z+FAEMrEq6oVMTckHpxT1U7ANmCB1DZ/CrSIJoneRZggGd20EZ9TUKO8aSfvNh3diQW9vSgL3EDxj5HUsSN27IBH0NRsyAcq7kHjIwR9akkxKqJM5wvIYg4z9RRGscrH7Q7bAMb1+bFLcYwZVizqNp/vpQW8kKyOTj7rben4GnKoiyQxKjgc/5zSBImLMwRiOChBGfegLiRmLzME7SRn5RnJ+lRbAxBCjcPvD/wDXUrROrkOpOBuUjnj+tMADAKAu7dnr19sHvQAzaACFMiqW5JH3fwqUhpFbzCGYDq3PHsRzSMzFiHU4IwQHx+BxRGXWPB8xlAwPmBKn270IYzYqb1wwUc8t/KoJAxh2nB2nOc4/SrDJjOQHUckEZI9uaWUx7sxgEey0DRUB6huVA79vrioXmIcGQj5ecsDmrke2ZnAYEHO8sMkemKoXiMULb3XGACB8pP1o2LiD3G0tuQKx+6R0z+NQvcMspB5Kt94Z6/hVG5BZSiMxyecYw3+FMJaMMuDuXGVORn0+orLnNowTLpuclSwAdemRlevcmrBn3AHAUkkk4+UH0BFZcUkqMjpHvwcNtOfXPBp1uwZl42s+SVJ4J9apSKcFY242ZlH7snPJRSenrzUsSqGCvgL6nP61TgG1VG48jg4Jyf8ACrqv+8U5V1BwdqYGMfzqk7nPJdiSeHb90xyDouOij61HIXAQMWUgdewFWVUMM7s54Uls49sGm+YxA+fa5+7s+UfjnvVMhMSPu2AXI75J+tSLkA8q7fdxnOfwFRIxCFCQN55Jz/MUrMUwUhJIHPQ+3FNMLXHzyJHEVXdnGGBXGTTVYEhfmBPo+cVHIu1RG+4HqF2YIpsasM/IwPocg5ouO1kS7FJ2yEAKfvZz+NOCRy43EAnnkcH/AApqb848xmB4IJA7VNtwoIUjI5PqaohjPKUIFzwvK7cZB/KjygjqqowYL93/ACKeI5FZmTcdvXcMEUoUyFyEZ8fM5znApArkIPlk5VVBHbg/WkRwp4I2kEYxzU204AVBwCe547Ck2hSWJBA456ilYq5FkgEk5Q8cVFMCclTjsPUVK7c7RGdpPH0qNXQgkcYwGOeevb3qbFWY4HMR5yOnJz09PalGVUAEBAckZ6+1KjBxnjPPI/wpCnyYA2kcnJ9fb1pXJe4glLY+VRjnJOfwoYZzgAA8kY4FNZAQCDhc7uT39KNp4UkAk9+9MLIRm2thUweuc8DtTxIC4AY71PHf+dRqT1zt9VA96QBixJBVvvZ6/Sk2Frj1/wBYNo4BIyDg+9OZsqoIB5wNucH6mmQkCTbg4HJbtTnycqG78444oQWI512EkHjPB9/SmxR7hjg55xnFSsS4Ctnp8oJpq8A4RtpwMdqY+gx1cE5wOM+3FBUvldzZI4PSpCSWyXOcn8RSMd3O07cd+hpJWAjUDHykg+gGCfxpemAME9qdKCy/3RkEYH+eKixyF6AdCO9JjEZQchRz356fSmsihmAY7c4xU4bI5yegAwMU1lBO7gc9KaQiBfv5Oc9lPSnXDhUI/TPGTTnfnA4xzx3qEgsWIQY65xTEiCfJyG+4BmmW6hIdoBqaRQoGfXp70mAoyFO3Hy59KVhvYq3I8vgng+g61G8oR+Dx0qS4Yb8jBPUCqDE9zhsY5pbMq14kesy/ukCnOeOa8u8Wr/xNXZj2HXrXotwwebjOFOFzXnvjMH+1W/3QfrXp4B3qnkZppSsc+ee9FB5or3Ej54+r3ZQ4IAGcHOd2T6j0HtTRhZtzx7Q3zAYxu+nakG2SL76o44AwfzpgRyAWjO0n7w4Cn69K+VZ9jEGxE2U3HP8ACwB579KQkgK67JASeQc5p7kiRN/y49MAkfWmTw+UVZ0Pk8gMGBP5ipGNf5lyqs4YdCeRQs7MrIpaMHGUUYDY9RT3+bBjgZIwvTdn8aVUX5g2WXbwx5K4ouMGRmZQVUMowSoxj608AI53rJkdGKjBFRKwXcFGGxwWGD9QaXzflAZ3655OAD6jtSuKxLxgCNkaNhuOM8cfpUauu8bJMSYxh1yB9DQwKuWJCnptf+fFDOY8KVDDcNrEZB9qAsOBRiueTnkZwPwoBQ7mbYByQSuQv4DrTN7CQPINyL0AbaR9KZn94WaYhh/DvwxGe3agXKxxiQx5ddjk/KQuA349qrtHukzKBgjkjJx78VZmaDzmZJGC44WZdpz3AI4qlfsElbbE0UZ6IrhgD3pNlxTZICHVSNzKOCO9RBCJWGNjA9MZx+VQRsuwyHa4HUA7TS/aV2DazAKOVJ/TNLmLsycDIyzAcEgc4z6ZppH7skRcEj5lOcVE0q7fnKEgcYXJH4inwyoQeSe5ycYFHMFmQTwhwWZlYN1HTH/16pzWyx9GYA8gN0/OtGRo3ZlyNo6bsjNNmjKxooYyIP4k6D2waTSKjJoxpbJ4fvoUZR8wQhvmPv8AT0oiiDAqrMyr8i7uP0q9JEgfY0ZbjI6j8RUqw7hjapLHhkbB49qVuxv7TQS1CIyfvZOeyD7oPatMIqIGnWQTsAcsOoHTiqsUDAl3EpHQEYyGNWZP3aHyyd3X58fjxVx0MJO7JWyZN6xKFYZG0nj8TSLywZm8oejIDjikSM7SAzLJ/JaI0UbtsioBltrZGf8A69Ve5mwiLBtjKhweVK8E0pQLwwwjHoEBx+RqZkxtDJsyA3LcAGgNGnKR4PbocH1FAyFcmUbNpZeM4IB/OpkjzkgfNjI3Htj1pE3TMdhkEnXAUAH8KepAQ4RcgduOfX3pxE2KUKgklgAMYbt7/SkzySz5fGWXdzj6HtSkquPJ3D2BO6nRqCVbZkdCWX9M07kEZAwVk3fNwM80FIx/y1AC9Dg4qRd23CJnC9zjHc9fpUJAZ87Y2GM/hRcaFGcHAVu55qG6kQc7sxsA2HYA/hipSSVk+4pByF7j6VUukMiYQFQOTwCMn/PSlc0glfUrPcjcdjJtB5B6gen/ANeo4rlMqQ2Dgjk9+2KqTRyBjufJYcHbx9KfZxEYVcNzySOM1LO3ljymoj5JL85OCB1qVVUqVBYgHptH86iSMr3wB0z2+tW4wqYKnIxxnvQcdRJCCNWO7BbJzxTSNjlmDE57fzqYFQpDEAFSwUD9KibaTkgA9cCgyIigO1lLnGTjGcj3PpTdpDZQtg9c1OeD75ySAcEU1kyMBc8DI60rFXEwQoIIYDjaewxTCqkhkJ3Z6n0xU7PtRlJAb9M1HIxc5AYnGDjjpzimMiVWBJJIweq9hSjaTycgdh2HvSnH3l5JweuRTDtMjBugPIHpQMHBbGQoz0HpQ2TkrtCg59TTznyyd4x0JPGP8inwx8SHj5Rx70rXF0I2YDk4JHB6/lTF2qDuwwNOjkV2YCQHbwwHO0+/51Ii5GSc57Z6etFhvQglG+IZ4U4PpS5AJIGAepPNSSLxkKT1AFQNleAfmzjOOKYtwZmLqCoPGT7UiKV4LE8ZxT8lAvHHr2JpmFxjAJyTntQJkU6s6Arx7981CeM7gwJ/SrUinHQMR+lQNlMFm3ccn0NAirOvcAZbqcVn3Me1SARtxySPWtGbqAMEdMk9arXCsY8HnAxzSC7RiuMR/JyRz9a4PxmAt5GSOSnNehXC4TIPJOB7VwXjiPa0LNjnjgV3YF2qo87Mlek2cmOKKG9+o6UV9CfOH1UVAh3Bt23gANyD9DT1kAtzGnmIWX5hnCk0w2kZIdA3mKMkbcgD696i8xc5EYC7cEgnBPr9a+TWh9ldDoZWRiUDbRwvH86kjQYBX7xXJVUPP1pq5YfO5VQODgDd+Hem7yTuAhwFwduRt7VI7XJGIwWbCv0G3jA/2hUShX3SYwegKrwff604uJH3xeZt6HcwJH09aeAp3OMZbI+U4GfpQGxEG2sAw2uoweTge1KQ0YUiQDHzMCeg9wetOmBeFuGRxjA2/KyikDyliFCp32g/KSPr1o2HcWQMq7AyNg8biP0NNjQ7eAFJO0HOOex9DSqRtCNs5yRkkBT34pHlCK0LxbC3VGYsn1x60hbkcgdAV2ws24A7lyDio2ZS7bYxkdY1XgnuBmmyMVCiNgTjlV4J+oqKR5Fb5gyuvzA8cexzSuWkO81ssfsuEGAQDxn3qnPdwAbQHUuOQ2Mqfb0FJfeYgjN5BgMMhmQruHqT61lXUrPEwZhI3G1XGGA/2WqJTsbwppl+5umYD96WYcgBvmH4dKhErvDJIkkT+XjKM21l/A9ay1ntstJKrbhyBg/MfcVBOiyL5iYjPYYOefTipT6mygka63QeTdG8Q2nJUpgH6+1TLN8o3ONuNw2jCn/GueaHBXzFO7rmN8n6VP5j28AkSQkN94EZP0FCT6g4Lob/ANs3j94uT6jk05ZE2Fwr4UZUsxHPrWDaX65HmvtUckBRz781pR3MUpUBf3WOD2+vvTUrkOnY1V2zfN5ayKBzvJHJ9zU8MJZSXhLhlOASoz+XWqcJiDAkLHgckpkmr8Z3ncEhbttCFcVojKQjJEtwAo4wMknP4g/0qYAZwV3grzlQTj1ApYkbbkRgKPm56EehNSvburkGHbnupyBkZxn/ABqjNvUjiRYm3B3yRkjODn1yP5VMkxjUgKwHBIPzAc+vXNOMCgnIick4Gcgj34GKiQK6YIxtH3Q2aBXuSs2xym3y8jLFx0/xpCqEq6gfMOCilcEdqSNpFTG4nILEBjwe2c05FG4AqrNgcZ6+ppiWg3BwG2N5nY9yPr61NtXBVlBPT0x+NAwrgqyoAe6/0PNKzvnAwzPli3/1j2poliAIVYRAjccAlifr+FMLMU6ADPI3H+VOlILK5RXQqQNpIz+XpUSAFGBMnTGAMUS0ESySAg7/ADF7hS3f8agICkoJWUtjIx1qR4yiliQUJyFb/OaUph23KWwMYBz9OPT6UhojKNuKtgYOMN1z2qA4LMSADnB4wD+NWGi8s5bO7u23+VRAqzFWCqvovWgtED26feZHyT03daatvtLfKSo7Y5HvVhtu7BbHORnvinJ8zY5fAyB3x/hU3K5nsJDEqgHy8gjr0qTgKdu0M3XA9KjZhtKYwOv3qbubeDnd0O0Hg/Q0XJauPQnJPA/iI6ZoyPmGVI6YPINNV1AwoIccMOvHrUjAgqVwR1wxz+BNANIrq7YKgAkc5zyaGL4PAwOue9SFFxkYXd3AzTQqswViwJyBjnn8aVwVhxcnA+UkdlGB/wDXpp3Els5zzkL94/0oCnvg4+U5oKZBKAAAA8Hv607jIiQBk8qwBwacy/uzjPTqOQabLGWLEFT3B5FOjDbtrKMEd/pSuPoNzt+9j3wOF+lTwFvm3cr1IA6/Wmr97BJHpx1NP2hB6qOXyelUmSyu9sgdtiBDIQS44LH3qwrKJBGOSBjpxUT8Biv3QO3enIyiME8DHHbHNA99xJ3yw527eSPQ4/8ArVCqjpggDBB7fWppVYtnBG4g888UyNvvcEkjpnqM96QNaAxYnPXsMdagc8BW4yMHjrVgg9jxjJIGOagmwAoP3zTIiRxsWwX4zwAe1Mm3EHADYoALMSMemPWnIqqgG7vyfSgpooy44YggAcL7+tQSgMuD3x83arkgxk46HnHeq868Ar8wIyT06UEszHU7Gz64BrivG0ObMt1EbcV3MiDYeuP61yvii3M1jKoHIGfxArow0uWaZyYuPNSkjzZup57/AJ0Up+ufwor6Zanyjdj6nYhZjGwOABxk5pQS8sio6KGzkHC5/DpSJvAIzg9DuPWosHzGMm0LnPByMf0r5Fux9qkTqCVQKWIHITPQdyDmkZAHJzCAwz8wPr0zRJIrYCoqHooQDk0q7QilkAOceXk4PvjtmgBvlxsVW2UqeSQ5BGf9n2o2xI+0yAbxwXyB9Dijcxtsl+QMKD8wIz0HHFRyfMuEUcHlQuDj19KQWuWGBYBfPXIOAsoz+IJp0rrcA71ijY8h0BAz6YpsNwiouwy+aOGyQQ3sB2oIKyr5hZCcEdvwzTEQzAbSjmN+cEKcAj1qjL0UsZQhPBIyR+JrRlQOjszKoHXp83Pb1qs0ZjZVLE4GduQAQfSoabKTKRkxGvmsu4/KXU5GPcdaiuJVNuyuYjtOcNGdzD6j1q5cx7P3bkgg5GQOR9az7ghQrFQIxkjI/wAODSNYu5Tlu5hE580vDkYGSwX0GPSs+8PmohkV2jB58tgevPGatXIhUtmRgrKSNjKTntn05rGmuCCocmPGAXC8Ee4/rUSOqCJ7a2890WKW63PkMJAAM+xqX+yrwu8tvKojBwzFs1c0mwNwodLzCnuxADH0q3BaQKpSeaXcc/6uUKM59OhreFNWuRKo1oYz2N8xba6MyrlyAMAfUVWuJZYh5UsEakgHOCNo/wAK6A29k0b+ZJMrD7u0cMf61Qa2hR+JX3MMY3A9exzTcLEKprqZbwSRRxlzFnqFBy2PepbB2RyMFWJ+8pxgelWfsDibymgMsikNhJDyPwqK5tGtyFWaSNt33JhhFP8Avd6ylBrY3jNPQ17W4JZFjcZweM5B49a0LW5MwJ++F7kHI/EVylqzPO3nDMucCQnBQ9jx1rctJ8ERzPO0YHzFD0HXH0z61KYTp6HQRPGHIMUiscA5YjHqMGrS8YK7Sq4+UgMv5Csi1n8iZJI2kZ1PJcbwa0YA0sjIobcAWypG38ien0rRM45RsWhtbGXZVHzbsAKvtimqRtwzRgE4ztJ/HIplu6CQsVeIkblyeM+uMdKe7HLEv87HJbbwc9aoztqSSLj51bIPZD19DT1ZnQ7gCQMHb8h/lSbcBSmwjqU80Nz9Bzip3ZWDBlYDsCTwfxpid5aIgjkJZg7EyOOhXO73pyllKrgOAwwjrhsY6j1omTcqMpDKOTjOV56c1Hkh3aNPLiYYJMm7HftzTQbokGGQLsZmY9QeV9uajCkDG7CnnkDJHqADUkas0mxgw+XKFnwDx78/hQ0KMNrhD82AXBG3nr9KbENDq3LRqofBDdh/+umSFAcrhiDwASD9QaR12sQHUcZG0bsn8ajlbYCvzPkDDM3T8RUNlRSY6RzgphWyc43Ywfr61SmnwDuXjHJ9/Sllf5myFBx2Gce/XmqckiuMFcDPGeT07ipbN4QuTG4LRvuCkcYYnkY9KmSRNvUh+pBGP5VnEbQA4JAyTwOp/wA9Klids5JUE9+oqOYt0zSTLcbVbAPB/ninbfkZRsOMdOg4qFVyoJB2g9TyB71ZgVG+8ArH8T71SMZaEAQoclR6Y6fj9Klix5TEDqecDPPrSzNh8KW64JxTcEMepxx+tPYnckmwxOAq/N0Az+tIwG1i5LcjA20sch3lMjp35Box8q7zwOhwetPclaCPgZ5POPr+dQSEsQQWyeCPTjk06RtzhU4xzz/SiVhsbbkse2cA+1GxokEhOAQAwx1xk/Sl2hh904xkg1GuWHGPQnP3c1KpwAAuRjA+vvQJoYgxu3HpyT/hQ5Vyo3ZIbJLd/WlzuBb+LHIPINJIrE45B6A9jSuCEdNzk4yD0we9JFgA8Y3DOO3FOWImLAXPOPc0q5YEEZYHhj/KgpEYfcqk8N0zn9KTAjYAAEgAMce/NByBkdP5j1poJYgljt6Y71QmKSwTHJyOnfHrVeRhuBzuIA5x3q0U255I7ciq7kLIQc7SMfT6UEoiZQuMqMd8Umcpnuv+eKsSIOUB68ioSNhTceoH596AuRzAZYg4HXFVHTlm559O1WGJPXmq8xLKC33gBQK1yncYQZyNnp6Vz+rDdE6leSuc1vSKXUIqg8k89/aqusWMNteRQT3LYAAnaNM+We4A74q4GU4q1meMXkUkFxJFKjRspzhlIOO3FFbPji0ns/EU8d1OZ2ZEaObJO+Mj5f0or6ak+eCkfJziozaZ9CFmUIcFlycbhj8iKRWdVDvnC8Z7fn60/b5e/wCUowOWAbIyfaiQb9pJCyf8tDkc/QV8tY+w5hTIGY7yvlscHeeW9e1VkbbNwsckRPAWQcfXNTZcQhd6eUeOQM59u9KoDq/mEqikAuq5I9PwoHdCZRmHmho07lFBz9PWpGjCBWQk4G4kEq3/AALPFDI+7Dybjnn91nA9aereXC+zkfxqwYhx2OKViX5AU3qDjbtXILphsevHXFNlVg6mSd5FHy78Hj254zSpKkgVGDxxg5O0n9AasM21SyPiQHPzjP8An6UxXaK3mFTKYcDjBC4GRUU0oZSFkTHCnDA/QgHpUl2TlWZQpKkAogxj6VVvZt5UsqFlAUlRjH4DpUOVikrkV0nIVim0njpj8cVQuojuMUUi/NkbImz+hq0jcckoCMckfNUZO1zi4BIGQHQMMfWkzSGhiys4yqbwGGxt6gE89AKzzEVlct+6cYGccY9638hRIdilmGcMFIY1kvHvBAcmRuCucYHvnrUM6YyuCQTxbVjcDGThVB/EH3qZ5LiCBcnKE5IIBwO2KqRRXEGI3eRQy5jO4MD6gZqOeRwAGL7hwFxxWsZA43L8eqzNuX7OsjlcKScY+npUNxc3oVWSyBQ4yrAMD7etUd0zIEXeWJGTkED8KvK93GkZj/esORvXIx06VpzXRm4alVb++RsJAsIB42J90fWrS6nOV2vdIMjDJs4I/KoGUybS4WOVj8xEZGfwq0V+zyEPJa3EIAz2xz05HWp17lcqRUVY7mQo8kC4BIdm2Y/H+lT2EzwQSLETvJwW3ckegFOuFWUbvsQEfqhB568g89KqQTvD+7itiiY+dkfIb0z6H6VlJdTaO1joLR1SNlkbjrjcBkf45rStTAyM5kClQCIyhO/1we1YdoMnDeWCfnLPkH0xWpbXQiDASSDdhQBJwD3/AKURMpxuayfePlyIpAwNzbQPp7+1TPMGByFU/dYK2Mkd6rxTny1TH7pmJIZfwycdTUu5WjG2RSm44+XkY781omczRaEbFgSuNgGflAGDzjI9qc+1m3opizgDD54x1zUMZCKSGZkz8pjHf8/6U5iQNwVtuODsyD7duapEbaj2A8s7yuFPOQGwPXI60IgYhyUAOVII24P/AOqmJKWdZQzqvZxGBn2wOlR75Aw4GQ/I25/EigLO5JHtKkb8R43BSQe1Kq5QAKCec7XO4+lGGDNtwecq4U7T68UsspcruwqE5BIySOnbn86CXcawkAlXa4C9VIzj0quyts+WMkKvzYIx/Pk1YG0qArlyDhl8wjP4UxvKO1pHABPzAKDkdBx3pMqOhmSOqBicLleuO9Z8swChsjj15BrUe2fywqgbl53hvwrNlh2s20RlyCOf8aykddNoYsoL7lGG6nFSWg3S4QHJOF78mo4YgFP+s4IIDDuetTImWUgjI75qTR2NSIAIpfLJ6HGf/rVP5mAuAe/IPTPWq1uAqoMAD1PA+lTfIw5OCOAF71aOR7kzqAckDdt64zn/AOvUakAowIVM4I7ginFQu4gEfTv7VGdueM7vTdj9KoklCdxkhSecdT3pu4gfMRjtkdeeg+tSEk+mByVJ4H400ovQ9DjJzniqJTIlTKAklccDFIqs4AbtycetShPlxtG7GOO9BKwqFyGOBzgcH1pM0T7EUafvMEDJBy2cc0buo55yTnv7/nTjIrcjluM545pChyc4Kjk/NSuIYDgBdoA9e/oRSOwViVz0JII6e1SykBmLA5Pbr2qKJW3KH6nlgxzn2pDWpLG5HI4GBjB6HvSE7AQGyetMUkEbjt4xz2/wqNgPOLF8Ejg9jTuNIcOW2jI47U18KWfBBJ5AqVUKhT0HHOaR+Q5zkg8f400xNkOT0JzgYJ/pUb7sfKAO/Tk08ZA+bg8nnt7/AEqIj7wU8gZHPemIRW3BlH38A5PaiYZVfXnkCmliTzkbvenI/wA4DEBueTQJop8jG0D1OewpsgyMg4GOtT7c5Y5wDnjpUOOWJPOOnqKAZnHq+M7QO3WtK7tXvNtzcaLNLMyhiyShFk9CQfWqLfLLnoA/4D/61Xtct4Lu6edNVtl8zBwzN8vHQe1XExqbnkvxNjuf7cM15EIpSijyh0RQPlA/CirvjmxHlkLNHP5eMSRk4Oe3NFe7g5p0lc+bxtNxqux7cGTycwq5YNgsdpGP50jI0xDTDLZHBUfz9KUkv8rKcIMfd7+5oyY5dke8YBDKQMDj1rwLn0wxrcqCylwRlvuYUD1pqM/mYYbWJBJKH8j61djuJCwTfNuHyjEh6f4VC8cnyN5syyDjCsGz6e9Dt0DUlBikzG8kcEfUNsJJ49v5GqoOPlCLHn5dwYgH8DTpk2EMzuQzYYMOVP0PWnxlmJCeSysSNjBen0PSkMcqhgiSLbpuGFfcRznvipJEwoSNnYqeVkwylvY/40xS5Zdq7Y/ufKpUD86R5HhfHmhASM4PAx0J6ihksZIGSCVA4RWx8pGCar+QrADyQ7EZJ3Zx78VoB/NberbpM7gzYILYx0xxUWxtwCLGjKcA7gcfj3zRYFJoom3XeY2zzjJKbiuOnvTbrK/6mSNPl5RgV2/n371oShoyoyDJkAL1OfTNQTmZV3SFmEpG9WBbPbHI/rSa0KTZh3Kkth5SFBO7CblHqf8A9VZ1zCuwgSbucr8v9a3ZkcvkDdIBhl2EDaPYVXljKsRuJh24xzj9c1FjohI5W+DAEwoUVRn5hx9aVdQMyGSZhvGFBxz0xz2rWntSwmO1UG3PysTg5qncWTy7JIw77RhtgJYD1+lJXT3NU00ViMvkbHOBgxEY45yfSrsbvFGchzu9Hxx+FYzPd2k4+y745CMOCmcexyKedaulV/tSAl2Ukqp/p0/GqjJdSrdjZgjZk+QNuwcq57+lSYguIJI7yNopABteOPGfQHn9aqWuqWrriJWiDNgsTkk/0q+LjTJNhlv5S7L821M4YdsmruidmZU1lE0X+gvMZl+8AeD+PX86o2/mxuUkViQflXn8xjsK0LyZpEkiiuMQA71+Ubs9Oo781Xt3kify5W82MDHTIA7H2rGVrm8G7ampZ7poyyPJsb75wxyPQ/StO32pIvmP+7ZMEtGRx6Dis2B1EQDNJ5xOTtQHI9D7VoR5G7ypp3A7MNp+mDSsZSLlsigKRMp5wRndx7cdavHbuXezqFXjbGNwPviqUCFpC6EKOxf5jx2OP51fUOqs22AFl+UgABuc5OR/KtYnPMsQSxsyhpImBAPII6HgVI2GDvH+7ycH0XjNUwrqmQ0gAHQgYOOxqzbrIRvwV6chwCCfzNXfoYTixE8pWcyAOe2w4x7EHt709I2DDZuMgzkHjj/OaWc7maQqrZOMk5bP4UyRihCzRg/KcfvMc+uOe1A07pMeM5z86Dg4Jzj246U1ZHAfaNm9drccNz6n39KISjf6sosmAMByCxz39Kc6gKylfu9FL5AJ9KGLrYazS+Yu8sr9W3KOP/rU8b5SW46gZODx9KYAAhUqodeMlsZpuGJJKkgruPzbR+FIb2GzQhUIAGQOcnOTnj/9VZ9zCTnAGSfmBGMd+1ajop27gdg+XeoBwP8AGoEUMuTFnPRj2+opNXLhKxkvHg5wGwM5XrVmCLO4YbeTnt096uSQFXxIpGGxtA6ULHuyNvzF/l7A+v1qeXUtzbIwpHQbgCTgck+nHpViJcj73B6DoT3wPSkTcdp3n5RweRjv+NOAVSX3ANycr3x2HvTtYzYsp2jaBuGMlumKrs2CQMHJ49asfKvDKWIJIAGc8VETlcnGeue4+nanuCHB8Biwzzyx7g+n0qN22jO7AycEdh6U85LHeeM/e6H8BTMA87Bt4+Y9hQwJIWDjJwhI6npUZUuuPX5c464p4GSWRCRknHrSkYOexPUdD/hS6FW7FZY9pALlht7Hkmnx5ZQ2FBC8Z9KdOuUIAwM+3+eaRPlXI5AOV5wD70hsaw+Q4O8cAE0wDBbGMHqSc1Iyk5ZlGO3rmk24OXIyR0x0NNALIqsDuxz1A6ZpIyCmQDkdR7U6IZHDd+h6470uSXbgZ9G9PemCYwbQ3VuQDn0psjdSx5HX9KcuSBkjI454470xkCoMk/e6DmmSyNs/d46HJzTWTPfHXJHSmznGcDnHXGDnsKWKUtGoLAgj0xzQFtLjZAQpUjceoqoSfMJBUj0NXxtKAjnsKpsp35YAHofSkVEN+6MlgOuKqFiHJxxjjirDsQuF5PUeuKrvyu85z3ouKw61uVtySLeCYOOPNG7FMudUBTP9nWP4pTGzsBB6cHjtVS7yUYLgKBjFUmzKUUc14q/06OVhDHDuUfJEMKMUVo6tBbrH/o9x5pwM5jIxkc/4UV1UqzgrHBXoKcrnpTpulDE8NywK9R6DBpPLJkDNkZ5IJPPtUwCkghsLjqT0onUJnhW3DG4x5A965TtTIwQytnzFGMDbkr9DnmpFQKqOBC2TjMfXjvzUMThHPmEMo6BiybvpinhVErARJtPcSMR9aChVRvMbZ5hc9cZ3MKCpUuGVsE4KPywP4iniJWxkspGfmBORSiMxooG4EqOCx+YduvOKQrjEjVoQEzvBwUcjafpUw3W7BWQRSL8w3IDn8jg4oDSxuAQjq4JOQDkd+KZE24MqgBX/AICox+famIe/mSSbRIqvj7yoO/0ptyoUhWiZcrzk54/LihE3q4RN0a/MfnUH0/zimcJuKbkLD+FzgjuCaQWIGZtibWBQcYXAZf0pGQ5AVmOTwpzkflxmrCplQy85baTvHP51GzqrmNd2c/eyOPypopMjdgABteNjkDGSwH6ZNU5bcLFvXYyj/WbjtPXgLmtMkTQsqqzdyQmSfxzxUEgwrkxBuCApjJ6/pSYJmO7FUXYJI2UkoyyAlSecEdDVJYgC/nh92PlHmbQvfnitlh5eWjcZcHcFUrj8+DUMkGyOOR1Ejv6xMB/ve/pxWbTN1JGTHGAqyBnV89SgKYPU+tMitYp2cGVcbcYWQIG9/pWr9l2BNqZYZyQMfXr0/KniMB5EjVCGGdwJIP54xSXYrmRy/wDZFsZGHlGXtgMcH6GnDQFEG+MyiXaWPzAqPf3Ht1ro2tw5XzY2KDjATPPsR1qOGBxM4hx5gHGwE7vpU9S/aXOYjsTGGJlEgUfw5GPatO3tGO3Y+8DkBOcLjp6VrbJA4ZlUncC24Dn65HHWhLAMocogjDHDAbj+a/SnYftCG3tCXEVlK7TE9VjwVXHUHI/Kpwzozh5bh42G1uQGbHTrVlLRJImAAzn7uM7R+eaelu8ahSmxSN2wsegHpjrTszPnGpbJIrvIu9wPl3SEEcdsf1qe3X9y4CxllCgEzHKe4GalSFZifKiiCg4UeYSQfx5NXmtnNqHMaYHI3HGMdQOOa0S7GMplKOL5N6suCdjMHJY556VMp2krGITIQXbbuDAe+ev4VPLGX5MaABMZRsDj19TSbZf9UAwJOAAQC3pVJakOV3cagEquxVAyYO4qeR0wP8KBGpbaGZAV/wCegwSf89Kmm8xWVZEmAUnH7wOVOepx1NQs8TlwUd0243AAnGcmnZCiyJsncpJOCMKI8c+vWpXYPguAG28Ax4H4etMh25zGudp2nBIOcVMcKy7dwcKQCeQvr9KRTGxLuVlUqQenzYH1IpVyN5AUgAZZBjFPBGS0iscjILYB6fTmmSOMsohQ7eCwPJPXoKLC1FYh22lWKbQoy3Tj9frULxYPCsQ2ByM//rFTOVDFRlXDAhNoII+oppXafkXcCcKcYzSBaEAUs2BtbAJHYEfj3qSNx8o3Jwc88j8KST5Vwyr15J9j2obzC7Z2KSTjnHHvSKBgq/OMMGB3ZTPPpnt1qtISBmJc8+nT2/8ArVaGAxV9sZHB5xk/SopArjOcknBY9cD2pMaI42kXarAYTI+n+FKVBPJUg/eA9KQqCi7gQvbHy8+/1qWMYDZXb6n+6v8AWmgkyIxHC7ujY+gwe9NVgSdq5APvz6VYcqAFYjk/eU8H6/hQwAZgF2npu9Pp7UwTsRK29g2Af4jzSnoWGQ3TkZ59acmclHC88ggU3d5YDHHr9Oe9IpDPvRhmAzycn+VN2K6EKckDp3+tTE7wGGSy9vf61GF/dAEAvjpjpx61IxoOCd24jGAFPIpWUtjnAz360pAjHPU9/rS7uWyDj+HHrx19qoAG0KA+CAc80sirtzxs68+tRspQZTB6Ac55okAddmevOfSgLEMpYthTzwSuO1AfcCS2WXg+gpSVMfJ6YGO5pG/1eCAWOSaYMhmAJBHTgD6UyMfK2QB8w2+w7VIMkEbjx1J6UL8qgLnpg55oGJjCcgZ4yCBVd+/zDn19KsDG0YHU8k1HIoB+vGaRK3IWGMcHO3AwOlQSHjaRjj86sqrDcpIJ7e2ary7jJvBO0jBB/nQkDK7ABRyRk8nPSte6t1szdzxWiEoFhtlZdwkY87sd6ySCox1JPT69qv6hDBbQSjzLhprOSMM3mYGT1Cjt9aqJlPojnfEsMcOpOkarHuRWeMdEYjJH50VFrluttfsiOzo4EiM3Uqwzz70VVyORM9Ix5at5cSuH/vL/APXqGRy4Xc23jk5PX09qmMb7eirtOC7cgfTHNVnwCQSGYfxZwCKllR1JYQzIBHEFkDZ38nj0x0qaLczYcYkB4DLhl96ht4RJJGYvMGASVV8c+mR7VNM7SsrSMxOAQxfJx6HNHQHdEc0j7sySyMvIyVBOanRBIIzuVPUyYUn0BGKSSNoSFEhBP8JGePqKfh8fMzkAc/Kflx2PFNeYmRhQoLK8btu3Y2EFj9cU4tuTjKBiSVGTjt0p4ZGjQMxB42MH4P4YqOcvG3zNJKhIw+0kE5zikJO5Dc7MId3zdMtgY/Cp/LAhXBlMJOTuZQM+w9KSQCSRSVKksflxhee4OTUaWwVuQxXGSWXGfb1x70WKQYk2Eeay4Py5bGfp/jSplSx2um7plshj6nNPTbCxR4YmPGC6bgPYGkk2s+9vJEg5bbyCPUACgSdxFjFwCE3gZAYjkZPao54UR8btxQYKp8ufpjP51N5gUuI3z2PJGQD9KUgu5ZYn2suTjOAM+9HQL2KrxoY182fKhTtQybj9AMdabawssqpEVZmyoUN0z0x0wavWyybnJUmPgt5QVTt55qtIoYqF3nbxliD16UNWKUuhHNbTxOiSBWdjnJYO2R7iiSGNjvlaSIEbiJE8zLZ6DgYqXYqZOXDqMrtG3n6U9n81FVpJN0Z3gvIxHuMdj70aA2+hSliDyFt0fuBHtwPw7/Sg2rbsRXQVMjLMGAQ+561YdwWLFndMAF957e+KlU/PiJwXLYy2QSP9ompsh3aKZiRcZuI3JByY8jb69eDmkjhbDSxqGjxlirbcfiOg+tXWjKEb8gnDHGCc9h7VL9lngjL/ALsZ7gjA+o6U+XuHNoQwuXUlAuwtwjbWP06dKT7LJv8ALaMbiNygLnP4g8VLM5J3Shc5/jwR6dBipLcPISPKtyM9dqqAfx7GmldkttaoFthA4LeSozkbwVHtyKeiIxXbCgfBBkWbcGPpgZx9aqOgGQrwoScEBAR9BzTt6pMNjREDK/Km0kevymqvYLXLUu9zul807RtB+nYg0xoy204VlA28KNx9/eoZXCvhGjmYYbJLBh7elTRyyGBDIqAAnbtCg4zzyOaNBOEkrobLDsiVhFLERj5mjAUDp0pjec25zvfH7tSFG36Y6ZqzI6uTgySbMbZQxIA9CD3qIHBXYZGwSMPGoxz+ppaBG6VmRzlpfneYllfC/KAVx0z/APWpyRxs6tKo2FsnYCWH0z1oJLIZGiLBmwHYY59OO9Iqx/edxwSNuzk57+woSG3oSRJsK4QbiMKjoxDjsT61GykBlZZFwTz7+9SsEG394koGPmUklf8ACo5AAChYE45bb39ifWiQkRMXYcM2Bz9fwoXjepY7gAAuDye9IGPmglyxH3fmzjHSpZXyBGNoLEkhh1Psc+lTYtkJkXKqmcn34PbGPrTVGwFQoII+96H6/h0pwDNJt2nHfKc4HegMOMqoUZ6DHf0oGJg7yqHgcHAzn3/+vTPLJI2ZZjx+Pf8ACrBBIBGAOxxio5IyvIBGBkUmK4FRuUE5J64Ofb/9VKCA2VVABzu6HjvURJJxsUKMcAdOakKuCxUSNKTtHH3j6U7hYjfa+SWIRiOGP60hdvJADYUflj1pYmI5PRjnOc9KUZ3KAwfJHP8A+vtigoYuSDwTz3HX6VGwG3btAToPQ1Ox2rtP3s/Kc8fhTQyhx5gAByGwuTjqamxREQF5BwvoaHC8hAQDwAATjjrUrjaSH4OPzB6HiiPCoO5HbOPrRYLkKspIbGM/lkdKJAr564PTngD3pThdxjzgfMAeoGKeE2gkcY4Jxx+HrTt3GxrcFQOcjG309KhfCllGc9x60sjDp94AYwBjPoaY4JdeDwMhqQIjdcoBltoBwenNSRkF8HBPsOtSFQACy5K4PFMYIudpAxyAOSKaBsCFBI6Ke3cetQNkEBTkLx9akbaVAOcj0pEQhGLEAjt1xmmSMUgDoCe2f61FcqNhByFbr6ihycbQoBUZIPekcnB7nHPNIaRGNyg9N31qF9wHyqSeBntUk3zYC89/rUMztySOMY9c0JlFdvlbB4DH72e1bMsV48TLcaZbzvLtJYzBd5X7pIzzWO6EgbwD3Iqzqdvb3073EeowRI2CVkJDR+wA/pVJmc99TB8RQX6TyXd9Dt3nbuQgqvHC8dPpRVvVb21e21V1kJ+0eXFHGw+ZtuMyH0opscU7ancS/e3ZIHXoBn8B0qNAyo0flsQ2CpjccfUGg7iRxvZcZzgjjinrJuYBmUYIzlentj0pGNiQxYJaVWWPOPmwWzTlbaTtbAxgncRmmxYKYk4YfKWAPQU9s7SBIj8cMpb8jTDqNjVgf3mUXHOQoJqVADjALMeTh8fr0qCOU5YjcdygH+GrJcAICgkd+q7iN34YGPwppqwNEVz5ypJHJISmfugq2G7VGigx4VkDgbmDSD86luC8gYOjqSw+XLfKPfIxSROxkSIyqkefvEEgc/rUhsR7Uc/Oowo4Cvk/hmmbGx5sbIrfxEEg4+mOKvTLExYefHJGOR5YwPp7GiUeYRJK02RjB54Hp/8ArpuKFzEccQeNvOMagjeGCs24+mRSrBIzgYdWAyCFbPI+7mlCckshL7jyO3tkVKpDlFkh3MTt2nAH1z/jQJtlafMUfDusR+9uK7ic8k47UyPepR02HPA+fbkevWnkxsjBomPJDASYU+1RsqG3k8oopU7grODnntxkmkWhyiSUFAJJfUxv8n0xj+tIEfDAxy7UOCSA2Prj+dMWdGZjKFZyQCpBJJ7txxUvlIVUouwsSTJJLtGMdOOlG4PTckQxCPe2HcjG137e4HIqurBpdoKQkjG8KeB6E96tKzHZGjh1bI2RzbsL9cfWozG8UpEiMvyZUbs5FNoSGqjNHvaSNtuRuZsZP86ci75Qqs2XGCu9eTjrz0pVG9jGMtv5AXkD9KLcGS52xmORuwkIxx9aQ7gi5QsgZHUgBs5z+GME/WjmJkOwBlGSXiz17mplCTMGKo/dleTaW9uO1NyyGMiQMsnyiNJGOBnp/wDrp2sSmV3ZnZhIHAkPJRPl/AdaQou8MvlyHj7xIwasESCUrJ5gbk8HLJz2waSSDeFBKqxxkkDcee9Iu/clSd5LnE7Qoqn5AQWT8MfSqtwIxw7RdCMfZmTf6ZNSuUUEMzHB7SbcH096bHC8qFEAZSNuWmXCj09vrTbvoJLrcgj09ZwGCgIMAsVb+QzxVgacqxD7LebgOSmGUcdcZFRRMd+wJMqOcFhISqnHoOtXIoY/Lba0hQqcSlnQH8MUopPoVKUo7MorMyOq7ARznzYxg/jU4kDykzIuT0YSbQeOe2KS5228IjjDMB3D7l+oBFU4yPl3OCCdxCBePw7UbaDtzK5dEZeZvJZlbsuTwPf/ABpu47mJG4EYOJM5HpzTI+SwIy4zwQCCe9JEBuOY94XjC8H60CsSORu3Tgs23hgQfzFSDLAKNyswB9AaikZ8gOWBB4VsHNCnnkowZjg7OQce9AmIFSRFyW8xiOpAUnNI7LuAZVdgCMgdPxpQVZs7W3HJ3EY/SpFYnaCckdF25x06UFepXY+WR5gDDOCvI2/WmRYBO0yK27oo6Dn1qSVmjykisB2U8j61XV8jAZeDkNnsaRSVy0hw2Ax4JHI4P19KVT5i5cBVbjdnGMDr+tQcvjEZzyDyefyp/wAvU4HQKQ3HPbFBNhJF3Mcrlugxkj9KjbzQ+CGUKfmAfO38aXO1c4YK3H97B9qHk+RTztHovQUrD1EZQCDwAencj2pOUxt6+jUhYb3XHyD3pZcZBUhuccdAfrTHYJZMjaMgcggd/rUecZLsN/YjqPpSkEg8ghTxnjHvSMuxxuzyevoPSoLsh65CHGwH+LnBoZflwFAHAPr+FMWQB8YGw8E44NKcsSSAzY52/wAPvTuTZilwH9RjkHvTi5PI5B6cYHNQjaTgDPcDvg9qPnUhep54PYUDauEgb7y454PGPy9MUi4IIY9f50/arYAbcFG049abg7WQbR3zjv60g2BhnOSe4xTGUAbsZUnFPc7Qck5xnJ9aZFIGXoQCDyfX0poXQikLhSCDxyO9ISeW79xihiG43Zx2PNNRwiP8uMnHTvVCH4y2TgED86rleSoBwam35UqOPU4prsOD1IGN1IE2VQS3BGD6U115ORkY6e9TMCr4Az6n1zTZMrkYyB0pId77FaQKhGehrVvbiSA36RWsA+zqjxAxBt6dCfesiUA5CDnI69Ks3bWtjeeW1xqH2iFdvmRkAD2Ge1UnYmSu0c34tyNVYvgb0Rtu37gK/d/CiodcCT3Uk1u0zo/VpTls984oqXubxWiuejLtIYsdzEgHIzgfj0pMDzCUIfBzkrj6d6kBZpCT8vfLZ5NDRoQz714XDCTgsfy5qzkHeYMfOGkX+6WbHFSoI23DIXI4Zg/yn61Bwq7cx/MMhQQf17VOiNjELSh2UfMsikZ9KLgRkRCUsdrqeBtyD9eKeBG+QQ4XGA2SxX3FMkkIdmBbg4BJ4/AU9HLSYDxkDjMhK7PxouBLxHEdjtLgYJZOT7EjNQgAuVRydw+6AQM+nWnoG37U8uVTzhZPmNKpbBJbanBG4Fhmh6iGKNoAHLd+ePrippGjZfl2IegVWcjA78mmBixbaygYyFC8HPWkSXYGfYyHgZVSR+fagGkydfK2tlcu3zFiwGPw70ibP4fMKqOwLfnjFOln3kAoXGMLvbn68VWkYpI29SoI6FjtX2zmnsSlcldE2L52+Jg3AGeeM5/pUAYGVXmZ0XGAUfcT6DnmliUZ24A6NnGRgd809ypDMqRqWPzIiYzxzzjA+lFrlLTQrxls5WQDBOA/H4HFXQ8UAkCG1kIO0bo2ZseozTSgdgZpIw2AB5eMj69KVnKs0Mb+apb7rKDn8qNgbuxs0jTSKkvl7/QxAEe/GM/nSSBmmfEYXJ5xF37cZ71KsDJIGlVwy9AZFUg9jzyQKGLhnErt5ZyV8yUfn05o6ak9dCBWmEgSTjoFaRSB9PSrEQTzw0kUMh5JU8qv4AilSRUjJKRTKyhfMO47Pz4NRyyM6RRgR70ByFjC847k9Tim7Ib94LdnRvMiIVBwoyOnp680MwfDAQ5wCxjBzj1PvSQqZDiJXIwN7eWGI9cY7fSpIWCkkxxvFym+UH65xml0C1hFgZotxMbMMEkE7gfT3zTosOchY89CHYDHPsM02UfvAVUDy8kquBtHrnmlfaSQGHHRXYs35gc0WHdNEkSzrh9rgK2CRlgDntkVG0cYbHlllJCkyQ55/wAacpByHVAwA2qN4Dfh0NJKiGVi1zEo5wChKn86bfYlb2ZA1s7KXiV2g3Y6HGfTB5z9KZ5Mq4Nv5qRryOeBn6mrlvF8khC2zZXPmM3zc9MDNRLDC7HMltzyyuWQH0GRSceqK5+5FNDJuCTs/mMPl+VOf1qP7Myli/zbfvDIIx2AAq1hoXGwLBuJKrIFKY6cEgnFNQPJ8g+zlx8xZWx29PSjlRUZMY0cwcGUM52Bh7LjikuVWNmPOwgPgqRtz2Gefenc7+AhTGQzMc/So5NvPyrtJHucDoOaGOJIql2IcuOxKLntRCC7ABnDH+5wcjvyfSmjYAyssJyBgKeQOxPr1p6ohQqSgXqMnqfYdaQN6kaxl23MW2qcYAzx3Gc05WLRHzVZl5IJGCuf/wBVKQVCqUU7fvBgTj0NMP8AA5TdzggL90/SjYNyGUYB3jJHHGOnbrVSCA/JsLbfQcE+uauuoY/MCQSSCB19Acmo/l2gHcrDjnoP/rVJcZdBykoFL7i6k5559sYphlVwxGwfLyVUcEfypsgZGLbCqk7eBwcf/rqsVMcgLF1IOCMcg49qZSinuTSzKWYKjoOBwd1NLYVgsmdw5VTjIqA88puLcFc+p7c9RVdpWQlQwDHKkbcjHf8AKmaqmP34I34A7Y706OdQ2VJBwc8dP8azbhyF3Ak7WwQv8PpVb7WS5LEkYxzzgg0joVG50KTB2yQeeB6fgKlZize3TPoKyLeRmQMjfj6CtCF/nIJDIOcnmkznnT5WSKuWzjOMAfSnZIA3cZyB2x9RThIrDICEHOMdqFOF3EEk8D3+tSY3YRIQ3ykcdSOppzrjJb68N/Km7sMhB4xgknFOYYOGGWHqO3amhO/QhjblyOOMZxjvSRknIII6kgjj8KTepXgHA9O9P3rkbuWI/Ac0iyOUrhSygHPTrmgpgKOoyeR601jukZiCcHOMdqcDwCDxjPy00J7EeNpORjIwMU3kgEjIHf3qZwBzwVIzkfSmc9DgenuKonmIjgu209OoNMIO8j+71471ZdcY4AJ596rs3zEL19qQ0xkhKjP5mmFsggfeI704kIu7LHjNAwo3EE5GKLiKTAFwW3dMYFbGptdLLiDTY5YlAEbNCXYjHc1TiihkJM1x5IHKkLuzUkn2cAA6zMCT12Nn+dUiZO7OZ1hJ2uJGmgWByAPKVNoHviirergfaHEdw064GJGGCT+NFQ0zSMtDrc/OVOAB2zx+BqWMnO7LjAwu0D9ac4RSRNvDjCsAQcf/AF6bJG4Pzc5G4DgfSrsc5KrM8bAhgCw6pycd+nFIEDAtLuQk5wImyT6EgVCqENIAWGORwCSPcZ4qXZwD90kdSpX+RoGM85lbjjByq9cf/WqVpHABR4AMcFV7e4pmWDDcqPzllwakkldQXAiUMMMnlnZn0pjZFseORC0angnHVf51YjyuzKtg87Yj90e2eKqM5kf5V2tjcfkA/KnSCMncC+M4y6kn8hxj2pXsNouSho532tcQq45HVsH14pMsFA3SBW5x/CT64zUNsZWmGEUvjpjAGfXNWFljiz59vDP2IJIH4Y6U9GQ7oA2FjwiOSASDx+BAH86hYs0wzF5QPGIxsHPuamkyY3YzSBFOQjsDjI4781AZBhSqgEjLNtBx6Hg1QImiYYZC8yKDjaJNw29+fWpTJMoCtLOsDnJHByP0qKNJGVsRksMEFVP61NIF3BWSVHUEtkfe57elHQT3ECNHJIUcMCPunBJH0oUmRTGJPk6qSFUZ47ntUO5WY/djycZQdf1qfaIV3AcdMlOuOpGakVrCNEryBWMLOrfdDE5wOnA6VF5PBClgP4QpAH0qT7TsjjAnzGD8i7iCD+FNjV9xxF9/OMIxPqcH1p3Q0mhkR4YlghHQFM/TB7VKJVdREAYwRiT7pJxzkcdfemHCyoBuCgAksuT/APrqYyRMpjmYjcOSzkcehAGKeon6DIt0cWEuFUAHoRnH48Z5p5iWLy2MiM7A8hgQPY8darOH2qYTJNHEMsyZIUdxhqso8bALAzrg5xI+4tn0GOaVhsY9w7Ak7gqEZbjAHTgAc1L5paHylecBWARWz+XA6n3pdwwEV5QseCyuCQzZ9hmmhkLlcuzEbxtjUEH8TwKaTEJt3cDOAchNxGPX8ac0ZfDoJTwCFyzBc8ck+9RpsZ3BVCdwxiPLcHnB7fWpJV3qRksegDuePUEDtQldA9xbeMqzlxsccKBEWOe/PtU0yyRoitDCyZxlo+T+BPXHtVdR5Y2jCbM7SMtk/hTmjKmKSRFRf7zI4Gf8fpTWwmnciZYAQIwVz8371wv1WowomChNo28/vJAoX2zSJOEk+WQ+Xjsu7PbvyDViEDaCykxOflwFwT75NLcrZEKPII9jfPj+FDkDj1pHQS4bGQBjOTn+XNTlVEmC8QTJBxng/h0+lQSbZOGkyMcr0GB6c1I0xETaoCEbVJYYG0D35pWUnBRd5yCcDrn0PanJIm5QdpU8bSdo/Eio3chmMbgMo5UOWx7ijTce4kzFAcKxw3DquOffPv3qEyee+5ECknJ2qAv4c05irgg9TgZL4Ix0prHaS2EIIwN43Ef4Ui0h0QHmGNw+SMKBhdp9fcUwDCMqsSvXBwOnB49MUhZAy/6vrj5hTFkBYDoOV56fpUjUWOYAJySvP3d3Wqk+GzsJIb6k5/CrchJjDKCo6E7unqeev0qtMvAPIJ4+Vzj6n/CmXApMSBtVMhsAg8H8O2KpN5hZm3d87S2OKuyYAUcFiMlmJII7ACqj+WFGGZiPmyOnX0xQdkDJuZ13pvchT1z1/HtVHzm+0Kp4VR8rMO1XrhCzOSpAfgHac/5NZ/l/Pk5zjABHTHWpZ307WN3TfnAJ4zk5J56ela0II3KzZGMAj8+KxbPCLjtjBI6D3+vNaseVcuT97gA9qaOGstS8xBXKrg9TinD5jnqOOO/NQwEkrz9anwSvzqAy/Ng9+ak4ZLUR0xjaMjOCOuajztBXc2NvU/WpCwBIJxnBFRSKpcM33T0b0/CmOKEEipkAEAcH3qJm2gndn/ZpJQNu1kIbGcE/57VH5TFA6/IN23HWoNUkiRXGcbsZ5+ntTFnJJ4KgHAI702BwHAbHHPH+etSKqsSoGeMD86aYpWJN24FcbT22jtSOOPvArjFKyhflGCcE89aBl0GeMjH4VaMvMaMBNvOQO55qNnCfXGcj+VOJ2yOD09M8moZCGlw3TA4/ChjFVgVDYOT1GKaw2nCjp0x3pVONwU7h6elEjFUJJ56UhNCQ2st47/Z1DFB83IGDUbaTf7zmIAEY++v+NRsCyjA54HXpWpLZ6ZALkNBPIbYqsjeZjdnqQO1WrMhto56/t5LeRop12sADwQf1oqzq8EcN6Y4U2xbVZAWzkEZB+popDWqOqQguGK7scHAB5FCsqsUDKeP4owMfnTZpZJZRukWQgYDE/MB9RTi4JwVc4JBIc5bP1q2zGw0hFkGXR26EGpkVNx4AQAltrdM+me9Rl3RGwzksMMcDBHpnFSovlxFQodgDkbRhfcEGpGweQRSyoGBhznLKMnjoccVWuSCHQqPbAFTl8Ivkr05DByP/AK1JKrz7G+ZlHP31JHPrQyloY53lvmSYheMeZg/QCrGcZEsThuuGfJqf7PEu5lyFztYZyT+OKUhYlChZFDdfmxn35qTXnuSRKmPuAgfx7jkjtn0NXV2FS0KEMB8zxhmH0OeKoReXuIkDq5HVCMH86khkLI2ViJPHJ2gD8DjNVFpGTjcuQhUc5Uk5PVwuM++OKiaT5gXA8sMTtYkZH1HWhDliAiSHB4VyCMdPahVeXeGwg4DLncc/Q1bI0GuRMQYUSEHg7ZCRkfXtQGXysbAO5wR2/OpY49wwsKLxg4HBHqcnrTfK3SYzncNyt5YycfTpSuNNXI4iDENxdUY8gDqfz/Wnsg3AMpR8/Moww/A55qWOKLefKikJIxndnBPcHH86YFFuh87dt6Y8sEj6/wD1qSQ20yNowWZZAuV+TazcqPzqaJAvCNuAGAvGce3vTEQM5wqu38OY8Z9+tORQqorAAdyuOPxFIT10ZIxA2xNuLAYPBOPQYpymX5Yj5hPmZXC9WHsec0IVZ5FQL0y2ZGXj0Jx6019jyhMHbnnALn25PNUSOk3FizqwcHIG0bwfcDnH4UquzZLtufGAHIB+p74/KnK67gsDlnX7zgiLPHApCwLNJGpQNx86l+fcmqsLXsEqBGUblPzdFJOD0wanjydsXkDaMHhAWb64NVjJ5zbA7MMjgLkLz/s0ofCkoI9qsTtYHB9TjOKQ2tAdjHIVBBKgqyykYH05z3oOHQKhZ1BwVWMEntnI/rSMxjOI2/ec8RYJ6egHHrikikKlyysT0BdjlQP7yDj8DT6jadiWULESF+1AkbR+7HJ9hUbbZXbLymTGECKcA/Q0jJK0gzCgJ+XYsRyajV5VMalmbK4A3Ff6daQW7ivwoD+Yjbsk4IAI9ff6UhkfzGm2uM9H3Nn+VCkh+FAlBbfmTr3OBg0jPLtWJXckqDhC3I9CPpU3KQLvkygIB+8RvI5PXPvxS2zSvI20SbQMMgHKgd+RxSKq+awY73K8Axbs4+p4+tJC4wu4MGPdmHB9adh27DXHzL5ibmHzYJPNMkXG5ArZB2gFgcDHNPkysgODjnnOcDvSb02EMqknpubj+VSUrkUIQHG3kcghsdfp3pk8kTvhkkX+8QRlsfWns3mOMyeWOQWBLAHt0qGQKWLRtzjj7xzSKVuowHOTwS3UjnHvTZSFyVLKM9V78cGj5VZRuONvJ2EZ/CnGQPON7NheAqnrUFgsgTIVtzYGTj+dO2bkYN/EMgjnmkQFmZmJxntxn8askIyjnB4PoCexpkt2KflqSCFZtpGcDHP9KrTWzODhcL0Ix1rQKlyQ3XpkHr+AqvNEFP7vJPbGTg/U0y4zZkXNu0m3POAevOB61QaBMqDkeg9+5Nbsygg7iM8A85zVWVUHUhwf7ox3zSbR106rK8Rwu0A7OvNXYExygwM465psdvgna+Q2GOR6VcghEeBkbPTHT6UGdSYkIXexB2v0yTUwIOAzjJ4poVt4AJB/ugfkakVxsO4BSBg5HT/PrSOd66kRVWGCcnow+lMOQrZJIIz0/CpSofcdy8dsUjp8m5gdjHvQwuUmLqzKmVPTJOeOlTWc7iMiRSwUj8TSOhLFSuCeVPam4ZcgfL9P1pK6NG01YjvZUZ28lflJBHHf/OalhZ2jB6IwA9/wqs6LkneWGanhwrBcHBGeelLqD2HlsDGc+gIp4ACkcYAySO1MKER464yQR39Kau5WztwSeRnqKtGTFTIYghWPrjnFRSJ8wC4BHIFSuRvO0nJ64qKZiQG2japOMdqbEr3Iwcbm7niopDuwc89x61NjOcjOfm61EzHgkD6ipKI9o+bJOMcCtF7iWDUEW7a33SRBZQw+XHbfjvVD58kqmdv8QGce9X7qK3uZDPPb3ySvguscW4Me+D2zVIiRm6uZm1CQXAUSADGz7oXHy49sUU3VLhpLx28p4gFVFQjkKBgD/wCvRSbHFaHSJwmTlsAY3IBg++DUnku5RUzIGJBVRzn8+aIjN82HdARkgMByaCnyvkFSG5Zk5BPuK0Rh1EfepYPGy+i8ce+KTzXiJQt5YzgsuDz6cdaAVBwwjZh91yxGRTWLMpVNqspGBvGMH8KTKRKhV2UsYy3XDN0p0pSUxK0cSOO8eFzn15pIpJFiDI7/ACnAAA/z+NPAeRVZzKu4c5AYfXjpRcGhhSRUYDccDJX3z7UiyclHZzkcbmYA/XjpUhhHDbFQZKqwJH489KQ+YrfMwGflBBVh19aQXIigckZUcnDD5hUYSUYdY/lHU+XyB/OpZlUJtLq57bXBwaiKcY2Y5+8oNGxSZLgNwIXhY/MvXgf1q0xEka7o5BL2+9yOuB+NU0CkqCZRgEgAdc9Oe30qxKWBG4bs/wC1jBHpzTIaHeUHAbClTyQGLH8f5UKBGqEDcOpXJB/GmoyrwkYZ25DN94Y7DnkUvDD5I1Pfawx+AwaCUiYsxUN5DRxkHAIz+vf8aRkk2gBSd2MYUjI9qf5LAqwgYLxwygj6cUqRllaSIxjb3ZgOPTbViuMma3JH7oJ2Yo2SMdTg96QOCj7Z1Kt1Xv8Aj2pzJueIRKN4U/L5gyfbGKaBMoxhyg5Y8HA+nrU3KQrMUV4yzLGzA5H8JHcDPNIxHmSHPuNwzu9+vWnbFEmUMpXrubaD9cUjDylIK7gRgqH2gH14poa0IMFJBswzADAAwSM9f/r1Y2MbdnZv3THDAyDk+mBnvVWblY/m5XjG4Nx+fSkD7SFCKpAwCpJOc9elDZVrrQtNKh2q04fn/Vknk+p6CrUTq3B80qvPDquP05rP5O/Crg9NowM0gcjYrGMEjIwoOfYmknYHDQvTqoVmWYllYqGRyOv0H61Ul+zoMF0YsBkmRjz3z602V1XhXTeuDgSKVB/2icD+dQ+c0m8qyR7j1Xr+HIqhqBMD5jDayp2GBk8d8nilWQxkkRtMF6gttx6ZwaoSTgldz78H5l2j+maU3CzSH55X8sZ4KrtP6UFOmWhK7lNyxqT8oO1iRVhC8jAxeUG2nd5alWUep5rKNwNxzGJB97Mj5JP58mpBMpVAIQvcnd078kVF7DdJlyRlRgxZVY8YWNjn8TUYkjV2Bjxg/dZiAw9ARVYyj7287l4G4Fgo+tTsoKggqMjAC449xzRcTjYWZwHwqSI2RzuJDeoOaaWEi7jjIyA3P+RT2JE5AZWzgbySM0gkJPB3HIXI5BHuB1pDvYUFHXPA3chuOT757U2ZlxhkUsfvc4HHuKfNvKuQgCnjBQAVEFAXBIXjGWXt7UEkOCCckHPIw2RTWQtg7CDnJw3NSoAQVGXZuc7OvNOSJWyW2nb947cY/CpsXzWGxqfk7Yz0IOKUMA580Blf0H5YpVcKqqoAH16+nSkBwQWxjuexHrQSMWMZXdyRk8NjB9KkljXkklhjkBs805QMggZ98gfpSvhjksDk9Bzg/UUAUSh+ckgrng45FRSRYLH7qkfNyCavSguC4JIb7pPQCljhD/Mx5OeVHHPeixam0VI0A4UfMTnaep9ParAUFUIzhhyCOf8A61RtDt2swJkIyc9V9qmAw23dnPGGGQKLCk7ke75s8jBzinEqHJA99zDrTmQNgDoOpx0qFjtXIO4Lxg5OaLErUlBw6lRlguMYGKAMAAqenJxnioy2VORjBzjPH1pchwrDgjr/APWoHYgkyCNoIHIz600KQoKZBP4VNIx2ME2oBxgc59aTHY7guPlxzilYtMgKEEAE4I546UqDaACRg9M9KllbaSc4xwtRsdoJI59PSiwm7iO2SBz7k+tN2E446dD3OacpyrZDEg5A7GgvtfC5B9x2polFYts4f5SD9OO1DyZdicjs2eCaZKcja+4855HU0Plpfnbk8fj2oLsCYePOBkHBNV59yglQM9Qc9am2nGS2BxkjvTJANxGOB04pBsxkUjpEVDMA4G4A9T9K2Z2SCby5dXu1c4DDbkL7daxnwV352ngj61sC3+2qtzcae/mNg8TBBJ74PP5VcbmU1rd/oUNUsR/pMq3kk8sW0yCRedp6Eeooou7ti12kkHl3EpCOc8Ki9FA/rRSfkVC9tTaQThA7RsyZwCOefSpmLM4Me9TjkcA5+mf1qMsQAWDNnkFZOnvTWQM0YYhFIPzuNwH4AVRgSlZX/wBYWGBlmKgim4iRlJPCnbvVTz74yKasZCOf3bBeCyscj8OM0n7xyNwJf1UZ/qaHoNBHGWmASPJbJDAHOPzoRXLg8Lg85BAI9c08KpjVP3TNtwx8kpg9hkdT9KVhJsZFO1VP8Lf5NAXuSwyjA/fJ8uSwDD+dKZAONrKTzycY/TmmQkyAAKZJAQMbWGR+GBR5SmR43Mg2EEtt+b/0Kn0F5jHfaXRQcDGcYJ/CmELuLAbcn5c9DTmZFcCMAbRhm2sM+5HNKEIYYaLduxuQsM5+vFSMgkAMYZsbgc9RjH480sDh8KwUlRn73GPrQyshyAOByducfU1I2CgZEWML6Hdn86SNBeRbIFcsg5xI3A9h60gQBN/lxBOBhuppvmASMMIwByenPoenSplfJ83zIQ4G7G47iM+3QU0TckiGY8iFY2VSRsRvz9KdIFDeYyEBjwCG447GmnayurbivorcZz79aUIsvEfmb+yl+fyxTJ2HggopaJi27gHBzj6nNPQZKq8KooPBK8fp1qALtlbOFI7Ek8jtmpSp3cFFYHDAPnNCFYdgtIV27lwOkR/kaEaVFLNEyxSDjKkD6+49qbIQQFJXPIJL8n25poyFGFVzng+YeKbHYDKXkG44GegHGT+FEuMoWVMDsJFz9eKYyybQSwdQezkY/HFMYAkqF2tk5BYLt9+TzSKSFEyo5bZEuf4txxj0waSaSIAtvQv0wM//AKgKiaRvLJV9qHqeGz+P+FQXhiEEnyLJxncz/wAx3po0jC7JpJWAMcO0A/wZBJ/EDpVC4uY2ASRoIzxlxGZH/Xr9AKx5L1lD5Uqo5yuRn6Me/wBBVXc0il0jMSNnaFG5mx/eORRds7oYbuaNzqUEbKgeSSTkKrjAz9KH1NpGaMQQfuxyYolCg+7Gk03wxq+pWy3AkS3gY4yQF5x6+nvmoZPDNx9pEDoXmxuYtJkA9wAetPknuPmoX5XLUct1MwBlmXPfawOP1qa2uh95Xk3HBLZGKotpFvaFze3agpguin7gPr7+1LeQGyCXFu3mWcq/u5GBH/66hwktynyPRG5HOzKVMwwB8oGMVPFOUUluc9SFzn8+lYdrfqdqvOiqRjkH+nWrltctIw/erKR1JGM+3NCMJ0mlqbbSloVSOVmA+bbtz37fWlIyzFkGCRtQ5/SqQZjEGwm3dyAckduKtBMAjC7AwG5uMn65oOZxaF+dWB2qDn3PfvnvSGMkZVMcY+vtz0pYXYrl0GM8kLnNLIkiocqxbjjJyPfigRF5xDqrYYH7uMnH5/rUoCmJy6bgeASAM+xoMiFPmAY4x82fzqUAGP5QExkA5z+VAmyq5kDAqW7YBHAz7U9A2QFywGAecc+1PYBm3nO1zjAP60IFPAxxwMkfzqbBzaEO1gpwNpP3sjjOacDub7yqBkjjjjripZlA3cAkdMndUBLZZyzEHjA6g07AtRm8MBjI6YI7VNG4IABYDBwRz+FQ4zIpyOBgj2p65VSE5bB68DHbB7UWG0iZg+fmUbsYz6fWmIMAYOXX5j3prHIABAlPXIzu/GpVx8vmLsUc/WmIiycDHPGDzjP41ES7FiATuAOPXnH4mpXyFHHJ9e4pGV9vygFQQc+9AIACCrFcheQxGR+NMMewKV4IPI7n/OafG5CnZ0IxyecU12YkBsYI/hPSlYG22RoBnttXg4HWlkjYqOCWGVBFMEoYjAw3C8U8ncxBbGOAc9TS0GMyDIwXpnAH9TTHUrIDnaCD/wDqoZlHI5JPABxj60oYBFblievfFBQyMleRjaegzTXG4hRwceuaVgApwMnqBTCyMy85z6etNaEojZQy4JJ9+mMe1RugfBUYA4zU5wB1BIOQR1FROy5wFHI6+lItELN8pBIYHoaG3YB4PY0YJjxnJ+7j+tCrhMOefX1NICJuoG3JHOPWtLUbcX1z9phvIBG+D+8faycdMe1U1iklJEcbyFRkBRmmyWdwUz9mm69PLPFNEPfcdq0qT3jvC+9FRV345cgYJ/GijWsRXhXbtbyo+AMYO0UUPccdkdCmyTOwjC4JyoPFSttiJ37SxG4cBuPzqOScuVVGkdUHysqDgenHan2wM+6KJHOfmCogyx/GtUYWI3by3BkU7852gEcY60TJ5o3BWJ+6R6e/NSblKhnkmXa3RgGP0waeqpty4AcHJAjGcZ+uPwpNNiuQMhjk2srfJjO1RnmnHc6khZGcc58gHP1xUkzoB+5K7c/eX5f05prM5yyyNCwXJKuevuKVrBcaxYj95nbz9+I8D1pnl5KdGDcjLAD8DU6Azu7PIz7F3KTIFwSewPUUyJFcH5I8Mc/KAMH8aB3EZSZN5DLxlmZiePrS7Ub5Y2VfdmIP9aeqZP7mKRdow7Kc4H0ppAEmwBtrDOSCCfSgBnl42/uxuP3mDE7/AH9qCQSSYhwdpYH9CMU4fcARQ2OCOcgexprRls8byBkkE5H1osFxJCDEEYoiDsVwT75ApsKFJFzJFEjD76/Mce+KV2wwUuTzglicge2abGqAjYvPXAOM/hjFJblWJ5Nz5VX3MOPl3Y9zUsbBwCUbYDk/J29KruD5gL7wRzyyqPbBHWpYh8jbgGI/us3NWJlghd/yhxkAfc2hgPXBpZYsvtj8x0I+84A/Dmo2DbcF0yRnIbOPwpS4VVCsQSM8EZNDsRqTYliVxhsEcZCdP51W/dMoJZwwP3uFxTSrrKAqSZY5GWA49TinrECxaRyoLHGOSR+JpbmiVtxJSowGUliSDnJzx6VGsCshGyThQ54wAMfTNDED5iS/rzhj6dKlMhljCvIfLUYGck47D6Ukha9Cm8aRKHYMEz8pZc5OO1UL+VhCD5byY4BYgAGrFx8qZV3PzdSwz9B6Vn3iExt5IcJjHzjd+GaLnXSRh3DT+eBHDF5hOzdI4bB9QOlRXjTWeptbzzTI/lpKCIRIzEjouOAPQmrllGJJJSY45LnI8mOWQIGPtxgfjXO63fX0t2sN1CbSSDgxBCDgdM56j9KFZK56EHzS5UzpbO5upLqRYLvUri88v503ZC45AH8IPcitH+0Y1snPiPW5433bSzhYlUeuAdznHc1xCX0uwLcvcC2UYMdvKkQOevPXmtvw3qOj2shZdK00TruxcXkxkk47qpBGa2pzvoznxFBxV0r+hlamNPO17KfUbwAZLum1c56j1/GrXhia9k1S00/ZcPYzyFZIGbepGCScdumTitvUtSs3QXNyGupsHDsRsAz2B69fSuZS7klvFbR4ZhNbN5nmxDIj5xuLdAo9O9ROCTujaMuek1JW9S5OtzFqFzGsKII3Iwi5UDtjmtezldIwskiqhGCAhzWPqjO2rXRZfNPmMTiTJY/h09avWu8KRKgiHByXzu9MYrK2rKl70E2bKSQkBT5iseBkdvWrsT8FF+UnHUc1mRljISZXlVsEtggH/wCsK0IhhlKlt+CxyP8A69M4ppWLiDBwqlmA6Dn8aAwZxhRkc8fnyahjyHUIWZcH+LH6VK7RK23licbdpP8ASkYW1Jlf7uSy4yQeOakWT72BtDc/dzVdlOQQBtOckD5vzqQlhJtBUtgZJ/SgzY9nbcMP8xOegwajKhuSwZwASMd6lkyPvjbxgKMc+5/HtUII3qwDM27aMn3/ACpgiQeZ85YDAb+HoAaiLliOB8vO5j+hH509WJJAGcAgnHUfT+tRscEjaOeRvHLEUDQhXy84IPQgY/WiVlWPKj5jnv09qCq8BW4HYjnPp+Rpcbg7ZLMqdhjA96AGR7QmFQuvQ9qkjPCqASF4BI96a2NpJbJzx2GPpTg22Q89M9sfTFACSMQwLA7Mc+9AwVBYlRnAOfekd/n6YHOPak3FkxycHIOM/rQAm8/NlcNkGo23Dg5BI6D1zSqrAZbsckVIwRgHJPrmlcHoQFANwGTk84FN37ep9vpUjEqQR9xeenOKrsVxuX5l/iz60mVHzI2fnjA46UqH5Mk/MDioZ1ILFSMHn9KZC56nnOCaVzRx0LbfwkYww5z2pqt8pUADByAD2oRhxkfL/e9+9JKUMhw5HPp1p9DOxHkZ4zyeSRTLgKRhD+ZqR+FYqMZIqEIdpErEY5BH9DQNIacZ+XPPp3pJQADjqMH5TmmzoQFKnbjv/jTl+71+YHPI60h9BEuJoBmCV4iRj5TjNMlv70ci7nAx/fNXLWOBorm5mQzLCAducAknv7Cmzww3ls0tkuyeP5ngzkFf7y/1FVZkXV9UZc8zzNvnZ3bGCWPJoq5rEEcN8FhULGY0O0dMletFJ7lJ3Wh0JQkkleevTBzRHs81Wl3BlHG0en06Gh42jbaVZW3A7wT+megqeNGkbCFnc8ktjOPrmr1RhoOR1LDfNIMAjjndn3xxTYQuGfaXIPBGDj86T95tG7c0KHbnAIH+AqNXDKUO1iByWA6e1V0JsSPkSZcjcDkkZ49/T8KG+YgkB+c4JHH40RqoOUcLt5wVz078CiLaMhVBJ6Hbj+nNSMkddp3FY1xgYjAXJ9MHrTch84EeVGOB8wx26Uu0j5s7UPAxnH1ximMQGJ2EryOGAzR1F0B0PVRnHGQRxToBlRun+df70eSPxpzAy5cBQOhAwfzz3pFlmdABvIXAwP8A9VAyTbxgnJH0AI7mmcuAoBeMZ+UDr9COtSB9nCjaPTGcn8RUBRW+XDZ5yVGP50xIjcAhsSbieCCMZ96cqoQqbYY2A+8zEEj0+tWERpCW2n1LKACB7c9ahKMzNkOCVzljnn60tik+ggPyrg9D1IB4+gFSM6lFBQkjguDz9MGkRWGWLEg8bs7SPy61LKU4bJy3cMcnjuT0qlsIRnIWP5gH7knn24ApWTc5UkHOG4BOarx7wTl2K4+VgDyfXOKIpCww0bMuOiHB+vPapGl2JvlVhiPkckMuQ3tTjEQmUQB+NwVcAZ7CowkfAOOByD1P4E/rUpKlm2ugBAyCRkU0DEJZY2LSlIl52MTj86qrMqs2VjfcDt2uVI9xn+tWAyFwQ2T0yV6c00x+XuJeQK2CwV13MfU56fhT32GuxWmmLhQHCN93IORjHXgdKpSQrJhJZwzEAd8e2M1oSKQRwSrH5S2G6/TmgHy2KxzQ3DHIdJI8BR2O40JGnMo7HOXdnKm5okiY5yMKM/T6VdvZ11HSjBf2Ubun7uKVz88Off26jmrt1bmZpHjiAGCT5Kn5R+dZc9uAxljWRxgZznafqKE7aG3Mp2b6HD6jZRoXylqjKcYW4JLAdxx+lZhVFjJi5fPKod2a76XR0YYj0tUlb5pN7cfgeoqjcabcwJsaazslI/hPzfQkc5qGj0YYi6sjDsLeSJvM1GxgVAcjzpmR29sA5/lWrdarq11dxWu20tbOfYjCBt25AeASR+lRQ6Ckrq1zdGOI/wAT8M/vjr+NX7i201Y44bGaVYAvzYDMd2ew6H8elOEnYidmzNnXZql2kknnymUjcGznJznjqa0reAKQFilX5trNJhc/4VJbW0sKKLW3NpEeskgw7ep55x7CtG2tYVEjAsxQ43sQoJ9QDkn6UiZVLKwsETPw7YTqRknd+NXljULgsqlh1C9Of1qOKM7VXIYn5iWyP51pRRZKhRsz/s8j6AUjjnMZaowG8bSAMhn/AKZpwRlkVduXKk4HG4d6dO7xkBw24Dau7auMdvXFRyhp0Uv5gIxzz+VPQxu2OEhdG+VNpAADP2707zAWAI8sDvtzTCzJwQ5ZskFlxgdunfrkU4gBzI25f7p24BPTNAgLg5KABTyOeAPxp6PtcsdxA6EY4P0qLcG+RABkgFtuQcfypdyLwjjZxluuPUe9AWHQAKGCpu6nBPbPt39qa2PnJLYKljz0pHkUPuU8k9T1I9h9KgRwe2OpIxxjvSuUokhkwAF577MUbiv+sVQMkAHqPpSttABb7oIyN2QKZG7yFAqgueBnv60XHYlRtu/jJPbbyO/5UvA4JBzkc9PrTUcffJbPGSRnn/8AVT5FKj7wPJ680EjDgIBlcdQ2acBnDAgk8ZznFIRkYOF7k9QT3p0CEJgsvcbfx60xMYpBk+csGzgdDzSSEEDgq3uKaxyT0VwP070bucnLKMYOeTSBkcynZ1Yt1Q5wR/8AWppViucHLccjoKkOHAOORnAqOTeA3zLjjGOT70mVErOox8q5U45NRlNnCgfe4I4x6VaJVcDrxk0gVSf9knIyOhpWLcnsRxlgMdFPIocbVUg8/wAPqD/jTnQhsdcjJ9qYGL8BQWweM5/Gq2JQi7vm4AJGOuMUxyA3OSDyDjrRKu6Nsggk5yPb0qBywJPX+tK4yNv9V8p5znnnNMWbDBWYDg4A6UrMy5JUEHJz/Ss93Aw+D757Ui4xujW06W5EpezR3YDDgLuBB7EU6K1v45VlitrhJFOQwQ8VSsLme1mjlg5IIBUfxr3Bq666gC0iw3SRZJCkscCqTujOSsyvqUlxJds14mybABGNueOOKKbKWY5csxP8ROaKTVxbHWS7hvXO4AfKUOVx3ODTOWKlV7ZOABmpR5u0AM3lk8E5P5VDLGAqqGDZ67gR/MVozBCoGBDYmWTnqg2j/GkhZ0IMUbL6kgfj9KVAmACHDA/Mwk4PsDjrT2Rc/dR2K8hk6fTmkMkIUMQzsSOCD0/PPNSStFhVAYMOd6Mct7UxJnKFRMiEdQMrj2xSRLk+YFztHZhnr05607k6g2WKgtKWGTGGTI/Hn+dJHIQMmVVB6qCOf1p8SM6ngAkE/M6jp60qqh2Al2JyAg4yep5FIp2I5Uwd/mqS3TbIR36k0gYs5OSwGSV38/metPjRd2NxyDg+/tTXJ3Mkgfb/AA7DjH1z1oEhWZi4PzIx6YFP3LvfLiRuu45/HimiI7SSylhxgv1H+e1AcsWRd8a9DgkjHrj0oAQplWyV9gO/vSzIQQpDKoHJZMEj1FMmSWMc7RnGSef605Myclj8hwV55zQCQ9CqsRKhK8cqOnpSO6hy3lopPYJjj8aaEAAKHc3GQVPH408bVAPl/OQT8hOcU7hYjnlXedm8EjkAfyFRB8na5JGOFPbBpzqCFygYZ4KjJH501MNt80sOMDeDg+/TFJ6lomXcVKKCcnoMdfr6VP8AP5ASVw20cDGRn32jmq6bwT5mwL91SWGPzp8Ms0IZobh1PTCYwfxpoTF2lGHluF3D5kbgfqaYMxytg4bHQEcenrSScEHfvLfe3A4x/nvTzhgcSK2OVw/f1xTEQvsPzOXEgJA6LnjuT/KjywQfkDqBn74GD9QOfpTsb4vKJgDfxNuAJH4imhY4YiwZ1BAGc4LfQZpst7aESgLu8yDceisrFSPfHGTSTxgEbUP935l/U4PWnlckJmHDDAb5ST7An+dTSKIvlLNwMAFwTj2waVtBXsZs8Bf7y3EjdRs/+vVIWUDFt4lwSMsinOfc+/tW7MxUcGfcxwQU6D8O1QuQHPm/MxGRuXkfXJ4/KpaNFUa2MmLS4IyJTE0oB481eCfTk/hmlFqRI2Ta26t6nJH0xWnKiBDIGtirNwqoS30JHQU9IoSrJFHI7YOHVNg/PqfrQojVZtGSII926dpZSByWkJz9B2FTQRKPuqqlj/EhyB7d81eNu7T7YiGXGM+c4Xp3/wD1U14FCneUbd0ChwDge3X0otYftO4xYpWkPmMSF4UFVAH1zTw4LqvLe46kd84HJpxKZ/doFyOhwOP50qo2A+RzgIAGVen86Qm76sVGQlucEDOMHDe/rUWN8ijDMxGDt7Y6dealWJQGGQWA6sSuPfH+NNMhYHDHBxjdHjJHYY9/zo1JT00H4KMAU246cgjPuR3pflKqC2Mdun489vekDkOrbSSuDhxlfp6UqfN8qlc46420Csx8alQNo656cEf40khJ2ogJ5yvTJB9etL5hcbSzFs85AxSMm1WZeAMDHv70ElcxNIgDnC9AuM49ajC7SAi45yAVx/kVOFQxg+Xsb+9uy2c1HnbLFtJ4yxVjkfWkzVNj1UsVCsCMclew9qaYijjup4UdjTo5SSN6qCFzzUh4AY/MBjgGhInW5EQyvlQQfQjrx2+lNeTyzlssoHOT2xT+qlYsYx0Y5FMIUghQcAenc0yh0JEyqQeBxgdR/wDXNPkU7iMkv7ntUEa7AxJByOV6Y+lTPINoCj5MZGeaCXuIkI3EuccZwB196bIPlK8KQeMU7dnknGBjHp6VG8vy5YcqOeOtA9WEb/MFYBio5AHb1zUchwCGTAHIPr6ilgUs2AQBjKg9eveo5MMMEcZ6Z7561I9hrgyHdtznB56igEYHdx19KkEeMEZxzzmmzLscM2emAKaBsRzlcjbkHqP61Xl+dQRzk8npg1Jux8rDAzyO/wD+qk7NgHbjJz6UbglYYVBiGT82exqOWMbif4WP5VZXDKGXDcVBKjeVtUnBGfzpWAzZyN3zru2nriqMoyQ2T7/Sr8qDLAnBJ45qJkyCnG4jOT61LN4Oxb0SU4uVhkSG7ZAsTscDrzg9jir622r7gfNkQjkuZhge/WszTIrdo7i4uEZ44FH7sHG4k4HPYVZktYJ4JLmxDL5Y/e27MWKj+8D3FVHYwmtWGsSxyXshjZWAChio4ZsckfjRUerRxwXe2BCsflocA9yKKbbuEVorHTyvvPQrjjO3H4Y4qMMSQqs5Yjo3T8OamdAQvDKue+WyfeowN+4Sp908YjAIq+upzofkoXZkCt94hVHr9aQy5A3SD2yuf1HSlMeZlRTtX7wO0DA9cE0pbaoVC6uDgbTyf6UMBTK8g43Y/wB7fj9KjZ3VAjKuOxZPmpSfnJkVcD3AP04qTzCrvuZ1LDIbkjHbrUjFi2tJgDO043BEHGPrSeaMEbd2Mjcx+YD2wajVhhyCBIvUlxuI9QMU6SWWPDbl3OCB82fzHagGhFmIwQihc4yScfjUxXbgmRcEjCCMj8qgAHKb1BHJGDz+FSM+wiPdycZbnpiqTBkk3ysQ0bbwOj5yM/Wow8inJZkxyFbJFBkB3EbPl+U5OST6kGkkwvyEgFeMZHJ/Ck2JIjkKFimxSxOS2AQR7U4E8DCBW7kD/IpsiGUgB8FTgjHP/wBcUFHGVcsxA4HUgd8c0ix2N3IyQOOU2gD1zUtuwdMAHGONpx/SoQwGMBWJ/vEcfTBqUO4VRIxUqepPIHfv3qk0hNDnVTlQCrgjocnHfrxVZ9m0FCQB1DDP61MjE5KYHOVHGc+vrQI1cjbuL/e3AdB7gdqT8hIhaQK2XGVHICkdfyqXe0jDP8WeWPAx7mlkG6Jsqh5+8FOTSRxuibdz4PzYP6UFOz1BhlQkswVVBI2nn370+MsmAm5gRtViMU9bcYDbCAOOMcEfjTGDIGXlSp6gjn9M00mS9SN2V2HPmBc9+/5U6OEsA7RdQMbwT+QApsmPlw0nJw27BDfhinsioWPzlMYYkA4+nSnqw8hshJf5onZ8YLAgZHptI4poRHiKmKQNnJJuFAx6Y9accOkkccQJbBI8v5uvXOM1HtWMRh88k4PlICfxJpjGuIU3eayKGHCglyf++TwaI0KrlI3ZM4BJ2DHtmmSK6qTbzQLJjZs27jyc9+AaejSRv5UvlsxGQyorEZ7nBNShvYkAdwDsQZOBvmDcj26/pTPKD8ouXwAPkfgdOpPT8KRCUcsRz/Flipx07Gn+U3mHadzf3QxbaPfii13oJqw148ltkQyrYwhxn8zyfwpAYztaQqmDk7pOc+nrVlmKErI0Soyts3Sbsj6AU2Rp3VJCgRRwDHDtXj9adgTuymwDly0yF+gDKxY+uKerZbdGZOOWYsI+DUrJ5siHYWUsSFEmAB6+tRrbKjAAx7ugOd4APbpUpGjZM6pJxLKVZu28ybvTocD8arkMd212XsfmwKlKlGVXATy+ilQOfpn+dJ821Qd4P3ceWCWz6f40MS0IVLIeB8wwAQCQPX2NISXjG0KOOoBPTtin4yxIdUYjGGBbd3/A04DK4LmMYA+Y5wfXjpSLTI1kZHXr5nqxLE/UUse3YC46fdzjBoSUEbpT5h6ctw3p05qRVZ5NyhEzyF9v60CloV9yYCPk+hz/ACx/Olk3RgM2QTyMgDcPWpJIy3D4DYzz2+lCwsRkY3dv/r0BdEUZHQL6n5Tk/lTzuDAkkY9Rgn05pwUs20OgIOBkYyO/NKqtjPJOcE+v0NAOSEIXOzOcDG4cZoYtt2/xZGBjg5pHRWIXnDHIy/PSkC8cqVAABAHJ+tJiQrscEYKtnB78etNTDRkB+h6HjFLwduRyueCdu4U5UzluCDznPei9ytCGXbg8HcRzg9aby+WxtB4xSzIWJxuxjkntTAR/FliAc/0pjHjb0yM4Pze9DcN8xBPelwoXnO7ryKhcsMN0BzkDk0tBLUlAAckHJPAI7VFLycZy2P8AIp8+8qpXGAMZ9vSmnJVCU4xg4PShARAjdyfn7+wpskgOTuO7HJ7UShw2SDkcU2M4LKcAdcetMdgySeBweuO9MlwWID4Tgdanfg8j5lxn0Iqq8bA/NwAc+tISKkw3MD/FjjNRsvGFOSD39KtMPlUsCwHBA6fjTXByDsA/z3qCuYgtriW0uMwBSHG1lddwYehFLDPJDMskD7JM8EenpirljarLK0rKJNpVVjzgMxPGfbvU8cpmuprdhayJHkhVj2h8dQpHIOM1SE5JlC8uGupzNKoBIC4UYHAx0op1zbrDO4jYtE6hkJ67SMjNFNpkrbQ3Zpjt+RM85LdO30psMxdyGVWUjG5z0qROYTn1apLUZh/4C1O92RYQnG3HlvwRnrj8hTW5Kgn5M4JXP6Zpm5hb8Ej5/X2ojJZhuOeT1pCLCtF867iQvTIyT+VKFU5wWkXqrbSD+Oe1TzoqrBhQMsM4HWs2Z3W6AVmA8voD7mm9EKxcjYGMo3zHPCjA/pSMSVZd/wA33flVQT/U/WoFYmTBJI9DVu+ULdIFAA9APYUDIFjYzfN8245+cjn/AAqYZHIDF++DirEkaCzBCKDnrimdJkx/dNBJEZFyFAG7PY4HTmljIVoyvfPT5ccVGxJhQE8Z/pT7YBpJQQCAo6/SgbSsJIi5xhd4weBx+tDKFKPtwnpjqc1DckhVwezf0pyOw3YYj5uxoQ1sAj2swBby+w4/mKkRSQimVOQOMcn8+lT2/wA1tKW5IBwT24qIMfsgOTnf1/ChCbHg8gPzlj2wPfpzQrcj5dqjggHbke/rU6qDpsjEAtkcnrUDEgoAePKH9ab0JWo7GSNkapxwRyaVcIWUDhOAzHj+XWo4GJdASSMevtSp80uG5AI4P1oAmb5mVEBUL3zn6nihj5cedxBPfgKR7980WQDXEgYAjOMH61agRRrewKAmR8uOPyq0JlA3EYTZu2RnDYD4DfU4zREN6B1XqcALxz75q0wB11VIBXf07VBZASXEXmAP+9A+bnjJoTGthVWWPku8YI4YOBg+uQD/ADqo/wAzBxs37h84kIye+eM/rWjbRp/a7jYuAxxx04q7p8aP9pZ0VjgckZ70C5nuYjRHGH8l1yMRhmkyfQgevvUiogDrGkR4OfLEkewfQcVPqzvHI4jZlGwHCnHeqgd3ngV2ZlaM5BOQadgTuMjhZUIKgxvzuA5+nPNLEJAdhQCTGDGuWI9BgEVotDEHjAjTBPPyj0rIviYnXyiU5P3eO9QO5ZdmhBMsIVAedrbdvbtz+FVmYvtJRR3GTkH8zzRYfPcSlvmIGQTzViD5raRm5YMoyaGzRKxGscWxMQQOxXkiQt+YxxVqPcwcGKQLjjaMYPvmnTDGis4+/wCaPm79az7d2YuGZiN56n/ZpEvVFmZ/LJHlKxUHAkPOe+WH8qgYq2APvDup9ex//XU2AZCCARhf51BETvuB2AOPzoKitCVlPQBVQjpt/Qf/AF6quuCpBUKV3Y2kK3rWmFXyV+Ucgk8e1Zy9F/3qGVESJQckYAX5jjjj2Gean3BZFAU46nkH61BJ97/toKtE4kXH/PT+tIc9yEKAu5cZz0B6D6U12kGTucKR0PT606ViNmCRlj0+pqNmPmdT91qCUKxAdeNoPTJ61MJfNOBhQTkDOTnNRQAEAkAnPWnQgZTjv/Q0XHyofJhEDKMBegP+FSHYw4OG7Y5BpH5tkz/f/oKpniVgOBgUMXQtt5QACnBPJJHH4VEGAIA3AD34z9adaclweQMfzqI/65h2yv8AWgBxTkKAwXqWPf3xVdiQTsIBznAOM+1M3HzBye/86Uk5HPY0DHoWBw4yT6GhkUoG4Uk8H/Go2/4+F/D+VOm/1ifU0AhhOU47E/QfSneX+8yje59/enSgbRwOtKei/Q0kht2IDEzMdz4wODUcMasSzFgw5JI9+tPb/WfhRMT+556imK7EK4LYLMGOTnsKZIEZMAfMRxg8U+4JwnJ60+QAKMDHBoEyiuPMJIPHUmiSPfjaeMdKcO3/AFz/AK1DJ/rvwNTuU2TWUqW7NG7NGr4IcjOxgeD9KtbFR3lC2cBYHMyy78Z67U9ay15LZ5pkvAGOOlO9hWvqSX86y3BeMFUACqvcKBgUVWk+5+dFIq1j/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lymphomatoid papulosis lesions in different evolution stages. A regressing lesion appears as red-brown papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13333=[""].join("\n");
var outline_f13_1_13333=null;
var title_f13_1_13334="Intracellular HME EM";
var content_f13_1_13334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Human monocytic ehrlichiosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph showing Ehrlichia chaffeensis, the organism responsible for human monocytic ehrlichiosis, in intracytoplasmic vacuoles (morulae) in the cytoplasm of an irradiated mouse embryo cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vsevolod Popov, PhD and Sheng-min Chen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13334=[""].join("\n");
var outline_f13_1_13334=null;
var title_f13_1_13335="CPAM prenatal ultrasound_length";
var content_f13_1_13335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55315%7EPEDS%2F63885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55315%7EPEDS%2F63885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 357px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The calipers are used to measure the longest dimension of the lesion (L).",
"    <div class=\"footnotes\">",
"     * CPAM&nbsp;was previously known as congenital cystic adenomatoid malformation, CCAM.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney Stephenson, MD and Andrew P Schuller, RDMS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound of a congenital pulmonary airway malformation (CPAM)*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After measuring the longest dimension of the lesion (L), the probe is turned 90 degrees and the \"width\" (W) and \"height\" (H) of the lesion are measured. The L x W x H x 0.52 = volume of CPAM. The CPAM volume ratio (CVR) is then calculated by dividing the CPAM volume by the head circumference.",
"    <div class=\"footnotes\">",
"     *CPAM was previously known as congenital cystic adenomatoid malformation (CCAM)",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney Stephenson, MD and Andrew P Schuller, RDMS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13335=[""].join("\n");
var outline_f13_1_13335=null;
var title_f13_1_13336="Overview of mechanical ventilation";
var content_f13_1_13336=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of mechanical ventilation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Anthony J Courey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Robert C Hyzy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13336/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/1/13336/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation is also called positive pressure ventilation. Following an inspiratory trigger, a predetermined mixture of air (ie, oxygen and other gases) is forced into the central airways and then flows into the alveoli. As the lungs inflate, the intraalveolar pressure increases. A termination signal eventually causes the ventilator to stop forcing air into the central airways and the central airway pressure decreases. Expiration follows passively, with air flowing from the higher pressure alveoli to the lower pressure central airways.",
"   </p>",
"   <p>",
"    The types of mechanical ventilation, as well as its benefits, indications, and initiation are discussed in this topic review. Potential complications are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=see_link\">",
"     \"Pulmonary barotrauma during mechanical ventilation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation can fully or partially replace spontaneous breathing. It is indicated for acute or chronic respiratory failure, which is defined as insufficient oxygenation, insufficient alveolar ventilation, or both. Some common acute disorders for which mechanical ventilation may be required are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef67457 \" href=\"UTD.htm?2/20/2381\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mechanical ventilation should be considered early in the course of illness and should not be delayed until the need becomes emergent. Physiologic derangements and clinical findings can be helpful in assessing the severity of illness (",
"    <a class=\"graphic graphic_table graphicRef66496 \" href=\"UTD.htm?33/59/34748\">",
"     table 2",
"    </a>",
"    ). However, the decision to initiate mechanical ventilation should be based upon clinical judgment that considers the entire clinical situation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Some of the objectives of mechanical ventilation are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef78508 \" href=\"UTD.htm?19/25/19867\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal benefits of mechanical ventilation during respiratory failure are improved gas exchange and decreased work of breathing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical ventilation improves gas exchange by improving ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      matching. This is primarily a consequence of decreased physiologic shunting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H12#H12\">",
"       \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Physiologic shunt'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The work of breathing can increase due to altered lung mechanics (eg, increased airways resistance, decreased compliance) or increased respiratory demand (eg, metabolic acidemia). The effort required to maintain this elevated work of breathing may result in respiratory muscle fatigue and respiratory failure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/1,3,4\">",
"       1,3,4",
"      </a>",
"      ]. Mechanical ventilation can assume some or all of the increased work of breathing, allowing the ventilatory muscles to recover from their fatigue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF BREATHS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation can deliver different types of breaths, including volume control, volume assist, pressure control, pressure assist, and pressure support. They are defined by the combination of three features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trigger &mdash; Breaths can be triggered by a timer (ventilator-initiated breaths) or patient effort (patient-initiated breaths). Breaths that are initiated by a timer occur at the set respiratory rate, while those that are initiated by patient effort occur when the patient causes sufficient change in either the pressure or flow in the circuit. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Trigger'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Target &mdash; The flow of air into the lung can target a predetermined flow rate (ie, the peak inspiratory flow rate) or pressure limit.",
"     </li>",
"     <li>",
"      Termination &mdash; The signal for a ventilator to end inspiration may be volume-, time-, or flow-related. Examples include delivery of the set tidal volume, completion of the predetermined duration of inspiration, or a decrease in the inspiratory flow to a predetermined percentage of its peak value, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Volume control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume control (VC) breaths are ventilator-initiated breaths with a set inspiratory flow rate. Inspiration is terminated once the set tidal volume has been delivered. Airway pressure is determined by the airways resistance, lung compliance, and chest wall compliance.",
"   </p>",
"   <p>",
"    Modes of mechanical ventilation that can deliver VC breaths include volume-limited assist control and volume-limited synchronized intermittent mandatory ventilation, which are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H2#H2\">",
"     \"Modes of mechanical ventilation\", section on 'Volume-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Volume assist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume assist (VA) breaths are patient-initiated breaths with a set inspiratory flow rate. Inspiration is terminated once the set tidal volume has been delivered. Airway pressure is determined by the airways resistance, lung compliance, and chest wall compliance.",
"   </p>",
"   <p>",
"    Modes of mechanical ventilation that can deliver VA breaths include volume-limited assist control and volume-limited synchronized intermittent mandatory ventilation, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H2#H2\">",
"     \"Modes of mechanical ventilation\", section on 'Volume-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pressure control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure control (PC) breaths are ventilator-initiated breaths with a pressure limit. Inspiration is terminated once the set inspiratory time has elapsed. The tidal volume is variable and related to compliance, airway resistance, and tubing resistance. A consequence of the variable tidal volume is that a specific minute ventilation cannot be guaranteed.",
"   </p>",
"   <p>",
"    Modes of mechanical ventilation that deliver PC breaths include pressure-limited assist control and pressure-limited synchronized intermittent mandatory ventilation, which are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H9#H9\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pressure assist",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure assist (PA) breaths are patient-initiated breaths with a pressure limit. Inspiration is terminated once the set inspiratory time has elapsed. The tidal volume is variable and related to compliance, airway resistance, and tubing resistance. A consequence of the variable tidal volume is that a specific minute ventilation cannot be guaranteed.",
"   </p>",
"   <p>",
"    Modes of mechanical ventilation that deliver PA breaths include pressure-limited assist control and pressure-limited synchronized intermittent mandatory ventilation, which are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H9#H9\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pressure support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pressure support (PS) breaths are patient-initiated breaths with a pressure limit. The ventilator provides the driving pressure for each breath, which determines the maximal airflow rate. Inspiration is terminated once the inspiratory flow has decreased to a predetermined percentage of its maximal value. Pressure support is a mode of mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H11#H11\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure support'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MODES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modes of mechanical ventilation are distinguished from another by the types of breaths that they deliver. Common modes include assist control, synchronized intermittent mandatory ventilation, and pressure support, although numerous other modes also exist (",
"    <a class=\"graphic graphic_table graphicRef77391 \" href=\"UTD.htm?19/30/19949\">",
"     table 4",
"    </a>",
"    ). The modes of mechanical ventilation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INITIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once it has been determined that a patient requires mechanical ventilation, numerous decisions need to be made including whether invasive or noninvasive mechanical ventilation is warranted, the mode of mechanical ventilation, the amount of support, and the initial ventilator settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Invasive versus noninvasive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mechanical ventilation can be delivered invasively or noninvasively. Invasive positive pressure is sometimes referred to as conventional mechanical ventilation or traditional mechanical ventilation. It is delivered via an endotracheal tube or tracheostomy tube. In contrast, noninvasive positive pressure ventilation (NPPV) is delivered through an alternative interface, usually a face mask.",
"   </p>",
"   <p>",
"    The decision about whether to initiate invasive or noninvasive mechanical ventilation requires that the entire clinical situation be considered, including the underlying disease, its severity, its rate of progression, and patient comorbidities. Generally speaking, a trial of noninvasive positive pressure ventilation (NPPV) is worthwhile in patients with acute cardiogenic pulmonary edema or hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD) who do not require emergent intubation and do not have contraindications to NPPV (eg, altered mental status, abundant secretions, emesis) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Invasive mechanical ventilation is appropriate for most other patients. Patient selection for NPPV is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link&amp;anchor=H2#H2\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Choosing a mode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of the mode is generally based on clinician familiarity and institutional preferences [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The modes of mechanical ventilation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link\">",
"     \"Modes of mechanical ventilation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Level of support",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of ventilatory support refers to the proportion of the patient's ventilatory needs that are met by the ventilator. It is an important consideration because insufficient ventilatory support does not provide adequate rest for fatigued ventilatory muscles, while excessive ventilatory support has potential complications. These include respiratory alkalosis with subsequent intracranial hypertension, decreased oxygen delivery with resultant ischemia, and atrophy of the ventilatory muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. One study identified diaphragm atrophy and markers of proteolysis even among patients whose ventilatory support lasted less than three days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/10\">",
"     10",
"    </a>",
"    ]. The optimal level of support provides enough rest for the ventilatory muscles to recover from fatigue, without allowing atrophy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=see_link&amp;anchor=H13#H13\">",
"     \"Physiologic and pathophysiologic consequences of mechanical ventilation\", section on 'Diaphragm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The level of ventilatory support is determined by the mode and other settings. Generally speaking, assist control tends to provide the most support, synchronized intermittent mandatory ventilation provides the widest range of support, and pressure support tends to provide less support:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of patient effort during assist control involves triggering ventilator-delivered breaths. Patients who do not need to trigger any breaths are receiving full ventilatory support, while patients who trigger some breaths are receiving somewhat less than full ventilatory support. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H5#H5\">",
"       \"Modes of mechanical ventilation\", section on 'AC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The level of ventilatory support can vary over the widest range during synchronized intermittent mandatory ventilation (",
"      <a class=\"graphic graphic_figure graphicRef64325 \" href=\"UTD.htm?9/53/10078\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/12\">",
"       12",
"      </a>",
"      ]. Full ventilatory support is provided when the set respiratory rate is high enough that the patient does not trigger any ventilator-delivered breaths. At the opposite end of the spectrum, no ventilatory support is provided when the set respiratory rate is zero and all breaths are spontaneous. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H7#H7\">",
"       \"Modes of mechanical ventilation\", section on 'SIMV'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pressure support can not provide full ventilatory support because patients must exert some effort to trigger each breath. The amount of ventilatory support provided during pressure support ventilation is directly proportional to the pressure support level. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H11#H11\">",
"       \"Modes of mechanical ventilation\", section on 'Pressure support'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous settings that need to be considered when mechanical ventilation is initiated. These include the trigger mode and sensitivity, respiratory rate, tidal volume, positive end-expiratory pressure, flow rate, flow pattern, and fraction of inspired oxygen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Trigger",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two ways to initiate a ventilator-delivered breath: pressure triggering or flow-by triggering. This section discusses each.",
"   </p>",
"   <p>",
"    When pressure triggering is used, a ventilator-delivered breath is initiated if the demand valve senses a negative airway pressure deflection (generated by the patient trying to initiate a breath) greater than the trigger sensitivity. A trigger sensitivity of -1 to -3 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O is typically set.",
"   </p>",
"   <p>",
"    The trigger sensitivity should allow the patient to trigger the ventilator easily. A trigger sensitivity that is too sensitive may cause a breath to be delivered in response to patient movement or subtle pressure deflections caused by water moving within the ventilator tubing. In contrast, a trigger sensitivity that is not sensitive enough increases patient effort. This may cause a prolonged period between the initial effort and the ventilator breath or patient-ventilator asynchrony (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Asynchrony'",
"    </a>",
"    below). Pressure triggering can be used with the assist control or synchronized intermittent mandatory ventilation modes of mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H5#H5\">",
"     \"Modes of mechanical ventilation\", section on 'AC'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H7#H7\">",
"     \"Modes of mechanical ventilation\", section on 'SIMV'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Auto-PEEP (intrinsic positive end-expiratory pressure) interferes with pressure triggering. Auto-PEEP refers to end-expiratory pressure that is created when inspiration begins before expiration is complete. The mechanism by which auto-PEEP interferes with pressure triggering is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H14#H14\">",
"     \"Positive end-expiratory pressure (PEEP)\", section on 'Potential sequelae'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When flow-by triggering is used, a continuous flow of gas through the ventilator circuit is monitored. A ventilator-delivered breath is initiated when the return flow is less than the delivered flow, a consequence of the patient's effort to initiate a breath (",
"    <a class=\"graphic graphic_figure graphicRef50688 \" href=\"UTD.htm?3/27/3519\">",
"     figure 2",
"    </a>",
"    ). Flow-by triggering has been shown to decrease inspiratory work during continuous positive airway pressure and the spontaneous breaths of synchronized intermittent mandatory ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H15#H15\">",
"     \"Modes of mechanical ventilation\", section on 'Continuous positive airway pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H7#H7\">",
"     \"Modes of mechanical ventilation\", section on 'SIMV'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tidal volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tidal volume is the amount of air delivered with each breath. The appropriate initial tidal volume depends on numerous factors, most notably the disease for which the patient requires mechanical ventilation. As an example, randomized trials found that mechanical ventilation using tidal volumes of &le;6 mL per kg of predicted body weight (PBW) improved mortality in patients with acute respiratory distress syndrome (ARDS) (",
"    <a class=\"graphic graphic_table graphicRef87507 \" href=\"UTD.htm?8/22/8544\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87147 \" href=\"UTD.htm?8/24/8576\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/16\">",
"     16",
"    </a>",
"    ]. Low tidal volume ventilation is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal tidal volume for patients who are mechanically ventilated for reasons other than ARDS is unknown. An initial tidal volume of approximately 8 mL per kg of predicted body weight (PBW, which is the same as ideal body weight) seems reasonable, albeit unproven and based only on clinical experience. Rarely should 10 mL per kg of PBW be exceeded. The tidal volume can then be increased or decreased incrementally to achieve the desired pH and arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ), while monitoring the auto-PEEP and airway pressure. Return to the previous tidal volume is indicated if the patient develops auto-PEEP &gt;5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O or a plateau airway pressure &gt;30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O following an increase in the tidal volume. Large tidal volumes can cause barotrauma or increase the risk for ventilator-associated lung injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    During volume-limited ventilation, the tidal volume is set by the clinician and remains constant. During pressure-limited ventilation, the tidal volume is variable. It is directly related to the inspiratory pressure level and compliance, but indirectly related to the resistance of the ventilator tubing. The clinician typically changes the tidal volume by adjusting the inspiratory pressure level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H2#H2\">",
"     \"Modes of mechanical ventilation\", section on 'Volume-limited ventilation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H9#H9\">",
"     \"Modes of mechanical ventilation\", section on 'Pressure-limited ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Respiratory rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An optimal method for setting the respiratory rate has not been established. For most patients, an initial respiratory rate between 12 and 16 breaths per minute is reasonable, although it may be modified according to the mode:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving assist control, the respiratory rate is typically set four breaths per minute below the patient's native rate (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H5#H5\">",
"       \"Modes of mechanical ventilation\", section on 'AC'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      For patients receiving synchronized intermittent mandatory ventilation, the rate is set to ensure that at least 80 percent of the patient's total minute ventilation is delivered by the ventilator (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=see_link&amp;anchor=H7#H7\">",
"       \"Modes of mechanical ventilation\", section on 'SIMV'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the tidal volume has been established, the respiratory rate can be incrementally increased or decreased to achieve the desired pH and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , while monitoring auto-PEEP. Return to the previous respiratory rate is indicated if the patient develops auto-PEEP &gt;5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. Other approaches are equally acceptable.",
"   </p>",
"   <p>",
"    For patients with ARDS, the required respiratory rate is higher (up to 35 breaths per minute), in order to facilitate low tidal volume ventilation. Setting the respiratory rate during low tidal volume ventilation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for auto-PEEP as the respiratory rate is increased should not be overlooked. In an observational study of 14 patients receiving low tidal volume ventilation, increasing the respiratory rate was associated with development of a mean auto-PEEP of 6 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/19\">",
"     19",
"    </a>",
"    ]. Increasing the inspiratory flow rate and the respiratory rate simultaneously may mitigate the development of auto-PEEP.",
"   </p>",
"   <p>",
"    Occasionally, patients may continue to have respiratory acidosis despite optimization of their tidal volume and respiratory rate settings. In this situation, permissive hypercapnic ventilation is appropriate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link\">",
"     \"Permissive hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     PEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Applied PEEP (extrinsic positive end-expiratory pressure) is generally added to mitigate end-expiratory alveolar collapse. A typical initial applied PEEP is 5 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O. However, up to 20 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O may be used in patients undergoing low tidal volume ventilation for acute respiratory distress syndrome (ARDS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevated levels of applied PEEP can have adverse consequences, such as reduced preload (decreases cardiac output), elevated plateau airway pressure (increases risk of barotrauma), and impaired cerebral venous outflow (increases intracranial pressure). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H4#H4\">",
"     \"Positive end-expiratory pressure (PEEP)\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Flow rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peak flow rate is the maximum flow delivered by the ventilator during inspiration. Peak flow rates of 60 L per minute may be sufficient, although higher rates are frequently necessary. An insufficient peak flow rate is characterized by dyspnea, spuriously low peak inspiratory pressures, and scalloping of the inspiratory pressure tracing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for a high peak flow rate is particularly common among patients who have obstructive airways disease with acute respiratory acidosis. In such patients, a higher peak flow rate shortens inspiratory time and increases expiratory time (ie, decreases the inspiratory to expiratory [I:E] ratio). These alterations increase carbon dioxide elimination and improve respiratory acidosis, while also decreasing the likelihood of dynamic hyperinflation (auto-PEEP) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=see_link&amp;anchor=H9#H9\">",
"     \"Positive end-expiratory pressure (PEEP)\", section on 'Auto (intrinsic) PEEP'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, there are costs to increasing the peak flow rate. Increased peak flow rates can increase the peak airway pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the decreased inspiratory time lowers the mean airway pressure, which can decrease oxygenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Flow pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microprocessor-controlled mechanical ventilators can deliver several inspiratory flow patterns, including a square wave (constant flow), a ramp wave (decelerating flow), and a sinusoidal wave (",
"    <a class=\"graphic graphic_waveform graphicRef75089 \" href=\"UTD.htm?14/49/15133\">",
"     waveform 1",
"    </a>",
"    ). The ramp wave may distribute ventilation more evenly than other patterns of flow, particularly when airway obstruction is present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/22\">",
"     22",
"    </a>",
"    ]. This decreases the peak airway pressure, physiologic dead space, and PaCO",
"    <sub>",
"     2",
"    </sub>",
"    , while leaving oxygenation unaltered [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/23\">",
"     23",
"    </a>",
"    ]. The effects of the different flow patterns on potential complications of mechanical ventilation (eg, hemodynamic impairment, pulmonary barotrauma, ventilator-associated lung injury) are unpredictable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Fraction of inspired oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lowest possible fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) necessary to meet oxygenation goals should be used. This will decrease the likelihood that adverse consequences of supplemental oxygen will develop, such as absorption atelectasis, accentuation of hypercapnia, airway injury, and parenchymal injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=see_link\">",
"     \"Oxygen toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oxygenation goal varies from patient to patient. As an example, a patient with ischemic heart disease requires greater oxygenation than a patient with chronic hypoxemia due to lung disease. Typical oxygenation goals include an arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) above 60 mmHg and an oxyhemoglobin saturation (SpO",
"    <sub>",
"     2",
"    </sub>",
"    ) above 90 percent. In patients with ARDS, targeting a PaO",
"    <sub>",
"     2",
"    </sub>",
"    of 55 to 80 mmHg and a SpO",
"    <sub>",
"     2",
"    </sub>",
"    of 88 to 95 percent is acceptable when the trade off would be higher plateau pressures and an increased risk of lung injury due to alveolar overdistension (ie, volutrauma) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/16,24\">",
"     16,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ASYNCHRONY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient-ventilatory asynchrony exists if the phases of breath delivered by the ventilator do not match that of the patient. It is common during mechanical ventilation: more than 10 percent of breaths are asynchronous in approximately 24 percent of mechanically ventilated patients, according to one observational study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patient-ventilator asynchrony can cause dyspnea, increase the work of breathing, and prolong the duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. It can be detected by careful observation of the patient and examination of the ventilator waveforms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/28\">",
"     28",
"    </a>",
"    ]. Generally, the abnormality that is most readily apparent is failure of the ventilator to trigger a breath when the patient makes an inspiratory effort. There are several common causes of patient-ventilator asynchrony:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ineffective triggering of a ventilator-delivered breath &mdash; Ineffective triggering may occur in as many as one-third of inspiratory efforts [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/29\">",
"       29",
"      </a>",
"      ] and may account for as many as 88 percent of asynchronous breaths [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/30\">",
"       30",
"      </a>",
"      ]. It may also prolong the duration of mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/31\">",
"       31",
"      </a>",
"      ]. Ineffective triggering is accentuated by an insensitive inspiratory trigger, higher levels of pressure support, higher tidal volumes, and higher pH [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/25\">",
"       25",
"      </a>",
"      ]. The problem can be lessened or eliminated by increasing the duration between the end of inspiration and the beginning of expiration with an end-inspiratory pause.",
"     </li>",
"     <li>",
"      Double triggering ventilator-delivered breaths &mdash; When this occurs, the ventilator delivers two breaths in rapid sequence. This can be lessened or eliminated by decreasing the trigger sensitivity (eg, from -1 to -3 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O).",
"     </li>",
"     <li>",
"      Prolonged inspiratory time &mdash; Inspiratory time is the tidal volume divided by the inspiratory flow rate. Attempts to increase the minute ventilation by raising only the tidal volume result in an increased inspiratory time, causing patient discomfort and asynchrony [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/19,29\">",
"       19,29",
"      </a>",
"      ]. This problem may be avoided by increasing the inspiratory flow rate when the tidal volume is increased, so that the inspiratory time remains constant [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breath stacking is a manifestation of asynchrony that occurs when a patient triggers a new breath before the completion of the prior ventilator-delivered breath. It is common during low tidal volume ventilation, a strategy that is typically used to mechanically ventilate patients with ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13336/abstract/33\">",
"     33",
"    </a>",
"    ]. Lung volumes during breath stacking exceed the set tidal volume (even in heavily sedated patients), which undermines the strategy of low tidal volume ventilation. Increasing the set tidal volume may reduce breath stacking, but the advantages of improved synchrony must be balanced against the potential harms of using larger tidal volumes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Causes of respiratory distress in a mechanically ventilated patient other than asynchrony are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21991?source=see_link\">",
"     \"Assessment of respiratory distress in the mechanically ventilated patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical ventilation is indicated for acute or chronic respiratory failure, defined as insufficient oxygenation, insufficient alveolar ventilation, or both. The principal benefits of mechanical ventilation are improved gas exchange and decreased work of breathing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Benefits'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical ventilation can deliver different types of breaths, including volume control, volume assist, pressure control, pressure assist, and pressure support. These types of breath are defined by a combination of three features: the trigger, target, and termination signal. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of breaths'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it has been determined that a patient requires mechanical ventilation, numerous decisions need to be made including whether invasive or noninvasive mechanical ventilation is warranted, the mode of mechanical ventilation, the amount of support, and the initial ventilator settings:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For many patients, typical initial settings include a tidal volume of 8 mL per kg of predicted body weight (PBW, which is the same as ideal body weight), a respiratory rate of 12 to 16 breaths per minute, a positive end-expiratory pressure (PEEP) of 5 to 10 cm H",
"      <sub>",
"       2",
"      </sub>",
"      O, a peak flow rate that creates an inspiratory to expiratory (I:E) ratio of 1:2 to 1:3, and the lowest fraction of inspiratory oxygen (FiO",
"      <sub>",
"       2",
"      </sub>",
"      ) sufficient to meet oxygenation goals. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Initiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute respiratory distress syndrome (ARDS), initial ventilator settings typically include smaller tidal volumes (6 mL per kg of PBW) and a higher respiratory rate than those described above. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link&amp;anchor=H2#H2\">",
"       \"Mechanical ventilation in acute respiratory distress syndrome\", section on 'Low tidal volume ventilation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient-ventilatory asynchrony exists if the phases of breath delivered by the ventilator do not match that desired by the patient. It is common during mechanical ventilation and can cause dyspnea, increase the work of breathing, and prolong the duration of mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Asynchrony'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/1\">",
"      Cohen CA, Zagelbaum G, Gross D, et al. Clinical manifestations of inspiratory muscle fatigue. Am J Med 1982; 73:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/2\">",
"      Slutsky AS. Mechanical ventilation. American College of Chest Physicians' Consensus Conference. Chest 1993; 104:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/3\">",
"      Gil A, Carrizosa F, Herrero A, et al. Influence of mechanical ventilation on blood lactate in patients with acute respiratory failure. Intensive Care Med 1998; 24:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/4\">",
"      Weinberger SE, Schwartzstein RM, Weiss JW. Hypercapnia. N Engl J Med 1989; 321:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/5\">",
"      Keenan SP, Kernerman PD, Cook DJ, et al. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. Crit Care Med 1997; 25:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/6\">",
"      Calfee CS, Matthay MA. Recent advances in mechanical ventilation. Am J Med 2005; 118:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/7\">",
"      Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face mask. N Engl J Med 1991; 325:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/8\">",
"      Esteban A, Anzueto A, Al&iacute;a I, et al. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am J Respir Crit Care Med 2000; 161:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/9\">",
"      Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/10\">",
"      Levine S, Nguyen T, Taylor N, et al. Rapid disuse atrophy of diaphragm fibers in mechanically ventilated humans. N Engl J Med 2008; 358:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/11\">",
"      Laffey JG, Kavanagh BP. Hypocapnia. N Engl J Med 2002; 347:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/12\">",
"      Marini JJ, Smith TC, Lamb VJ. External work output and force generation during synchronized intermittent mechanical ventilation. Effect of machine assistance on breathing effort. Am Rev Respir Dis 1988; 138:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/13\">",
"      Sassoon CS, Giron AE, Ely EA, Light RW. Inspiratory work of breathing on flow-by and demand-flow continuous positive airway pressure. Crit Care Med 1989; 17:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/14\">",
"      Hill LL, Pearl RG. Flow triggering, pressure triggering, and autotriggering during mechanical ventilation. Crit Care Med 2000; 28:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/15\">",
"      Sassoon CS, Del Rosario N, Fei R, et al. Influence of pressure- and flow-triggered synchronous intermittent mandatory ventilation on inspiratory muscle work. Crit Care Med 1994; 22:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/16\">",
"      Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/17\">",
"      Dreyfuss D, Soler P, Basset G, Saumon G. High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure. Am Rev Respir Dis 1988; 137:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/18\">",
"      International consensus conferences in intensive care medicine: Ventilator-associated Lung Injury in ARDS. This official conference report was cosponsored by the American Thoracic Society, The European Society of Intensive Care Medicine, and The Societ&eacute; de R&eacute;animation de Langue Fran&ccedil;aise, and was approved by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 1999; 160:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/19\">",
"      Vieillard-Baron A, Prin S, Augarde R, et al. Increasing respiratory rate to improve CO2 clearance during mechanical ventilation is not a panacea in acute respiratory failure. Crit Care Med 2002; 30:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/20\">",
"      Tobin MJ. Mechanical ventilation. N Engl J Med 1994; 330:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/21\">",
"      Chiumello D, Pelosi P, Calvi E, et al. Different modes of assisted ventilation in patients with acute respiratory failure. Eur Respir J 2002; 20:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/22\">",
"      Al-Saady N, Bennett ED. Decelerating inspiratory flow waveform improves lung mechanics and gas exchange in patients on intermittent positive-pressure ventilation. Intensive Care Med 1985; 11:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/23\">",
"      Yang SC, Yang SP. Effects of inspiratory flow waveforms on lung mechanics, gas exchange, and respiratory metabolism in COPD patients during mechanical ventilation. Chest 2002; 122:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/24\">",
"      Brower RG, Lanken PN, MacIntyre N, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004; 351:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/25\">",
"      Thille AW, Rodriguez P, Cabello B, et al. Patient-ventilator asynchrony during assisted mechanical ventilation. Intensive Care Med 2006; 32:1515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/26\">",
"      Hansen-Flaschen JH. Dyspnea in the ventilated patient: a call for patient-centered mechanical ventilation. Respir Care 2000; 45:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/27\">",
"      Georgopoulos D, Prinianakis G, Kondili E. Bedside waveforms interpretation as a tool to identify patient-ventilator asynchronies. Intensive Care Med 2006; 32:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/28\">",
"      Nilsestuen JO, Hargett KD. Using ventilator graphics to identify patient-ventilator asynchrony. Respir Care 2005; 50:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/29\">",
"      Tobin MJ, Jubran A, Laghi F. Patient-ventilator interaction. Am J Respir Crit Care Med 2001; 163:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/30\">",
"      de Wit M, Pedram S, Best AM, Epstein SK. Observational study of patient-ventilator asynchrony and relationship to sedation level. J Crit Care 2009; 24:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/31\">",
"      de Wit M, Miller KB, Green DA, et al. Ineffective triggering predicts increased duration of mechanical ventilation. Crit Care Med 2009; 37:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/32\">",
"      Manning HL, Molinary EJ, Leiter JC. Effect of inspiratory flow rate on respiratory sensation and pattern of breathing. Am J Respir Crit Care Med 1995; 151:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13336/abstract/33\">",
"      Pohlman MC, McCallister KE, Schweickert WD, et al. Excessive tidal volume from breath stacking during lung-protective ventilation for acute lung injury. Crit Care Med 2008; 36:3019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1640 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-56E69E3A75-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13336=[""].join("\n");
var outline_f13_1_13336=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF BREATHS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Volume control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Volume assist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pressure control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pressure assist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pressure support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MODES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INITIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Invasive versus noninvasive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Choosing a mode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Level of support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Trigger",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tidal volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Respiratory rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - PEEP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Flow rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Flow pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Fraction of inspired oxygen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ASYNCHRONY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1640\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1640|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/53/10078\" title=\"figure 1\">",
"      Decreased SIMV support in ARDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/27/3519\" title=\"figure 2\">",
"      Flow by triggering",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1640|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/20/2381\" title=\"table 1\">",
"      Conditions needing ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/59/34748\" title=\"table 2\">",
"      Indications for ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/25/19867\" title=\"table 3\">",
"      Objectives of mechanical vent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/30/19949\" title=\"table 4\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/22/8544\" title=\"table 5\">",
"      Predicted body weight and tidal volume for men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/24/8576\" title=\"table 6\">",
"      Predicted body weight and tidal volume for women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1640|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?14/49/15133\" title=\"waveform 1\">",
"      Flow waveforms mechanical vent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21991?source=related_link\">",
"      Assessment of respiratory distress in the mechanically ventilated patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43784?source=related_link\">",
"      Modes of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28407?source=related_link\">",
"      Oxygen toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26119?source=related_link\">",
"      Physiologic and pathophysiologic consequences of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30663?source=related_link\">",
"      Positive end-expiratory pressure (PEEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/10/32934?source=related_link\">",
"      Pulmonary barotrauma during mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_1_13337="Treatment of AIDS-related cytomegalovirus retinitis";
var content_f13_1_13337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of AIDS-related cytomegalovirus retinitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13337/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13337/contributors\">",
"     Mark A Jacobson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13337/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13337/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13337/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13337/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/1/13337/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV) retinitis is the most common serious ocular complication of AIDS. The majority of disease is related to reactivation of latent infection. However, the introduction of highly active antiretroviral therapy has led to changes in the incidence, natural history, and management of CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of CMV retinitis will be reviewed here. The epidemiology, clinical manifestations, and diagnosis of CMV retinitis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT REGIMENS FOR CMV",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of initial therapy for CMV retinitis should be individualized based on the location and severity of the lesions and other factors, such as concomitant medications and ability to adhere to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the majority of patients, we recommend oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    over the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    implant, intravenous ganciclovir, or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    due to its ease of administration and the reduced risk of complications or toxicity, as recommended by the Centers for Disease Control and Prevention, the National Institutes of Health and the HIV Medicine Association guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, for patients with sight-threatening lesions (lesions &lt;1500 microns from the fovea or adjacent to the optic nerve head), we recommend initial therapy with local (intravitreal injection or implant) or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . If local therapy is used, we also recommend initiating oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    as well [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ]. If oral valganciclovir is initiated within 72 hours of the initial intravitreal injection, subsequent injections are not necessary. For patients initiated on systemic therapy, we recommend switching intravenous ganciclovir to oral valganciclovir after 72 hours. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Oral valganciclovir'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Ganciclovir intraocular device'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although immune recovery related to HAART has been associated with immune reconstitution inflammatory uveitis, the risk of this complication is not related to the interval between starting anti-CMV therapy and HAART. Therefore, the administration of HAART should not be delayed [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, lack of immune reconstitution in a patient with CMV retinitis increases the risk of progressive CMV disease and retinal detachment with subsequent vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other effective treatments include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef72861 \" href=\"UTD.htm?26/6/26732\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/5\">",
"     5",
"    </a>",
"    ]. However, their use has been largely replaced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and the ocular implant. Initial induction therapy is followed by lower-dose maintenance therapy. Dosing regimens, monitoring for side effects, and treatment of drug-induced complications are summarized in the following tables (",
"    <a class=\"graphic graphic_table graphicRef80535 \" href=\"UTD.htm?23/41/24221\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef70634 \" href=\"UTD.htm?4/25/4509\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"     \"Ganciclovir and valganciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=see_link\">",
"     \"Foscarnet: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=see_link\">",
"     \"Cidofovir: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     IV ganciclovir and IV foscarnet",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the beginning of the CMV treatment era, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    were used for CMV retinitis therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The induction dose for ganciclovir is 5",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    every 12 hours for 14 to 21 days; the maintenance dose is 5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    as a single daily dose for seven days a week or 6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for five days per week. The induction dose for foscarnet is 60",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    every eight hours for 14 to 21 days; the maintenance dose is 90 to 120",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    as a single infusion.",
"   </p>",
"   <p>",
"    In the pre-HAART era, therapy entailed life-long daily intravenous infusions and patients often relapsed eventually despite ongoing therapy. However, use of these systemic formulations has declined with the availability of better oral medications and the advent of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    intraocular implant device. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Oral valganciclovir'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Ganciclovir intraocular device'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The only large trial comparing IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    for the treatment of CMV retinitis demonstrated equivalent efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/8\">",
"     8",
"    </a>",
"    ]. The main adverse events of ganciclovir are hematologic; those of foscarnet are mainly related to renal toxicity and electrolyte disturbances. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link&amp;anchor=H22#H22\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\", section on 'Patient monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ganciclovir intraocular device",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     Ganciclovir",
"    </a>",
"    can be administered via an implantable intraocular device that contains 4.5 mg ganciclovir and continuously releases drug into the vitreous for up to eight months. This implant, which was first used in 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/9\">",
"     9",
"    </a>",
"    ], results in substantially higher intravitreal drug concentrations than can be achieved with standard intravenous ganciclovir therapy.",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated that the efficacy of the intraocular device as initial therapy for CMV retinitis is better than that of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In one randomized study, 188 patients with CMV retinitis were randomly assigned to treatment with an implant delivering 1 microgram of ganciclovir per hour, an implant delivering two microgram of ganciclovir per hour, or intravenous ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk of progression was approximately three times as great among patients treated with intravenous ganciclovir as among those treated with an implant.",
"   </p>",
"   <p>",
"    However, the use of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    implant alone, in the absence of any systemic anti-CMV therapy, is associated with subsequent development of extraocular CMV disease or contralateral retinitis in patients treated for unilateral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Therefore, concomitant treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    should be strongly considered for patients receiving an implant.",
"   </p>",
"   <p>",
"    The implantation procedure, which can be performed on an outpatient basis, typically causes a transient decrease in visual acuity, from a median",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/80,",
"    </span>",
"    that resolves within the first four weeks after implantation. The most serious risks associated with implant therapy are surgical complications that can permanently impair visual function:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 10 percent of patients in two trials had a vision-compromising adverse event [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. The majority were retinal detachments, but major intravitreal bleeding and endophthalmitis also occurred. In another study, the most common adverse event was vitreous hemorrhage (10 percent), which resolved by 60 days [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of pathological findings in 33 eyes from 19 patients who had received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      implants, fibrous ingrowth was present but had limited extension; mild vitreous hemorrhage was present in 18 of 33 eyes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/14\">",
"       14",
"      </a>",
"      ]. Biodegradable implant devices are being developed that may be associated with less long-term consequences [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Implants need to be replaced after every five to eight months, since the device dose not reliably release drug after this time period. Replacement does not need to be considered if the patient is no longer at risk. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Discontinuation of maintenance therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Oral valganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , an orally administered prodrug of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , was demonstrated to be as effective as intravenous ganciclovir for the treatment of CMV retinitis in a multicenter trial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/16\">",
"     16",
"    </a>",
"    ]. Valganciclovir is given at doses of 900 mg twice daily with food for the first 21 days of induction therapy; after this period, valganciclovir dosing is reduced to 900 mg daily for maintenance therapy. Oral bioavailability is approximately 60 percent and is 10-fold higher than that with oral ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, this study initially excluded patients with immediately sight-threatening retinitis (eg, lesions located &lt;1500 microns from the fovea). Because of the small number of patients with immediately sight-threatening retinitis studied in this trial, and concerns about the duration of time that may be necessary to achieve adequate intraocular drug levels, we recommend initial therapy with local (intravitreal injection or implant) or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    for patients with retinitis within 1500 microns of the fovea, for the first few days until steady state intraocular drug levels from oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    will be achieved.",
"   </p>",
"   <p>",
"    Although there are no comparative clinical trial data available on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    for chronic maintenance therapy of CMV retinitis, use of valganciclovir is supported by its pharmacokinetics. Valganciclovir is a valine ester of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    that is converted in vivo to ganciclovir after oral administration and results in a ganciclovir bioavailability of approximately 60 percent. The ganciclovir AUC achieved with 900 mg oral valganciclovir tablets by mouth is equivalent to that achieved with 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenous ganciclovir dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxicity profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is identical to that of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and is mainly related to its effect on bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/19\">",
"     19",
"    </a>",
"    ]. Its oral formulation offers cost savings and the advantage of avoiding catheter-related complications associated with chronic intravenous therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cidofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    (HPMPC) is a nucleoside monophosphate analogue with potent in vitro activity against CMV that is 10- to 100-fold greater than that of other anti-CMV drugs. However, due to its toxicity, requirement for intermittent intravenous administration, and the availability of other effective alternatives, cidofovir is rarely used.",
"   </p>",
"   <p>",
"    In the pre-HAART era, two randomized trials demonstrated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    for the treatment of patients without immediately sight-threatening retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Cidofovir was also demonstrated to have utility in the treatment of patients who had failed therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Salvage therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     Cidofovir",
"    </a>",
"    has caused serious, irreversible nephrotoxicity via dose-dependent proximal tubular cell injury. The initial manifestations of renal toxicity are proteinuria and increased serum creatinine concentrations; with continued treatment some patients have had a life-threatening Fanconi-like syndrome and renal failure. Saline hydration and high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    therapy is given concomitantly with cidofovir in an attempt to reduce the risk of serious renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The oral probenecid regimen is 2 g three hours before the infusion and 1 g at both two and eight hours after the infusion.",
"   </p>",
"   <p>",
"    Nephrotoxicity or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"     probenecid",
"    </a>",
"    intolerance (eg, fever, nausea, vomiting, rash) is treatment-limiting in approximately one-third to one-half of patients. Neutropenia, peripheral neuropathy, abnormally low intraocular pressure, anterior uveitis, and alopecia have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk of vision-compromising low intraocular pressure and uveitis appear to be much greater in patients receiving concomitant HIV protease inhibitor drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/24\">",
"     24",
"    </a>",
"    ]. Serum creatinine, blood urea nitrogen, and urinalysis should be performed before infusions to detect renal dysfunction or proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Salvage therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite continued antiviral therapy, most patients with CMV retinitis who are not treated with or do not respond to HAART do eventually relapse with breakthrough viral reactivation that results in further retinal necrosis. Renewed activity is manifested as new retinal lesions or new opacification at the border or advancement of the border of old lesions. Development of drug resistance also may play a role in the pathogenesis of viral reactivation, especially when progression is rapid or fails to stop with increased drug doses.",
"   </p>",
"   <p>",
"    Strategies used to manage relapse of retinitis in this situation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reinduction with more frequent intravenous administration of the currently administered drug [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Switching therapy",
"     </li>",
"     <li>",
"      Combining drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Use of intraocular implants in those who started with systemic medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been only one adequately powered, randomized, controlled trial of salvage therapy for patients with AIDS and relapsed CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/5\">",
"     5",
"    </a>",
"    ]. In this trial, patients were randomized to one of three regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      (induction with 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two weeks followed by maintenance at 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      (induction with 90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two weeks followed by maintenance at 120",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"     <li>",
"      Continuation of previous therapy plus induction with the other drug (either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       foscarnet",
"      </a>",
"      ) for two weeks followed by standard maintenance doses of both ganciclovir (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) and foscarnet (90",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined regimen was twice as effective as either drug alone, delaying time to further progression: 1.3 months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    ; 2.0 months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ; and 4.3 months with combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/5\">",
"     5",
"    </a>",
"    ]. Several other visual outcome measures (rate of visual field loss and change in amount of retinal area involved by CMV) were also significantly better in patients given the combination regimen. Thus, ganciclovir (eg,",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"      valganciclovir",
"     </a>",
"     )/foscarnet",
"    </span>",
"    combination therapy is the only evidenced-based effective treatment strategy for patients who relapse on maintenance therapy and can tolerate both drugs.",
"   </p>",
"   <p>",
"    For information regarding dosing and adverse event monitoring with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link&amp;anchor=H22#H22\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\", section on 'Patient monitoring'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Fomivirsen, an antisense oligonucleotide, was used in the past for salvage therapy, but is rarely used anymore [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment in resource-limited settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to developed countries, CMV retinitis is largely undiagnosed and untreated in resource-limited settings [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/29\">",
"     29",
"    </a>",
"    ]. The prevalence and incidence of CMV retinitis is not well-known since routine retinal examinations are not commonly performed in most clinics and the diagnosis is usually not considered until the patient has irreversible vision changes. In a large clinic in Chang Mai, Thailand, 19 percent of cases of bilateral blindness were caused by CMV retinitis, exceeding glaucoma, age-related macular degeneration, and diabetic retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, successful treatment of CMV retinitis requires specific medication against CMV infection and recovery of immune function through the use of ART. At this time, only intraocular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    injections are considered a viable option in resource-limited settings due to significant cost considerations of first-line therapies, such as intravenous ganciclovir or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    . Limitations of using intraocular injections of ganciclovir in resource-limited settings include [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Local treatment will not prevent involvement of the other eye or additional systemic involvement (eg, CMV gastrointestinal disease)",
"     </li>",
"     <li>",
"      Weekly clinic visits are needed for intraocular therapy, which can be difficult for patients with limited social or financial support",
"     </li>",
"     <li>",
"      Need for patient acceptance and cooperation",
"     </li>",
"     <li>",
"      Lack of medical personnel trained in this technique",
"     </li>",
"     <li>",
"      Potential onset of serious adverse events related to intraocular injections (eg, endophthalmitis, vitreous hemorrhage, retinal detachment)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical relapses that occur in less than three months are usually due to progression of disease in absence of effective HAART or lack of anti-CMV medication adherence. However, with prolonged use of anti-CMV therapy, clinical relapses may be due to drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/17\">",
"     17",
"    </a>",
"    ]. The onset of drug resistance has implications for therapeutic management and is associated with an increased risk of CMV retinitis progression and for developing disease in the contralateral eye [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistant CMV strains have been reported in the setting of HIV more than other immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the incidence of resistance in HIV-infected patients has declined with the introduction of potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ]. In one prospective observational study of 257 patients with CMV retinitis, the incidence of drug resistance decreased from 28 percent prior to 1996, to 9 percent after 1996 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/33\">",
"     33",
"    </a>",
"    ]. All cases of resistance occurred among patients with CD4 counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL;",
"    </span>",
"    CMV positive blood cultures were also associated with a 4-fold risk of developing resistance. Other proposed risk factors for drug resistance include inadequate drug concentrations and frequent discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug resistance can be the result of alterations in two different viral gene products, namely pUL97 and the viral DNA polymerase (pUL54). Low level",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    resistance is due to mutations on the CMV UL97 phosphotransferase gene; high-level resistance is due to mutations in both UL97 and UL54 DNA polymerase genes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/34\">",
"     34",
"    </a>",
"    ]. Low-level resistance can be overcome with use of the ganciclovir implant. High-level resistance requires addition of another drug; however, cross resistance to other medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    , may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Phenotypic resistance is measured by the ability of CMV to grow in the presence of an anti-CMV drug; genotypic resistance is defined by the presence of a mutation known to confer resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/36\">",
"     36",
"    </a>",
"    ]. Phenotypic and genotypic analyses of drug resistance in patients with CMV retinitis have suggested that the development of resistance may correlate with a poor ocular outcome. However, phenotypic assays are not well standardized and take four weeks to perform so are not practical for clinical use, while genotypic assays can be completed within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 197 AIDS patients with CMV retinitis treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      found that 19 developed phenotypic and 18 developed genotypic resistance to the drug as determined by urine and blood testing; resistance was associated with a greater likelihood of progression of the retinitis and a greater area of involved retina [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/38\">",
"       38",
"      </a>",
"      ]. HAART and the ganciclovir implant both reduced the probability of retinitis progression.",
"     </li>",
"     <li>",
"      Another report demonstrated resistance mutations to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      after amplifying target regions in isolates from four of eight eyes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/39\">",
"       39",
"      </a>",
"      ]. The resistance mutations were not always the same in the two eyes of patients with bilateral disease. Ganciclovir implants were still useful in patients with resistance mutations in the UL97 and UL54 genes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29575?source=see_link\">",
"       Foscarnet",
"      </a>",
"      resistance arose in 13, 24, and 37 percent of patients treated for 6, 9, and 12 months, respectively, in a series of 44 AIDS patients with CMV retinitis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/40\">",
"       40",
"      </a>",
"      ]. Development of drug resistance was correlated with disease progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both phenotypic and genotypic testing of culture isolates may take more than four weeks to process, which is limiting for timely clinical decision-making. However, genotyping of CMV can also be accomplished by directly amplifying the UL97 gene from blood specimens via polymerase chain reaction in less than 48 hours. A prospective study of 845 paired specimens was conducted to compare direct PCR amplification of blood specimens to culture isolates for accuracy in susceptibility testing and their association with progression of CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/36\">",
"     36",
"    </a>",
"    ]. The study was demonstrated the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was &gt;90 percent agreement in the genotypic results of direct amplification of blood specimens compared to culture isolates.",
"     </li>",
"     <li>",
"      The agreement between phenotypic resistance and the detection of UL97 mutations was &gt;92 percent for PCR-amplified blood specimens and &gt;97 percent for culture isolates.",
"     </li>",
"     <li>",
"      Progression of retinitis was correlated with the detection of UL97 mutations in PCR-amplified blood specimens (odds ratio 7.0 for leukocytes, 9.0 for plasma) and for culture isolates (odds ratio 18.0).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although blood culture results were the strongest predictor of progression of CMV retinitis, the much faster results obtained with direct PCR amplification of blood suggests potential clinical utility of this approach. Testing for CMV resistance is not yet available commercially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4687766\">",
"    <span class=\"h1\">",
"     USE OF GROWTH FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic growth factors (eg, granulocyte-colony stimulating factor [G-CSF] or granulocyte macrophage colony-stimulating factor [GM-CSF]) are widely used to counter the effects of myelosuppressive agents, such as chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/41-47\">",
"     41-47",
"    </a>",
"    ]. These colony-stimulating agents are well tolerated and can be used to facilitate dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    ; they have also been shown to reduce the risk of bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one controlled trial, 53 HIV-infected patients with CMV retinitis were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      with or without GM-CSF (1 to 8",
"      <span class=\"nowrap\">",
"       mcg/kg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/48\">",
"       48",
"      </a>",
"      ]. Patients who received GM-CSF were less likely to develop neutropenia (absolute neutrophil count [ANC] &lt;500 cells) than those who did not receive this intervention (13 versus 45 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The positive effect of growth factors on lessening the risk of bacterial infections may be through improved neutrophil chemotaxis and phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/46,51,52\">",
"     46,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subcutaneous administration of G-CSF (10",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    or GM-CSF (10 to 20",
"    <span class=\"nowrap\">",
"     mcg/kg/day)",
"    </span>",
"    is suggested in a patient with an ANC &lt;500",
"    <span class=\"nowrap\">",
"     cells/mm3",
"    </span>",
"    with a target to keep the ANC in the 500 to 750 cell range; laboratories should be drawn just before the next dose of growth factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CMV retinitis requires close monitoring by an experienced ophthalmologist and the HIV provider. Dilated indirect ophthalmoscopy should be performed after completion of induction therapy, one month after the initiation of therapy, and monthly thereafter while the patient is on anti-CMV treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"     2",
"    </a>",
"    ]. Monthly fundus photographs are optimal for detecting early relapse.",
"   </p>",
"   <p>",
"    Patients who have been successfully treated for CMV retinitis also need ongoing ophthalmologic examinations to monitor for the onset of immune recovery vitritis or uveitis, which can occur years after diagnosis of retinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\", section on 'CMV immune recovery uveitis'",
"    </a>",
"    .) Monitoring at three- to six-month intervals is appropriate with progressively longer intervals over time. Patients should be instructed to call immediately should visual symptoms recur.",
"   </p>",
"   <p>",
"    Information on laboratory monitoring and treatment-related side effects is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=see_link\">",
"     \"AIDS-related cytomegalovirus gastrointestinal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DISCONTINUATION OF MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small observational studies suggest that patients who have sustained CD4 counts &gt;100 cells for six months or longer on HAART can safely discontinue CMV maintenance therapy without recurrence of CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/2,53-56\">",
"     2,53-56",
"    </a>",
"    ]. The patients described in these reports generally had absolute CD4 cell counts that were less than",
"    <span class=\"nowrap\">",
"     50/mm3",
"    </span>",
"    at the time of CMV retinitis diagnosis but rose to more than",
"    <span class=\"nowrap\">",
"     150/mm3",
"    </span>",
"    after initiating potent combination antiretroviral regimens. These observations suggest that HAART may reconstitute CMV-specific immunity. Most of the patients who relapsed had CD4 counts that dropped to &lt;50 mm3 by the time of relapse.",
"   </p>",
"   <p>",
"    We agree with the recommendations of the Infectious Diseases Society of America that anti-CMV therapy should be discontinued in patients with quiescent retinitis who have sustained CD4 counts &gt;100 for six months or longer on HAART. Patients whose CD4 counts drop below 50 should reinitiate anti-CMV therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On occasion, patients with improved CD4 cell counts and viral suppression can still have a relapse of CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Thus it is important to discuss the symptoms of CMV retinitis when therapy is discontinued. Although there may be an increase in the absolute CD4 T cell count on HAART, some patients may not have full immune reconstitution of all T cell subsets. In one study using immunophenotypic markers, patients on HAART with a history of prior CMV retinitis had significantly lower numbers of CD4+ naive and memory T-cells than AIDS patients with a prior history of Pneumocystis pneumonia but not CMV retinitis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maintenance therapy should be reinitiated if the patient has clinical decline of CD4 counts &lt;50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    to prevent reactivation of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CMV IMMUNE RECOVERY UVEITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After an initial period of treatment with anti-CMV therapy and HAART, patients may develop significant intraocular inflammation secondary to immune recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/3\">",
"     3",
"    </a>",
"    ]. This entity is known as immune recovery uveitis (IRU) and can lead to significant ocular morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/1,4,62-64\">",
"     1,4,62-64",
"    </a>",
"    ]. Immune recovery uveitis is associated with vitreous inflammation with or without cystoid macular edema, epiretinal membrane, or retinal neovascularization in patients with HAART-mediated immune recovery and inactive CMV retinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Uncontrolled treatment studies with anti-CMV therapy or corticosteroids have not provided convincing evidence that either intervention is beneficial in patients with IRU, although treatment with corticosteroids is often attempted by ophthalmologists to decrease the inflammatory response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/34,65-67\">",
"     34,65-67",
"    </a>",
"    ]. Severe complications, such as epiretinal membranes or vitreous hemorrhage, may require vitrectomy. There are no proven therapies for macular edema, which is an important cause of vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13337/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any patient with a history of immune recovery, quiescent CMV retinitis, and new visual symptoms, should be referred promptly for ophthalmic examination to evaluate for CMV progression, relapse, or immune recovery uveitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the majority of patients, we recommend oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      However, for patients with sight-threatening lesions (lesions &lt;1500 microns from the fovea or adjacent to the optic nerve head), we recommend initial therapy with local (intravitreal injection or implant) or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). If local therapy is used, we also recommend initiating oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      as well. If oral valganciclovir is initiated within 72 hours of the initial intravitreal injection, subsequent injections are not necessary. For patients initiated on systemic therapy, we recommend switching intravenous ganciclovir to oral valganciclovir after 72 hours.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      implant should be considered for such patients with immediately sight-threatening lesions who are unlikely to be able to adhere to a regimen of daily oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Oral valganciclovir'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Ganciclovir intraocular device'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although immune recovery related to HAART has been associated with immune reconstitution inflammatory syndromes (IRIS), the risk of this complication does not appear to be related to the interval between starting anti-CMV therapy and HAART. Therefore, the administration of HAART should not be delayed (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Any patient who develops vision loss, visual blurring, floaters, or ocular pain after weeks to months of CMV therapy, should be evaluated by an ophthalmologist to determine if these symptoms are related to CMV progression, relapse, retinal detachment, or immune recovery syndromes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment regimens for CMV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dilated indirect ophthalmoscopy should be performed after completion of induction therapy, one month after the initiation of therapy, and monthly thereafter while the patient is on anti-CMV treatment. Monthly fundus photographs are optimum for detecting early relapse. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Patient monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who experience clinical relapse on treatment should be considered for salvage regimens. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Salvage therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who have sustained CD4 counts &gt;100 cells for six months or longer on HAART we suggest discontinuation of CMV maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Discontinuation of maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/1\">",
"      Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina 2005; 25:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/2\">",
"      Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/3\">",
"      Holland GN. AIDS and ophthalmology: the first quarter century. Am J Ophthalmol 2008; 145:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/4\">",
"      Goldberg DE, Wang H, Azen SP, Freeman WR. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol 2003; 87:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/5\">",
"      Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch Ophthalmol 1996; 114:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/6\">",
"      Jacobson MA, Stanley HD, Heard SE. Ganciclovir with recombinant methionyl human granulocyte colony-stimulating factor for treatment of cytomegalovirus disease in AIDS patients. AIDS 1992; 6:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/7\">",
"      Palestine AG, Polis MA, De Smet MD, et al. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 1991; 115:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/8\">",
"      Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. Studies of Ocular Complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. N Engl J Med 1992; 326:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/9\">",
"      Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006; 26:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/10\">",
"      Martin DF, Parks DJ, Mellow SD, et al. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol 1994; 112:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/11\">",
"      Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med 1997; 337:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/12\">",
"      Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 1999; 340:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/13\">",
"      Dunn JP, Van Natta M, Foster G, et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 2004; 24:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/14\">",
"      Srivastava SK, Martin DF, Mellow SD, et al. Pathological findings in eyes with the ganciclovir implant. Ophthalmology 2005; 112:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/15\">",
"      Yasukawa T, Ogura Y, Kimura H, et al. Drug delivery from ocular implants. Expert Opin Drug Deliv 2006; 3:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/16\">",
"      Martin DF, Sierra-Madero J, Walmsley S, et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/17\">",
"      Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/18\">",
"      Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/19\">",
"      Drugs for non-HIV viral infections. Treat Guidel Med Lett 2007; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/20\">",
"      Cvetkovi RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005; 65:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/21\">",
"      Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997; 126:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/22\">",
"      Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Ann Intern Med 1997; 126:264.",
"     </a>",
"    </li>",
"    <li>",
"     Lalezari JP, Kemper C, Stagg R, et al. A randomized, controlled study of the safety and efficacy of intravenous cidofovir (CDV, HPMPC) for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS (abstract Th.B .304). XIth International Conference on AIDS, Vancouver, July 7-12, 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/24\">",
"      Davis JL, Taskintuna I, Freeman WR, et al. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997; 115:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/25\">",
"      Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs 2000; 9:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/26\">",
"      Vitravene Study Group. Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS. Am J Ophthalmol 2002; 133:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/27\">",
"      Vitravene Study Group.. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/28\">",
"      Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002; 133:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/29\">",
"      Heiden D, Ford N, Wilson D, et al. Cytomegalovirus retinitis: the neglected disease of the AIDS pandemic. PLoS Med 2007; 4:e334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/30\">",
"      Pathanapitoon K, Ausayakhun S, Kunavisarut P, et al. Blindness and low vision in a tertiary ophthalmologic center in Thailand: the importance of cytomegalovirus retinitis. Retina 2007; 27:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/31\">",
"      Jabs DA, Enger C, Dunn JP, Forman M. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. CMV Retinitis and Viral Resistance Study Group. J Infect Dis 1998; 177:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/32\">",
"      Jabs DA, Martin BK, Forman MS, et al. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am J Ophthalmol 2001; 132:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/33\">",
"      Martin BK, Ricks MO, Forman MS, et al. Change over time in incidence of ganciclovir resistance in patients with cytomegalovirus retinitis. Clin Infect Dis 2007; 44:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/34\">",
"      Jabs DA, Martin BK, Forman MS, et al. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2001; 183:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/35\">",
"      Chou S, Miner RC, Drew WL. A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. J Infect Dis 2000; 182:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/36\">",
"      Jabs DA, Martin BK, Ricks MO, et al. Detection of ganciclovir resistance in patients with AIDS and cytomegalovirus retinitis: correlation of genotypic methods with viral phenotype and clinical outcome. J Infect Dis 2006; 193:1728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/37\">",
"      Drew WL. Cytomegalovirus resistance testing: pitfalls and problems for the clinician. Clin Infect Dis 2010; 50:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/38\">",
"      Jabs DA, Martin BK, Forman MS, et al. Cytomegalovirus resistance to ganciclovir and clinical outcomes of patients with cytomegalovirus retinitis. Am J Ophthalmol 2003; 135:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/39\">",
"      Kuo IC, Imai Y, Shum C, et al. Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am J Ophthalmol 2003; 135:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/40\">",
"      Weinberg A, Jabs DA, Chou S, et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003; 187:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/41\">",
"      Markham A, Faulds D. Ganciclovir. An update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/42\">",
"      Scadden DT, Bering HA, Levine JD, et al. Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma. J Clin Oncol 1991; 9:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/43\">",
"      Miles SA, Mitsuyasu RT, Moreno J, et al. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood 1991; 77:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/44\">",
"      Davey RT Jr, Davey VJ, Metcalf JA, et al. A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 1991; 164:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/45\">",
"      Walsh C, Wernz JC, Levine A, et al. Phase I trial of m-BACOD and granulocyte macrophage colony stimulating factor in HIV-associated non-Hodgkin's lymphoma. J Acquir Immune Defic Syndr 1993; 6:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/46\">",
"      Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/47\">",
"      Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000; 30:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/48\">",
"      Hardy D, Spector S, Polsky B, et al. Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. The ACTG 073 Team. Eur J Clin Microbiol Infect Dis 1994; 13 Suppl 2:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/49\">",
"      Kaplan LD, Kahn JO, Crowe S, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991; 9:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/50\">",
"      Ross SD, DiGeorge A, Connelly JE, et al. Safety of GM-CSF in patients with AIDS: a review of the literature. Pharmacotherapy 1998; 18:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/51\">",
"      Grant SM, Heel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression. Drugs 1992; 43:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/52\">",
"      Pitrak DL. Filgrastim treatment of HIV-infected patients improves neutrophil function. AIDS 1999; 13 Suppl 2:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/53\">",
"      Jabs DA, Bolton SG, Dunn JP, Palestine AG. Discontinuing anticytomegalovirus therapy in patients with immune reconstitution after combination antiretroviral therapy. Am J Ophthalmol 1998; 126:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/54\">",
"      Macdonald JC, Karavellas MP, Torriani FJ, et al. Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus retinitis. Ophthalmology 2000; 107:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/55\">",
"      Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA 1999; 282:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/56\">",
"      Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis 1998; 177:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/57\">",
"      Song MK, Karavellas MP, MacDonald JC, et al. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina 2000; 20:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/58\">",
"      Komanduri KV, Feinberg J, Hutchins RK, et al. Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis. J Infect Dis 2001; 183:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/59\">",
"      Crum NF, Blade KA. Cytomegalovirus retinitis after immune reconstitution. AIDS Read 2005; 15:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/60\">",
"      D'Amico R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol 2005; 25:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/61\">",
"      Torriani FJ, Freeman WR, Macdonald JC, et al. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy. AIDS 2000; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/62\">",
"      Kempen JH, Min YI, Freeman WR, et al. Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology 2006; 113:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/63\">",
"      Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm 1999; 7:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/64\">",
"      Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol 2000; 129:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/65\">",
"      Karavellas MP, Azen SP, MacDonald JC, et al. Immune recovery vitritis and uveitis in AIDS: clinical predictors, sequelae, and treatment outcomes. Retina 2001; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/66\">",
"      Kosobucki BR, Goldberg DE, Bessho K, et al. Valganciclovir therapy for immune recovery uveitis complicated by macular edema. Am J Ophthalmol 2004; 137:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13337/abstract/67\">",
"      Henderson HW, Mitchell SM. Treatment of immune recovery vitritis with local steroids. Br J Ophthalmol 1999; 83:540.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3731 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13337=[""].join("\n");
var outline_f13_1_13337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT REGIMENS FOR CMV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IV ganciclovir and IV foscarnet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ganciclovir intraocular device",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Oral valganciclovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cidofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Salvage therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Drug resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4687766\">",
"      USE OF GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DISCONTINUATION OF MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CMV IMMUNE RECOVERY UVEITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3731\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3731|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/6/26732\" title=\"table 1\">",
"      Efficacy Rx CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/41/24221\" title=\"table 2\">",
"      Drug monitoring CMV retinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/25/4509\" title=\"table 3\">",
"      Complications Rx CMV retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/62/22504?source=related_link\">",
"      AIDS-related cytomegalovirus gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37620?source=related_link\">",
"      Cidofovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/13/44244?source=related_link\">",
"      Foscarnet: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/51/37688?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_1_13338="Treatment of severe falciparum malaria";
var content_f13_1_13338=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of severe falciparum malaria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Terrie E Taylor, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Johanna Daily, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/1/13338/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/1/13338/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria is endemic throughout most of the tropics. Of the approximately 3 billion people living in 108 countries who are exposed, approximately 243 million will develop symptomatic malaria annually [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of these are attributable to P. falciparum (90 percent), but P. vivax and P. knowlesi can also cause severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Around 863,000 deaths are caused by malaria each year; over 80 percent of the deaths occur among children in sub-Saharan Africa.",
"   </p>",
"   <p>",
"    Severe malaria is acute malaria with major signs of organ dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high level of parasitemia. In endemic areas, young children and pregnant women are at high risk for severe malaria. Older children and adults develop partial immunity after repeated infections; these groups are thus at relatively low risk for severe disease. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and so are at high risk for severe disease.",
"   </p>",
"   <p>",
"    Management of patients with severe malaria presents a broad array of clinical challenges given the complex pathophysiology of the infection involving multiple organ systems. These challenges are increased manyfold in endemic areas where access to diagnostic and therapeutic tools may be limited. Nevertheless, it is possible to provide excellent care for these patients.",
"   </p>",
"   <p>",
"    The approach to treatment of severe falciparum malaria will be reviewed here. Issues related to management in both endemic and nonendemic areas will be addressed. The treatment of nonsevere malaria is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe malaria is generally defined as acute malaria with high levels of parasitemia (&gt;5 percent)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    major signs of organ dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered consciousness with or without convulsions",
"     </li>",
"     <li>",
"      Deep breathing, respiratory distress (acidotic breathing, costal indrawing, use of accessory muscles, nasal alar flaring)",
"     </li>",
"     <li>",
"      Metabolic acidosis (plasma bicarbonate M 15",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      or whole blood lactate &gt;5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Circulatory collapse",
"     </li>",
"     <li>",
"      Pulmonary edema or acute respiratory distress syndrome (ARDS)",
"     </li>",
"     <li>",
"      Renal failure, hemoglobinuria (\"blackwater fever\")",
"     </li>",
"     <li>",
"      Clinical jaundice",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Severe anemia",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of severe malaria vary with age and geography. In areas where malaria is endemic, young children (ages 2 to 5 years) are at high risk for severe malaria, as are pregnant women. Older children and adults develop partial immunity to febrile malaria episodes (but not to malaria infection) after repeated infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/7\">",
"     7",
"    </a>",
"    ], and thus are at relatively low risk for severe disease. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and so are at high risk for progression to severe disease if infected with P. falciparum [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. For this reason, it is important to consider malaria in the differential diagnosis of all febrile patients with a history of travel to areas where the disease is endemic.",
"   </p>",
"   <p>",
"    Seizures and severe anemia are relatively more common in children, whereas hyperparasitemia, acute renal failure, and jaundice are more common in adults. Cerebral malaria (with coma), shock, acidosis and respiratory arrest may occur at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of malaria are discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=see_link\">",
"     \"Clinical manifestations of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of malaria infection and the degree of parasitemia are established by blood smear. In general, the heavier the parasitemia, the sicker the patient, but there are many asymptomatic patients with high parasitemia, and patients with severe malaria can present with low density infection.",
"   </p>",
"   <p>",
"    Other techniques for diagnosis for malaria are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=see_link\">",
"     \"Diagnosis of malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Death due to severe malaria can occur within hours of presentation, so prompt assessment and initiation of antimalarial therapy is essential. Patients should be evaluated with attention to findings consistent with malaria as well as additional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alternative causes of presenting symptoms. A full neurologic assessment should be performed, including assessment of the Blantyre coma score for children (",
"    <a class=\"graphic graphic_table graphicRef74361 \" href=\"UTD.htm?9/54/10092\">",
"     table 1",
"    </a>",
"    ); the Glasgow coma scale is suitable for adults (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"UTD.htm?28/62/29676\">",
"     table 2",
"    </a>",
"    ). Temperature, heart rate and rhythm, respiratory rate and rhythm, blood pressure oxygen saturation, and weight should be noted, as should capillary refill and degree of pallor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=see_link\">",
"     \"Evaluation of stupor and coma in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Of primary importance in the treatment of malaria is the provision of prompt, effective therapy and concurrent supportive care to manage life-threatening complications of the disease. Supportive measures (eg, oxygen, ventilatory support, cardiac monitoring, and pulse oximetry) should be instituted as needed. During this time, intravenous catheters should be placed and fingerprick blood samples should be obtained for laboratory tests needed immediately. Point-of-care testing machines can be used for rapid determination of hematocrit [packed cell volume (PCV) or hemoglobin (HemoCue&trade;)], glucose, and lactate. Parasitemia can also be determined quickly but requires a microscope. Additional tests can be done",
"    <span class=\"nowrap\">",
"     if/when",
"    </span>",
"    indicated: electrolytes, full blood count, type and cross, blood culture, and clotting studies. Unconscious patients should have a lumbar puncture to rule out concomitant bacterial meningitis in the absence of contraindications (eg, papilledema). These tasks should overlap with institution of antimalarial treatment as well as other ancillary therapies as needed (including anticonvulsants, intravenous glucose and fluids, antipyretics, antibiotics, and blood transfusion).",
"   </p>",
"   <p>",
"    Repeat clinical assessments should be performed every two to four hours for prompt detection and management of complications (in an intensive care setting, if possible). If the coma score decreases after initiation of treatment, investigations should focus on the possibility of seizures, hypoglycemia, or worsening anemia. Repeat laboratory assessments of parasitemia,",
"    <span class=\"nowrap\">",
"     hemoglobin/hematocrit,",
"    </span>",
"    glucose, and lactate should be performed in 6 hour intervals. A flow chart summarizing the vital information may be used to guide management decisions (",
"    <a class=\"graphic graphic_table graphicRef79603 \" href=\"UTD.htm?34/41/35475\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important independent predictors for fatality among African children with severe malaria include acidosis, impaired consciousness (coma",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    convulsions), elevated blood urea nitrogen, and signs of chronic disease (lymphadenopathy, malnutrition, candidiasis, severe visible wasting, and desquamation) (",
"    <a class=\"graphic graphic_figure graphicRef83924 \" href=\"UTD.htm?10/5/10321\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/12\">",
"     12",
"    </a>",
"    ]. This was illustrated in a large clinical study including 5246 African children with severe malaria. Others factors that were statistically significant predictors of death in univariate analyses but not in the multivariate model included tachypnea, deep breathing, shock, prostration, low pH, hyperparasitemia, severe anemia, and jaundice. Clinical features previously identified as being poor prognostic features that did not correlate with mortality in this study included age, glucose level, axillary temperature, parasite density, and blackwater fever. &nbsp;",
"   </p>",
"   <p>",
"    Careful observation and thoughtful responses to changes in clinical status are the most important elements in looking after patients with severe malaria. Patients can make remarkable recoveries, and the time and effort to address the components of clinical care described in the following sections can reap tangible rewards in a relatively short period of time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antimalarial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major classes of drugs available for parenteral treatment of severe malaria: the cinchona alkaloids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ) and the artemisinin derivatives (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    , artemether and artemotil) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]. Data comparing quinine and artemisinins suggest that intravenous artesunate is preferable for treatment of adults and children with severe falciparum malaria (in areas where intravenous artesunate of reliable quality is readily available) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4,13,14\">",
"     4,13,14",
"    </a>",
"    ]. If intravenous artesunate is not an option, intravenous quinine (or quinidine in the United States) remains the drug of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Artemisinins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Artemisinin derivatives clear parasitemia more rapidly than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    . They are active against a broader life-cycle range of blood stage parasites than quinine and they are active against gametocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Artemisinin derivatives include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    , artemether and artemotil. Artesunate is the preferred artemisinin; clinical experience with artemether and artemotil drugs is limited and they should not be used for treatment of severe disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     Artesunate",
"    </a>",
"    is the preferred therapy for treatment of severe falciparum malaria in adults and children in areas where intravenous artesunate is available [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4,13\">",
"     4,13",
"    </a>",
"    ]. This approach is based on data suggesting that artesunate is superior to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    for treatment of adults in Asia and children in Africa with severe malaria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 1461 patients in Bangladesh, India, Indonesia, and Myanmar randomized to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      , lower mortality was observed among those who received artesunate (15 versus 22 percent, respectively; risk reduction 34 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/17\">",
"       17",
"      </a>",
"      ]. The life saving impact of artesunate was noted among patients who survived more than 24 hours after starting treatment. Artesunate was well tolerated, while quinine was associated with a threefold increased risk of hypoglycemia.",
"     </li>",
"     <li>",
"      Among 5425 children in Africa with severe malaria randomized to receive therapy",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      , lower mortality was observed among those who received artesunate (8.5 versus 10.9 percent, respectively; risk reduction 22.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/13\">",
"       13",
"      </a>",
"      ]. The life saving impact of artesunate was apparent throughout the course of treatment. Hypoglycemia was less frequent in the artesunate group than the quinine group (1.8 versus 2.8 percent). There were no differences in the rate of neurological sequelae between the two groups.",
"     </li>",
"     <li>",
"      A meta-analysis of seven randomized trials compared the survival rates among recipients of parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      ; artesunate was superior with respect to mortality (overall odds ratio 0.69, 0.57-0.84, p&lt;0.00001), and there was no significant heterogeneity between results from Africa and Asia [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    of reliable quality is not yet available in many countries; in these areas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    remains the treatment of choice. In the United States intravenous artesunate is not approved by the Food and Drug Administration but is available for use under an investigational protocol by enrollment with the Centers for Disease Control (CDC Malaria Hotline: (770) 488-7788 Monday-Friday 8a to 4:30p EST; (770) 488-7100 after hours, weekends and holidays) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/18\">",
"     18",
"    </a>",
"    ]. Eligible patients include those with parasitemia &ge;5 percent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other signs of severe malaria, as well as those with uncomplicated malaria who require parenteral therapy due to intolerance of oral medications. The CDC also requires that artesunate be available at least as rapidly as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    or that there be quinidine intolerance, failure or contraindication [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Quinine/quinidine'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     Artesunate",
"    </a>",
"    is the most rapidly acting of the artemisinin compounds because of its water solubility. The standard dosing regimen for intravenous artesunate consists of five doses: 2.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    as the first dose, followed by 2.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at 12 and 24 hours, followed by 2.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily (",
"    <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. Studies are underway to evaluate whether the five dose regimen of intravenous artesunate may be simplified. A study including 171 children with severe malaria in Gabon and Malawi demonstrated that a three-dose regimen of artesunate was not inferior to the standard five-dose regimen; the same total dose (12",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    was administered in three doses (4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at 0, 24, and 48 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/19\">",
"     19",
"    </a>",
"    ]. The number of patients with &gt;99 percent parasite clearance at 24 hours in the five-dose and three-dose group was 85 and 78 percent, respectively. There were no significant differences in safety or tolerability. In very ill patients, intravenous therapy for more than three days may be warranted. Additional studies evaluating the three-dose regimen, comparing intravenous and intramuscular routes, are underway. Following intravenous artesunate, oral antimalarial treatment may be administered if the patient is able to tolerate oral therapy. Artesunate can also be administered intramuscularly, orally, or via rectal suppository [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Completing therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Prereferral treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     Artesunate",
"    </a>",
"    dosing need not be adjusted for hepatic or renal failure, nor for concomitant or previous therapy with other medications (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/15\">",
"     15",
"    </a>",
"    ]. The most common adverse effects associated with artemisinins include nausea, vomiting, anorexia, and dizziness, although these may be due to malaria rather than drug toxicity. There is no convincing evidence of neurotoxic effects in humans due to oral or intravenous artemisinins, although neurotoxicity has been described in animals and attributed to fat soluble artemisinins more frequently than to artesunate [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/21\">",
"     21",
"    </a>",
"    ]. Limited data are available on the use of artesunate for severe malaria during pregnancy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Pregnancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Emergence of artemisinin resistance is an important concern, and combination of artemisinins with other active agents may protect against the development of resistance to individual drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/22\">",
"     22",
"    </a>",
"    ]. Pending further data, use of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    monotherapy remains appropriate for treatment of severe malaria. After the patient is no longer critically ill, oral combination therapy is typically used to complete the course of treatment. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Completing therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Quinine/quinidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    remains the treatment of choice for areas where intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    of reliable quality is not readily available.",
"   </p>",
"   <p>",
"    In the United States, parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    was withdrawn by the CDC in 1991; intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    is available for treatment of severe malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     Quinine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ) should be administered by intravenous infusion beginning with an initial loading dose (",
"    <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      dihydrochloride 20 mg",
"      <span class=\"nowrap\">",
"       salt/kg",
"      </span>",
"      (in 5 percent dextrose) loading dose over 4 hours, followed by 20 to 30 mg",
"      <span class=\"nowrap\">",
"       salt/kg",
"      </span>",
"      divided into two to three equal administrations of 10 mg",
"      <span class=\"nowrap\">",
"       salt/kg",
"      </span>",
"      (over 2 hours) at 8 or 12 hour intervals (maximum 1800 mg",
"      <span class=\"nowrap\">",
"       salt/day).",
"      </span>",
"      Solutions diluted to 60",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      quinine dihydrochloride are less painful than more concentrated preparations [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      gluconate 10 mg",
"      <span class=\"nowrap\">",
"       salt/kg",
"      </span>",
"      loading dose (maximum 600 mg salt) in normal saline over 1 hour, followed by 0.02",
"      <span class=\"nowrap\">",
"       mg/kg/minute",
"      </span>",
"      continuous infusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If intravenous infusions cannot be given,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    can be administered via intramuscular injection. Two injections of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    quinine (diluted to 60 to 100",
"    <span class=\"nowrap\">",
"     mg/mL)",
"    </span>",
"    should be administered 4 hours apart. The anterior thigh is preferred over the gluteal region to minimize the risk of sciatic nerve damage.",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    can act as pancreatic secretagogues, leading to hyperinsulinemic hypoglycemia. Other toxic effects include tinnitus, reversible hearing loss, nausea, vomiting, dizziness, and visual disturbances. Quinidine can cause QT prolongation and should be administered with electrocardiographic monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/25\">",
"     25",
"    </a>",
"    ]. Infusions should be done with care and the rate should be reduced if the corrected QT interval becomes prolonged by more than 25 percent of the baseline value. Such monitoring is not necessary in the setting of quinine administration in patients without cardiac abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"     \"Major side effects of class I antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to parenteral treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ) depends on the clinical circumstances (",
"    <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"     table 4",
"    </a>",
"    ). For patients with malaria acquired in SE Asia, parenteral treatment with quinine (or quinidine) should be combined with one of the following:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"     table 4",
"    </a>",
"    ). For children with malaria acquired in Africa, clinical management consists of administering parenteral quinine (at least three doses) until the child can swallow, followed by oral therapy with an artemisinin combination drug. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Completing therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Prereferral treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of death due to severe malaria is greatest in the first 24 hours of illness. In rural endemic areas where patients with severe malaria cannot begin intravenous therapy immediately, patients should be treated with a prereferral dose of intramuscular or intrarectal therapy and triaged to an acute care facility. Options include intramuscular administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    or an artemisinin, or rectal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    A single",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    rectal suppository pending transport has been demonstrated to reduce mortality. This was illustrated in a randomized trial of over 12,000 patients in rural Bangladesh, Ghana and Tanzania with suspected severe malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/20\">",
"     20",
"    </a>",
"    ]. Dosing consisted of 100 mg for children 6 months to 6 years of age and 400 mg for patients &gt;6 years. Mortality was significantly lower among those who received prereferral rectal artesunate than among those who received placebo (1.9 versus 3.8 percent, respectively; risk ratio 0.49, 95 percent CI 0.32-0.77).",
"   </p>",
"   <p>",
"    If referral is impossible, intramuscular or rectal treatment should be continued until the patient can tolerate oral medication, at which point a full course of oral therapy should be administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Completing therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the total duration of therapy with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"      quinine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"      quinidine",
"     </a>",
"    </span>",
"    for severe malaria is 7 days. The total duration of therapy with artemisinin based therapy is 3 days.",
"   </p>",
"   <p>",
"    After the acute stage of illness has been treated with parenteral therapy and the patient can swallow, a course of oral therapy should be administered based on known susceptibility data to complete the treatment course. In general, the class of agent administered parenterally may be used for oral completion of therapy when feasible. Patients receiving parenteral",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"      quinine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"      quinidine",
"     </a>",
"    </span>",
"    can be transitioned to oral quinine, and those receiving parenteral artemisinin therapy can be transitioned to oral artemisinin combination chemotherapy.",
"   </p>",
"   <p>",
"    Patients completing oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    treatment should also receive a second agent. Options for coadministration with quinine include 7 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    for children or pregnant women) (",
"    <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"     table 4",
"    </a>",
"    ). Options for oral artemisinin combination therapy are outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=see_link\">",
"     \"Treatment of uncomplicated falciparum malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, a full course of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/56/902?source=see_link\">",
"     atovaquone-proguanil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    may be administered as for uncomplicated malaria (",
"    <a class=\"graphic graphic_table graphicRef72019 \" href=\"UTD.htm?32/63/33790\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Regimens containing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/21/17751?source=see_link\">",
"     mefloquine",
"    </a>",
"    should be avoided if the patient presented with altered consciousness, since there is an increased incidence of neuropsychiatric toxic effects associated with mefloquine following cerebral malaria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Respiratory status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia and rales are not common in the setting of severe malaria; the presence of either should raise suspicion for a concomitant lower respiratory tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/26\">",
"     26",
"    </a>",
"    ]. Pulmonary edema may develop, particularly in the settings of renal impairment or severe malarial anemia. Acute respiratory distress syndrome (ARDS) can also complicate severe malaria. The approach to ventilatory management ranges from supplemental oxygen to mechanical ventilation with positive end expiratory pressure (PEEP). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Deep breathing (Kussmaul respirations) is a clinical indicator of metabolic acidosis and is associated with a worse outcome in patients with falciparum malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/27\">",
"     27",
"    </a>",
"    ]. Often deep breathing is associated with hyperlactatemia, although a study of 3248 Tanzanian children noted that among the 164 deaths, 45 children with admission blood glucose concentrations &gt;5",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    had no evidence of deep",
"    <span class=\"nowrap\">",
"     breathing/respiratory",
"    </span>",
"    compensation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/28\">",
"     28",
"    </a>",
"    ]. This same study confirmed previous findings of the prognostic significance of hyperlactatemia; that association was even more pronounced in children with severe nonmalarial illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard clinical case definition of cerebral malaria includes the following criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blantyre coma score &le;2 (",
"      <a class=\"graphic graphic_table graphicRef74361 \" href=\"UTD.htm?9/54/10092\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      P. falciparum parasitemia (any density)",
"     </li>",
"     <li>",
"      No other identifiable cause of coma (eg, hypoglycemia, meningitis, or a post-ictal state) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic hallmark of cerebral malaria is cerebral sequestration of parasitized erythrocytes. Autopsy-based studies have demonstrated that cerebral malaria may be incorrectly diagnosed (based on the clinical case definition) in about 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Rather, the most reliable clinical indicator for cerebral malaria in patients who meet the standard clinical case definition (above) is the presence of one or more elements of malaria retinopathy: white-centered hemorrhages (",
"    <a class=\"graphic graphic_picture graphicRef65241 \" href=\"UTD.htm?39/55/40820\">",
"     picture 1A",
"    </a>",
"    ), vessel changes (",
"    <a class=\"graphic graphic_picture graphicRef64492 \" href=\"UTD.htm?29/19/30001\">",
"     picture 1B",
"    </a>",
"    ), and whitening in areas of the retina (",
"    <a class=\"graphic graphic_picture graphicRef50690 \" href=\"UTD.htm?39/51/40753\">",
"     picture 1C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of cerebral edema in the pathogenesis of cerebral malaria is uncertain. In an Indian trial in which 126 adults with cerebral malaria were randomized to treatment with intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    or placebo, there was no evidence of benefit for mannitol, even though 63 percent of participants had evidence of cerebral edema on CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/33\">",
"     33",
"    </a>",
"    ]. An autopsy study of 20 Vietnamese adults with fatal malaria showed no association between clinical coma and postmortem evidence of edema and compromised vascular integrity on histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical evaluation includes full physical exam, a complete neurologic examination, calculation of Blantyre coma score, and funduscopic evaluation. Patients with altered sensorium should undergo lumbar puncture (in the absence of contraindications) to exclude concomitant bacterial meningitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blantyre coma score &mdash; The Blantyre coma score is a clinical indicator of severity in children with altered consciousness due to malaria (",
"      <a class=\"graphic graphic_table graphicRef74361 \" href=\"UTD.htm?9/54/10092\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/35\">",
"       35",
"      </a>",
"      ]. It was developed based on modifications of Glasgow coma score because some key Glasgow indicators are not appropriate for evaluation of altered consciousness in pediatric malaria. Examples include eye opening in response to pain (open-eyed children can be in coma) and verbal response to pain (many children with severe malaria are not yet able to speak) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/36\">",
"       36",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The Blantyre coma score is outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef74361 \" href=\"UTD.htm?9/54/10092\">",
"       table 1",
"      </a>",
"      ). Fully conscious children score 5; children who do not respond to painful stimuli score 0. Blantyre coma score &le;2 is associated with high risk of mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/36\">",
"       36",
"      </a>",
"      ]. Among 2030 children admitted to a pediatric ward in Malawi with Blantyre coma score &le;2, the mortality in children with a score of 0, 1 or 2 on admission was 34.2, 16.7 and 10.4 percent, respectively. Patients meeting the standard clinical case definition of cerebral malaria had overall mortality of 17.8 percent. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Neurologic status'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The Blantyre coma score should be reassessed at regular intervals following initiation of therapy. A decrease should prompt reevaluation for seizures (including consideration of unwitnessed or subclinical events), anemia, and hypoglycemia.",
"     </li>",
"     <li>",
"      Funduscopic exam &mdash; Malarial retinopathy is pathognomonic for cerebral malaria in patients who satisfy the standard clinical case definition [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/37\">",
"       37",
"      </a>",
"      ]. The optic fundi should be evaluated following instillation of mydriatics for pupillary dilatation. Examination should be performed via direct ophthalmoscope (which provides magnification) and indirect ophthalmoscope (which provides three-dimensional perspective and wide field of view). Features of malarial retinopathy include white-centered hemorrhages, vessel changes, and whitened areas of the retina (",
"      <a class=\"graphic graphic_picture graphicRef65241 graphicRef64492 graphicRef50690 \" href=\"UTD.htm?6/34/6698\">",
"       picture 1A-C",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lumbar puncture &mdash; Patients with altered sensorium should undergo lumbar puncture (in the absence of contraindications) to exclude concomitant bacterial meningitis. If clinical instability or papilledema on ocular fundus examination preclude lumbar puncture, presumptive antibiotic therapy for bacterial meningitis should be initiated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"       \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=see_link\">",
"       \"Lumbar puncture: Technique; indications; contraindications; and complications in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients with cerebral malaria, the mean opening pressure is about 16 cm of CSF. Laboratory examination may be normal or may demonstrate slightly elevated total protein level and cell count. In a study comparing CSF findings from 12 children with cerebral malaria and 14 children with presumed viral encephalitis, patients with cerebral malaria had lower white cell count, glucose, and protein levels [",
"      <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/38\">",
"       38",
"      </a>",
"      ]. Children with malaria had a mean white cell count of 0",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (range 0 to 4",
"      <span class=\"nowrap\">",
"       cells/microL);",
"      </span>",
"      children with viral encephalitis had a mean white cell count of 4",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      (range 0 to 9",
"      <span class=\"nowrap\">",
"       cells/microL).",
"      </span>",
"      A CSF glucose concentration below 3.4",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      (61",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      was the best discriminator of cerebral malaria from presumed viral encephalitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Seizure management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur in up to 70 percent of children with severe malaria; subclinical seizures occur in 15 to 20 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/37,39\">",
"     37,39",
"    </a>",
"    ]. In an African study comparing 132 pediatric survivors of retinopathy-positive cerebral malaria with age-matched controls, epilepsy or other neurobehavioral sequelae were observed in nearly one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/37\">",
"     37",
"    </a>",
"    ]. These observations suggest that enhanced seizure control may improve long-term outcomes.",
"   </p>",
"   <p>",
"    Seizures may be generalized or focal, and the clinical signs may be subtle (nystagmus, irregular respirations, hypoventilation, or a drop in the Blantyre coma score). It is also important to evaluate for causes of seizure besides cerebral malaria (eg hypoglycemia, fever) and to treat accordingly as outlined in the following sections.",
"   </p>",
"   <p>",
"    Benzodiazepines are useful first line agents for seizure treatment.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    (0.4",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be administered intravenously or per rectum;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    can be administered intravenously or intraosseously. These doses can be repeated once if seizures do not cease within 5 minutes of the initial dose. Benzodiazepines should not be combined due to risk of respiratory depression. If seizures are not controllable with benzodiazepines, other options include phenobarbitone (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    slow IV push) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (18",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    diluted in 100 mL normal saline, infused over 20 minutes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If seizures recur, repeat single doses of benzodiazepine may be administered. Alternatively, maintenance doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (5 to 15",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    administered orally, via NG tube, or via slow IV push in divided doses every 12 hours) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    IV) may be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"     \"Management of status epilepticus in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For many years",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/35/24117?source=see_link\">",
"     paraldehyde",
"    </a>",
"    was used as an intramuscular injection to treat seizures in the setting of severe malaria (0.2 to 0.4",
"    <span class=\"nowrap\">",
"     mL/kg);",
"    </span>",
"    its chief advantage is that it does not cause respiratory suppression. The cost of this agent has increased dramatically, and it is therefore out of reach for many formularies in malaria-endemic areas.",
"   </p>",
"   <p>",
"    Patients with severe malaria should not receive routine seizure prophylaxis in the absence of clinical seizure activity. In a study of 340 children with cerebral malaria randomized to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or placebo upon admission to hospital, the mortality in the phenobarbital group was significantly higher than the placebo group (18 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Anemia and coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of infected and uninfected erythrocytes from the circulation is associated with rapid development of anemia. Patients with severe anemia may present with or without altered consciousness. In endemic areas hemoglobin concentration may decrease gradually over the course of repeated malaria infections, so patients can be fully alert with hemoglobin concentrations of 2 to 3",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (hematocrit &lt;10 percent). Evaluation for pallor of the conjunctivae, nail beds, and palms can provide a rough estimate of the degree of anemia, since blood vessels in these areas are close to the surface (",
"    <a class=\"graphic graphic_picture graphicRef70130 \" href=\"UTD.htm?25/20/25923\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=see_link\">",
"     \"Anemia in malaria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin concentration and hematocrit are routinely measured components of complete blood counts, but this may not be available in resource limited settings or the results may not be available in a timely manner. In such circumstances the hematocrit can be measured on a fingerprick sample of blood collected into a heparinized capillary tube and centrifuged using a handheld mechanical device (",
"    <a class=\"graphic graphic_picture graphicRef61513 \" href=\"UTD.htm?6/37/6737\">",
"     picture 3",
"    </a>",
"    ). Alternatively, the hemoglobin concentration can be determined from fingerprick samples of blood collected into cuvettes. This method is more expensive than \"spinning a hematocrit\" but can be performed readily near the bedside.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In areas where malaria and HIV are common infections, blood transfusion is associated with important risks. Most blood banks in endemic areas screen for HIV, hepatitis B, and syphilis, although such screening may miss HIV infected donors who have not yet mounted a detectable serologic response to the infection.",
"   </p>",
"   <p>",
"    Logistical constraints including limited blood supplies, and nurse staffing should also be considered. In endemic areas, a single unit of blood may be typed and cross-matched for several children, such that each receives an aliquot from the same unit. Such infusions require careful attention for prompt discontinuation to ensure that no more than the intended volume is transfused.",
"   </p>",
"   <p>",
"    For these reasons, transfusion should be reserved for patients with dire prognoses &mdash; eg, patients with altered consciousness, high output heart failure, respiratory distress, cool peripheries, hyperlactatemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high density parasitemia. Laboratory parameters of concern include low hemoglobin concentration (&le;4 to 5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    or low hematocrit (&le;10 to 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of anemia and the level of parasitemia may be useful parameters for predicting the need for a blood transfusion and for determining the volume of blood to transfuse, but there have been no conclusive studies in this area. In general, 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of packed red blood cells or 20",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of whole blood transfused over 2 to 4 hours is appropriate. Blood should be typed and cross-matched prior to infusion.",
"   </p>",
"   <p>",
"    Blood transfusions are generally well tolerated in the setting of severe malaria since patients are relatively hypovolemic; diuretics are rarely needed. Monitoring of hemoglobin concentration or hematocrit should continue until the parasitemia clears, since repeat transfusion may be required.",
"   </p>",
"   <p>",
"    Exchange transfusion has been proposed as a means of removing infected red blood cells from the circulation, thereby lowering the parasite burden and replacing with unparasitized cells. However, we do not favor this approach as there is no consensus on the indications, approach, benefits, or risks of this procedure. The WHO guidelines indicate that it is not possible to make any recommendations regarding the use of exchange transfusion based on the available evidence [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]. The CDC recommends consideration of exchange transfusion for patients with parasite density of &gt;10 percent with end organ complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Coagulopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically evident disseminated intravascular coagulation in the setting of severe malaria is rare (&lt;5 percent), but profound thrombocytopenia is common, and the microcirculation in many organs is occluded by fibrin thrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/29\">",
"     29",
"    </a>",
"    ]. The approach to this complication is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=see_link\">",
"     \"Disseminated intravascular coagulation in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Fluids and nutrition",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia (traditionally defined as blood glucose &lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or &lt;2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    is a common complication of malaria and a marker of severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. It should be suspected in any patient who is comatose or who deteriorates suddenly.",
"   </p>",
"   <p>",
"    In a prospective study of 437 children in Mali with presumed severe malaria (85 percent of whom had microscopic evidence of P. falciparum",
"    <em>",
"    </em>",
"    infection), a significant difference in admission glucose concentration was observed between those who died and those who survived (median 4.6 versus 7.6",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    P &lt;0.001) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/45\">",
"     45",
"    </a>",
"    ]. Children with initial blood glucose concentrations &lt;2.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    were classified as hypoglycemic, those between 2.2 and 4.4",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    were classified as low glycemia, those between 4.4 and 8.3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    were categorized as normoglycemia, and those with concentrations &gt;8.3",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    were classified as hyperglycemia. The case fatality rates for hypoglycemia, low glycemia, normal glycemia and hyperglycemia were 61, 46, 13, and 7 percent, respectively. The adjusted odds ratio was 0.75 (0.64 to 0.88) for case fatality for each 1",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    increase in admission blood glucose concentration, suggesting that the traditional cut-off of 2.2",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    may be too low for adequate sensitivity in the setting of pediatric cerebral malaria.",
"   </p>",
"   <p>",
"    The pathogenesis of hypoglycemia is not fully understood; it may be related to parasite glucose consumption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    impaired host gluconeogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/44\">",
"     44",
"    </a>",
"    ]. Malnutrition, adrenal insufficiency and hyperinsulinemia are not likely causes of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition to primary hypoglycemia, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    (insulin secretagogues) can cause iatrogenic hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Hypoglycemia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    therapy is less common than with quinine or quinidine.",
"   </p>",
"   <p>",
"    Clinical manifestations of hypoglycemia include seizure and altered consciousness, although these are not reliable clinical indicators and blood glucose concentration should be assessed as part of routine evaluation. In resource limited settings this may be performed via fingerprick samples of whole blood on indicator strips (with or without handheld glucometers).",
"   </p>",
"   <p>",
"    Hypoglycemic patients should have intravenous access established promptly, followed by administration of initial bolus of dextrose (0.25",
"    <span class=\"nowrap\">",
"     g/kg",
"    </span>",
"    of body weight). This is usually achieved with 2.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 10 percent dextrose solution, since extravasation of higher concentrations of glucose can cause severe tissue damage. Blood glucose measurement after 15 minutes should be repeated, with administration of repeat boluses until the patient is normoglycemic. If glucose measurement is not possible, comatose patients with parasitemia at the time of initial assessment should receive a bolus of 2.5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of 10 percent dextrose solution. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=see_link\">",
"     \"Approach to hypoglycemia in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance intravenous fluids should contain at least 5 percent dextrose; patients with recurrent hypoglycemia should receive 10 percent dextrose (10 percent dextrose can be prepared quickly by withdrawing 100 mL from a one liter bag of a 5 percent dextrose solution and replacing it with 100 mL of a 50 percent dextrose solution).",
"   </p>",
"   <p>",
"    Patients presenting with normoglycemia can develop hypoglycemia during the course of treatment. In addition, those managed promptly for hypoglycemia at presentation can have subsequent recurrent hypoglycemia. Therefore, blood glucose should be monitored closely during the course of illness with prompt management as outlined above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Volume management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravascular volume status in the setting of severe malaria is uncertain; there are data to both support and refute the presence of hypovolemia in the setting of severe malaria infection [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Adults with malaria appear to be more vulnerable to fluid overload than children; there is a thin line between underhydration (and thus worsening renal impairment) and overhydration (and risking pulmonary and cerebral edema). Therefore, fluid requirements should be assessed on an individual basis. Reliable markers of intravascular volume depletion in patients with severe malaria include cool peripheries, delayed capillary refill, low venous pressure and low urine output. Deep breathing (reflecting lactic acidosis) may also be a reasonable indicator of hypovolemia.",
"   </p>",
"   <p>",
"    Clinical symptoms of hypovolemia frequently resolve with blood transfusion (when warranted). When transfusion is not indicated, data suggest that repeated boluses of normal saline or albumin may be counterproductive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/50\">",
"     50",
"    </a>",
"    ]. In a large study involving 3141 African children with severe infection and impaired consciousness",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased work of breathing as well as evidence of impaired perfusion (over half of whom had malaria), patients who received saline or albumin bolus had higher mortality at 48 hours than patients who received no bolus (10.6 and 10.5 percent versus 7.3 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/50\">",
"     50",
"    </a>",
"    ]. Therefore, aggressive fluid resuscitation and specific treatment for acidosis are of uncertain benefit in these settings. Some data suggest that volume resuscitation with crystalloid is favorable over colloid, although it is uncertain whether crystalloid increases risk of exacerbating cerebral edema in the setting of a fragile blood-brain barrier [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of acute renal failure, institution of renal replacement therapy is appropriate if feasible. Hemofiltration is associated with lower mortality than peritoneal dialysis; there have been no comparative trials of hemofiltration and hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=see_link\">",
"     \"Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Maintenance fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance intravenous fluids should include 5 percent dextrose. The rate of fluid administration should be determined by weight. Patients weighing 1 to 10 kg should receive fluids at a rate of 4",
"    <span class=\"nowrap\">",
"     mL/kg/hour.",
"    </span>",
"    For patients weighing 10 to 20 kg, patients should receive 40 mL per hour for the first 10 kg PLUS 2",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    for each kg above 10 kg. For patients who weigh more than 20 kg, patients should receive 60 mL per hour for the first 20 kg PLUS 1",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    for every kg above 20 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/53\">",
"     53",
"    </a>",
"    ]. At body weights above 80 kg, the contribution of water to total body weight falls, so these methods would significantly overestimate the fluid requirements. Total maintenance needs are generally capped near 2.5 liters daily. Intravenous fluid support should be continued until oral intake is tolerated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most hospitals in endemic areas do not have infusion pumps, and intravenous fluids are usually available in one liter bags only. Therefore, fluid delivery can be difficult to monitor and there is real risk of iatrogenic volume overload. To prevent this problem, interposition of a burette (or \"drip chamber\") between the patient and the bag may be placed for monitoring IV fluid administration. A chamber is filled with a known amount of fluid (generally 2 hours' worth), labeled with tape, and the drip rate is set. In this way, providers can tell at a glance if the infusion is proceeding as scheduled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional supplementation should be provided by nasogastric tube (NG) for patients with prolonged coma who are unable to eat and drink within 24 to 48 hours. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=see_link\">",
"     \"Enteral nutrition in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most endemic areas no commercially prepared enteral products are available; substitutes (such as \"eggnog\" containing eggs, milk, sugar and oil) or high calorie drinks may be used. The volumes calculated for intravenous fluids can be administered via NG; the intravenous fluid infusion rate should be decreased accordingly. Most patients are able to eat and drink within 5 to 7 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;High fevers (&gt;38.5&ordm;C) are common in the setting of malaria infection and may reflect the host response to endogenous pyrogens released at the time of schizont rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/54\">",
"     54",
"    </a>",
"    ]. The optimal approach to treatment of fever is uncertain, although use of antipyretics in patients with high fever is appropriate given the association between high fever and convulsions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]. Aggressive temperature control may help reduce long-term neurologic outcomes in pediatric patients with retinopathy-positive cerebral malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Paracetamol (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ; 15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 6 hours; maximum dose 1000 mg) is a reasonable antipyretic agent; oral therapy can be used for patients able to swallow. Otherwise, suppository formulations are acceptable [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]. If fever persists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 6 hours; maximum dose 1200 mg per day) can be administered (orally, via nasogastric tube, or intravenously) alone or on an alternating schedule with paracetamol every 3 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Bacterial infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia is an important contributor to morbidity and mortality in the setting of severe malaria, and severe anemia has been implicated as a primary risk factor for nontyphoidal Salmonella septicemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. A comprehensive study of bacteremia in Kenya identified falciparum infection as a major risk factor for bacteremia with multiple organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/57\">",
"     57",
"    </a>",
"    ]. When the prevalence of malaria parasitemia was 29 percent, 62 percent of bacteremia cases were attributable to malaria; the prevalence of bacteremia declined in parallel with the prevalence of malaria infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=see_link\">",
"     \"Approach to the patient with nontyphoidal Salmonella in a stool culture\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to empiric antibiotic therapy in the setting of severe malaria is contentious. Bacterial infection should be suspected in patients with severe anemia together with signs or symptoms of sepsis (hypotension, cool extremities, delayed capillary refill, hyperlactatemia). In such cases, blood cultures should be obtained and broad spectrum antibiotic therapy with activity against gram-negative bacilli should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women are more likely to develop severe P. falciparum malaria than other adults, particularly in the second and third trimesters. Complications such as hypoglycemia and pulmonary edema are more common than in nonpregnant individuals. Maternal mortality can approach 50 percent, and fetal death and premature labor are common.",
"   </p>",
"   <p>",
"    Prompt antimalarial therapy and supportive care should be administered as outlined in the preceding sections. If there is a choice of therapy available,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"     artesunate",
"    </a>",
"    or artemether are preferred over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    in the second and third trimesters since quinine is associated with recurrent hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/1/13338/abstract/4\">",
"     4",
"    </a>",
"    ]. In the first trimester, either artemisinins or quinine are acceptable choices; during this period the risk of hypoglycemia associated with quinine is lower and the uncertainties regarding the safety of artemisinins are greater.",
"   </p>",
"   <p>",
"    Other issues related to malaria and pregnancy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe malaria is acute malaria with major signs of organ dysfunction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high level of parasitemia. In endemic areas, young children and pregnant women are at high risk for severe malaria. Older children and adults develop partial immunity after repeated infections and therefore are at relatively low risk for severe disease. Travelers to areas where malaria is endemic generally have no previous exposure to malaria parasites and so are at high risk for severe disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of malaria infection and the degree of parasitemia are established by blood smear. In general, the heavier the parasitemia, the sicker the patient, but there are many asymptomatic patients with high parasitemia, and patients with severe malaria can present with low-density infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For treatment of nonpregnant adults and children with severe falciparum malaria, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      (in areas where intravenous artesunate of reliable quality is readily available), rather than intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"       table 4",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For treatment of pregnant women with severe falciparum malaria in the second and third trimesters we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/54/4965?source=see_link\">",
"       artesunate",
"      </a>",
"      (in areas where intravenous artesunate of reliable quality is readily available) (",
"      <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"       table 4",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For treatment of pregnant women with severe falciparum malaria in the first trimester we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The total duration of therapy with",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"        quinine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"        quinidine",
"       </a>",
"      </span>",
"      for severe malaria is seven days. The total duration of therapy with artemisinin based therapy is three days. After the acute stage of illness has been treated with parenteral therapy and the patient can swallow, a complete course of oral therapy (selected on the basis of known parasite drug susceptibility or national treatment guidelines) should be administered (",
"      <a class=\"graphic graphic_table graphicRef79194 \" href=\"UTD.htm?27/49/28445\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Completing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of pre-referral treatment to patients in rural endemic areas with suspected severe malaria who cannot begin intravenous therapy immediately (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Prereferral treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Death due to severe malaria can occur within hours of presentation, so prompt assessment and initiation of antimalarial therapy are essential, followed by concurrent supportive care to manage life-threatening complications of the disease:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary complications of severe malaria include pulmonary edema, acute respiratory distress syndrome, and lower respiratory tract infection. Management requirements may range from supplementary oxygen to mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Respiratory status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neurologic complications include altered sensorium, seizure, and coma. Clinical evaluation includes full physical examination, calculation of Blantyre coma score (",
"      <a class=\"graphic graphic_table graphicRef74361 \" href=\"UTD.htm?9/54/10092\">",
"       table 1",
"      </a>",
"      ), funduscopic exam, and lumbar puncture. Seizures should be managed as outlined above. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Neurologic status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hematologic complications include severe anemia and coagulopathy. Decisions regarding transfusion should be tailored to individual patient circumstances. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoglycemia (blood glucose &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or &lt;2.2",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      is a common complication of malaria and a marker of severe disease; it should be suspected in any patient who deteriorates suddenly. Hypoglycemic patients should have intravenous access established promptly followed by administration of 50 percent dextrose (1",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      with repeat blood glucose measurement after 15 minutes. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypovolemia should be assessed on an individual basis. Adults with malaria appear to be more vulnerable to fluid overload than children; there is a thin dividing line between underhydration (and thus worsening renal impairment) and overhydration (and risk of pulmonary and cerebral edema). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Volume management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Malaria Report 2008, Geneva, World Health Organization, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/2\">",
"      Baird JK. Severe and fatal vivax malaria challenges 'benign tertian malaria' dogma. Ann Trop Paediatr 2009; 29:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/3\">",
"      Cox-Singh J, Hiu J, Lucas SB, et al. Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report. Malar J 2010; 9:10.",
"     </a>",
"    </li>",
"    <li>",
"     WHO guidelines for the treatment of malaria. Geneva, World Health Organization, 2010. file://whqlibdoc.who.int/publications/2010/9789241547925_eng.pdf (Accessed on December 30, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/5\">",
"      White NJ. The treatment of malaria. N Engl J Med 1996; 335:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/6\">",
"      Crawley J, Chu C, Mtove G, Nosten F. Malaria in children. Lancet 2010; 375:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/7\">",
"      Bejon P, Warimwe G, Mackintosh CL, et al. Analysis of immunity to febrile malaria in children that distinguishes immunity from lack of exposure. Infect Immun 2009; 77:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/8\">",
"      Mali S, Steele S, Slutsker L, et al. Malaria surveillance--United States, 2006. MMWR Surveill Summ 2008; 57:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/9\">",
"      Phillips A, Bassett P, Zeki S, et al. Risk factors for severe disease in adults with falciparum malaria. Clin Infect Dis 2009; 48:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/10\">",
"      Dondorp AM, Lee SJ, Faiz MA, et al. The relationship between age and the manifestations of and mortality associated with severe malaria. Clin Infect Dis 2008; 47:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/11\">",
"      Taylor T, Olola C, Valim C, et al. Standardized data collection for multi-center clinical studies of severe malaria in African children: establishing the SMAC network. Trans R Soc Trop Med Hyg 2006; 100:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/12\">",
"      von Seidlein L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial. Clin Infect Dis 2012; 54:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/13\">",
"      Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet 2010; 376:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/14\">",
"      Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev 2012; 6:CD005967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/15\">",
"      Rosenthal PJ. Artesunate for the treatment of severe falciparum malaria. N Engl J Med 2008; 358:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/16\">",
"      ter Kuile F, White NJ, Holloway P, et al. Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp Parasitol 1993; 76:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/17\">",
"      Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366:717.",
"     </a>",
"    </li>",
"    <li>",
"     New Medication for Severe Malaria Available Under an Investigational New Drug Protocol. MMWR Surveill Summ 2007; 56:769. file://www.cdc.gov/mmWR/preview/mmwrhtml/mm5630a5.htm (Accessed on February 20, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/19\">",
"      Kremsner PG, Taylor T, Issifou S, et al. A simplified intravenous artesunate regimen for severe malaria. J Infect Dis 2012; 205:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/20\">",
"      Gomes MF, Faiz MA, Gyapong JO, et al. Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet 2009; 373:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/21\">",
"      Nontprasert A, Pukrittayakamee S, Nosten-Bertrand M, et al. Studies of the neurotoxicity of oral artemisinin derivatives in mice. Am J Trop Med Hyg 2000; 62:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/22\">",
"      Noedl H, Se Y, Schaecher K, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med 2008; 359:2619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/23\">",
"      Treatment with quinidine gluconate of persons with severe Plasmodium falciparum infection: discontinuation of parenteral quinine from CDC Drug Service. MMWR Recomm Rep 1991; 40:21.",
"     </a>",
"    </li>",
"    <li>",
"     The complete drug reference 36th edition [online]. Sweetman SC (Ed), London, Pharmaceutical Press. Available at: file://www.medicinescomplete.com/ (Accessed on March 05, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/25\">",
"      White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007; 7:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/26\">",
"      Bassat Q, Machevo S, O'Callaghan-Gordo C, et al. Distinguishing malaria from severe pneumonia among hospitalized children who fulfilled integrated management of childhood illness criteria for both diseases: a hospital-based study in Mozambique. Am J Trop Med Hyg 2011; 85:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/27\">",
"      Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/28\">",
"      Hendriksen IC, Mtove G, Pedro AJ, et al. Evaluation of a PfHRP2 and a pLDH-based rapid diagnostic test for the diagnosis of severe malaria in 2 populations of African children. Clin Infect Dis 2011; 52:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/29\">",
"      Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/30\">",
"      Lewallen S, White VA, Whitten RO, et al. Clinical-histopathological correlation of the abnormal retinal vessels in cerebral malaria. Arch Ophthalmol 2000; 118:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/31\">",
"      Beare NA, Taylor TE, Harding SP, et al. Malarial retinopathy: a newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006; 75:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/32\">",
"      Beare NA, Harding SP, Taylor TE, et al. Perfusion abnormalities in children with cerebral malaria and malarial retinopathy. J Infect Dis 2009; 199:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/33\">",
"      Mohanty S, Mishra SK, Patnaik R, et al. Brain swelling and mannitol therapy in adult cerebral malaria: a randomized trial. Clin Infect Dis 2011; 53:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/34\">",
"      Medana IM, Day NP, Sachanonta N, et al. Coma in fatal adult human malaria is not caused by cerebral oedema. Malar J 2011; 10:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/35\">",
"      Newton CR, Chokwe T, Schellenberg JA, et al. Coma scales for children with severe falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/36\">",
"      Molyneux ME, Taylor TE, Wirima JJ, Borgstein A. Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children. Q J Med 1989; 71:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/37\">",
"      Birbeck GL, Molyneux ME, Kaplan PW, et al. Blantyre Malaria Project Epilepsy Study (BMPES) of neurological outcomes in retinopathy-positive paediatric cerebral malaria survivors: a prospective cohort study. Lancet Neurol 2010; 9:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/38\">",
"      Jakka SR, Veena S, Atmakuri RM, Eisenhut M. Characteristic abnormalities in cerebrospinal fluid biochemistry in children with cerebral malaria compared to viral encephalitis. Cerebrospinal Fluid Res 2006; 3:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/39\">",
"      Crawley J, Smith S, Muthinji P, et al. Electroencephalographic and clinical features of cerebral malaria. Arch Dis Child 2001; 84:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/40\">",
"      Crawley J, Waruiru C, Mithwani S, et al. Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study. Lancet 2000; 355:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/41\">",
"      Bojang KA, Palmer A, Boele van Hensbroek M, et al. Management of severe malarial anaemia in Gambian children. Trans R Soc Trop Med Hyg 1997; 91:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/42\">",
"      Zucker JR, Campbell CC. Malaria. Principles of prevention and treatment. Infect Dis Clin North Am 1993; 7:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/43\">",
"      White NJ, Miller KD, Marsh K, et al. Hypoglycaemia in African children with severe malaria. Lancet 1987; 1:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/44\">",
"      Taylor TE, Molyneux ME, Wirima JJ, et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 1988; 319:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/45\">",
"      Willcox ML, Forster M, Dicko MI, et al. Blood glucose and prognosis in children with presumed severe malaria: is there a threshold for 'hypoglycaemia'? Trop Med Int Health 2010; 15:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/46\">",
"      White NJ, Warrell DA, Chanthavanich P, et al. Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 1983; 309:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/47\">",
"      Limburg PJ, Katz H, Grant CS, Service FJ. Quinine-induced hypoglycemia. Ann Intern Med 1993; 119:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/48\">",
"      Maitland K, Levin M, English M, et al. Severe P. falciparum malaria in Kenyan children: evidence for hypovolaemia. QJM 2003; 96:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/49\">",
"      Planche T, Onanga M, Schwenk A, et al. Assessment of volume depletion in children with malaria. PLoS Med 2004; 1:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/50\">",
"      Maitland K, Kiguli S, Opoka RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 2011; 364:2483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/51\">",
"      Brown H, Hien TT, Day N, et al. Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathol Appl Neurobiol 1999; 25:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/52\">",
"      Maitland K, Pamba A, English M, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: preliminary evidence of albumin benefit. Clin Infect Dis 2005; 40:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/53\">",
"      Duke T, Molyneux EM. Intravenous fluids for seriously ill children: time to reconsider. Lancet 2003; 362:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/54\">",
"      Hensmann M, Kwiatkowski D. Cellular basis of early cytokine response to Plasmodium falciparum. Infect Immun 2001; 69:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/55\">",
"      Berkley J, Mwarumba S, Bramham K, et al. Bacteraemia complicating severe malaria in children. Trans R Soc Trop Med Hyg 1999; 93:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/56\">",
"      Bronzan RN, Taylor TE, Mwenechanya J, et al. Bacteremia in Malawian children with severe malaria: prevalence, etiology, HIV coinfection, and outcome. J Infect Dis 2007; 195:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/1/13338/abstract/57\">",
"      Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5667 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-812927D4EA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13338=[""].join("\n");
var outline_f13_1_13338=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antimalarial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Artemisinins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Quinine/quinidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Prereferral treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Completing therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Respiratory status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic status",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Seizure management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Anemia and coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Coagulopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Fluids and nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Volume management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Maintenance fluids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Nutrition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Bacterial infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5667\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5667|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/5/10321\" title=\"figure 1\">",
"      Diagram mortality predictors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5667|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/55/40820\" title=\"picture 1A\">",
"      White-centered hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/19/30001\" title=\"picture 1B\">",
"      Vessel changes in optic fundi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/51/40753\" title=\"picture 1C\">",
"      Retinal whitening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/20/25923\" title=\"picture 2\">",
"      Anemic palmar pallor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/37/6737\" title=\"picture 3\">",
"      Microhematocrit determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5667|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/54/10092\" title=\"table 1\">",
"      Blantyre coma score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/62/29676\" title=\"table 2\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/41/35475\" title=\"table 3\">",
"      Observations chart malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/49/28445\" title=\"table 4\">",
"      Parenteral rx severe malaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/63/33790\" title=\"table 5\">",
"      Treatment of uncomplicated malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19754?source=related_link\">",
"      Anemia in malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8201?source=related_link\">",
"      Approach to hypoglycemia in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/8/26761?source=related_link\">",
"      Approach to the patient with nontyphoidal Salmonella in a stool culture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5543?source=related_link\">",
"      Clinical manifestations of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/0/10248?source=related_link\">",
"      Diagnosis of malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/31/8697?source=related_link\">",
"      Disseminated intravascular coagulation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11529?source=related_link\">",
"      Enteral nutrition in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/6/19561?source=related_link\">",
"      Lumbar puncture: Technique; indications; contraindications; and complications in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/58/25513?source=related_link\">",
"      Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure) in adults: Indications, timing, and dialysis dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/41/25241?source=related_link\">",
"      Treatment of uncomplicated falciparum malaria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_1_13339="Etiology of priapism";
var content_f13_1_13339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The etiology of priapism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       1-Primary (idiopathic)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       2-Secondary",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hematologic (sickle cell anemia, leukemia, thalassemia, multiple myeloma, thrombotic thrombocytopenic purpura)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Neurologic (spinal shock)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tumors (metastatic cancers)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Perineal, pelvic or penile trauma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Iatrogenic (intracavernous injections)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Drugs (anticoagulants, anti-hypertensives, anti-depressants, PDE5 inhibitors, intracavernous injections, alpha-blockers, cocaine)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infection (malaria, spider toxins)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metabolic disorders (gout, hemodialysis, high lipid content, total parenteral nutrition, diabetes, amyloidosis)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13339=[""].join("\n");
var outline_f13_1_13339=null;
var title_f13_1_13340="Disorders that can mimic PD";
var content_f13_1_13340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58941&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Disorders that can mimic Parkinson disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neurodegenerative causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alzheimer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticobasal degeneration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dementia with Lewy bodies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frontotemporal dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Huntington disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple system atrophy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parkinsonism-dementia-ALS complex of Guam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive supranuclear palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinocerebellar ataxias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Symptomatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drug-induced (neuroleptics, other dopamine receptor antagonists)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infectious (post-encephalitic, Creutzfeldt-Jakob disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic (Wilson disease, neurodegeneration with brain iron accumulation, hepatocerebral degeneration, parathyroid disorders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-traumatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toxic (carbon monoxide, manganese, MPTP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential tremor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Normal pressure hydrocephalus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SWEDD (Scans Without Evidence of Dopaminergic Deficit): patients with relatively isolated upper extremity tremor resembling early Parkinson&nbsp;disease who",
"        <span style=\"font-family: 'verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: 'times new roman'; mso-fareast-theme-font: minor-fareast; mso-bidi-font-family: 'times new roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: en-us; mso-fareast-language: en-us; mso-bidi-language: ar-sa;\">",
"         lack evidence of nigrostriatal dopamine deficiency on dopamine transporter imaging",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13340=[""].join("\n");
var outline_f13_1_13340=null;
var title_f13_1_13341="mCRC severe chemo tox";
var content_f13_1_13341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of severe chemotherapy toxicity by age in trials of metastatic colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Author",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Regimen",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Neutropenia",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Thrombocytopenia",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Mucositis",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Diarrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       &lt;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &ge;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &lt;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &ge;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &lt;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &ge;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &lt;70 yrs, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       &ge;70 yrs, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Sargent, D; 2001",
"      </td>",
"      <td>",
"       5-FU/LV",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       5-FU/Lev",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       31",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       11",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Folprecht, G; 2006",
"      </td>",
"      <td>",
"       5-FU",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       23",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Irinotecan/5-FU",
"      </td>",
"      <td>",
"       35",
"      </td>",
"      <td>",
"       39",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       34",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Goldberg, R; 2006",
"      </td>",
"      <td>",
"       FOLFOX",
"      </td>",
"      <td>",
"       43",
"      </td>",
"      <td>",
"       49",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       11",
"      </td>",
"      <td>",
"       13",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Arkenau, H; 2008",
"      </td>",
"      <td>",
"       FOLFOX or CAPOX",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       9",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Sastre, J; 2009",
"      </td>",
"      <td>",
"       CAPOX",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       25",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FOLFOX",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       21",
"      </td>",
"      <td>",
"       33",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Jackson, N; 2009",
"      </td>",
"      <td>",
"       FOLFIRI, mIFL, CAPIRI",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       46",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       26",
"      </td>",
"      <td>",
"       30",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       FOLFIRI, mIFL + bevacizumab",
"      </td>",
"      <td>",
"       36",
"      </td>",
"      <td>",
"       55",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       NR",
"      </td>",
"      <td>",
"       23",
"      </td>",
"      <td>",
"       20",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     5-FU: 5-fluorouracil; LV: leucovorin; FOLFOX: infusional 5-flourouracil, leucovorin, oxalipltin; NR: not reported.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13341=[""].join("\n");
var outline_f13_1_13341=null;
var title_f13_1_13342="Gram stain CSF 2";
var content_f13_1_13342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain CSF 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13342=[""].join("\n");
var outline_f13_1_13342=null;
var title_f13_1_13343="Sarcoid arthropathy";
var content_f13_1_13343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sarcoid arthropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 254px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hand radiograph shows multiple phalangeal cysts with erosion of the cortex in a patient with sarcoid arthropathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_1_13343=[""].join("\n");
var outline_f13_1_13343=null;
